Company name State City address

Molecular Testing Labs Washington 98684 Vancouver 14401 SE 1st St.

HTG Molecular Diagnostics Arizona 85706 Tuscon 3430 E. Global Loop

Siemens Healthcare Molecular DiCalifornia 94710, Berkeley 725 Potter St.

California 94710
Caribou Biosciences Berkeley 2929 Seventh Street #105

GeneID Lab - Advanced MolecularNJ 07645 Montvale 136 Summit Ave

WA 98105
UWMC Molecular Microbiology Seattle St Room NW177
2809 BOSTON STREET,
Personal Genome Diagnostics MD 21224 BALTIMORE SUITE 503

Integrated Cellular And MoleculaMD 20770 Greenbelt 6305 Ivy Lane, Suite 100

MNG Laboratories GA 30342 Atlanta 5424 Glenridge Dr

Machaon Diagnostics, Inc. California 94609 Oakland 3023 Summit St

Spectrum Diagnostics New York 10013 New York 139 Centre St Suite 818
 369 Lexington Ave. 26th
acuamark diagnostics NY 10017 New York, Floor

12212 Technology Blvd

Luminex TX 78727 Austin Suite 130
Cepheid CA 94089 Sunnyvale 904 Caribbean Drive

NY
Enzo Biochem Inc 10022 New York 527 Madison Avenue
LaunchWorks Manufacturing La MA 01915 Beverly 123 Brimbal Ave

WI 53711, USA
5399, 2800 Woods Hollow
Promega Corporation Fitchburg Rd

10222 Barnes Canyon Road

Invivoscribe, Inc. CA 92121-2711 San Diego Building 1
 760 Parkside Avenue
Downstate Biotechnology
Incubator
AzurRx BioPharma, Inc NY 11226 Brooklyn Suite 304

Building 31

NHLBI MD 20892 Bethesda 31 Center Drive

AmbryGenetics CA 92656 Aliso Viejo 15 Argonaut

Aridis Pharmaceuticals, Inc. CA 95138 San Jose 5941 Optical Court

Volition America Inc. Texas, 78701 Austin 100 Congress Avenue

430 East 29th Street | Suite

Chimeron Bio NY 10016 New York 100

Massive Bio, Inc. NY 10006 New York 90 West St., Suite 12M

1633 Broadway
Delcath Systems Inc NY 10019 New York 22nd Floor, Suite C

17 State Street
Tyme Technologies Inc. NY 10004 New York 7th Floor

TOYOBO USA., INC. NY 10017 New York 666 Third Avenue, Suite 603
Basepair Tech NY 10017 New York 415 Madison Ave fl 4

Gilead Sciences, Inc. CA 94404 Foster City 333 Lakeside Drive

Allergan plc (NYSE: AGN NJ 07940 Madison 5 Giralda Farms

Cystic Fibrosis Continuity of Care.

Cystic Fibrosis Pharmacy and F FL 32803 Orlando 3901 E. Colonial Dr.

1731 Embarcadero Road,
Cystic Fibrosis Research, Inc. CA 94303 Palo Alto Suite 210

825 East Gate Boulevard,

Advanced Inhalation Therapies (A
NY 11530 Garden City Suite 320
AbbVie Inc. Illinois 60064 North Chicago 1 N. Waukegan Road

26525 North Riverwoods

AbbVie Inc. Illinois 60045 Mettawa Blvd.

AbbVie Inc. Illinois 60085 North Chicago 1401 Sheridan Road

AbbVie Inc. California 94063 Redwood City 1500 Seaport Blvd

AbbVie Inc. California 94080 South San Francis 450 East Jamie Court

AbbVie Inc. California 94085 Sunnyvale 999 East Arques Avenue

AbbVie Inc. California 94080 South San Francis 601 Gateway Blvd, Suite 100

AbbVie Inc. Massachusetts 021 Cambridge, 200 Sidney St

AbbVie Inc. Massachusetts 016 Worcester 100 Research Drive

1399 New York Ave NW,

AbbVie Inc. D.C. 20005 Washington Suite 600

230 CityPoint
Galapagos, Inc. MA 02451 Waltham 230 Third Avenue

Genentech, Inc. CA 92056 Oceanside One Antibody Way

Genentech, Inc. CA 95688 Vacaville 1000 New Horizons Way

Genentech, Inc. CA 94080 South San Francis 1 DNA Way

4625 NW Brookwood
Genentech, Inc. OR 97124 Hillsboro Parkway
 500 River Ridge Drive
Corbus Pharmaceuticals Holdings
MA 02062 Norwood Second Floor

940 West Valley Rd, Suite

EXTEDO Inc. PA 19087 Wayne 1302

99 Hayden Avenue | Suite

Pulmatrix, Inc. MA 02421 Lexington 390

ProQR Therapeutics MA 02142 Cambridge 1 Broadway 14th Floor

 One Newton Executive Park
Alcresta Therapeutics, Inc. MA 02462 Newton Suite 100

Ontario
Arch Biopartners M5V 1M1 Toronto 545 King Street West

Ontario
Arch Biopartners M4T 2M5 Toronto 27 St. Clair Avenue East
TGV-inhalonix NY 10016 New York 303 5th Avenue, Suite 2012

RespirTech MN 55113 St. Paul 2896 Centre Pointe Drive

80 Guest Street
Proteostasis Therapeutics MA 02135 Boston 5th Floor
 150 South Wacker Drive,
Horizon Pharma IL 60606 Chicago Suite 3200

Horizon Pharma IL 60045 Lake Forest 150 S Saunders Road

2000 Sierra Point Parkway,

Horizon Pharma CA 94005 Brisbane Ste 400

Wilmington
AstraZeneca Delaware
AstraZeneca Maryland Gaithersburg

B
AstraZeneca Massachusettes Boston

Moderna Therapeutics MA 02139 Cambridge 200 Technology Square

Moderna Therapeutics MA 02062 Norwood, Clinical Manufacturing Facility

Editas Medicine MA 02141 Cambridge 11 Hurley Street

Cyclacel Pharmaceuticals, Inc. NJ 07922 Berkeley Heights 200 Connell Drive #1500

Suite 195
PARION SCIENCES NC 27713 Durham 2800 Meridian Parkway

Anthera Pharmaceuticals CA 94545 Hayward 25801 Industrial Blvd, Suite

CURx Pharmaceuticals CA 92121 San Diego 3210 Merryfield Row

Celtaxsys GA 30363 GA 30363 201 17th Street, Suite 530

Concert Pharmaceuticals, Inc. MA 02421 Lexington 65 Hayden Avenue, Suite 300

WA 981119

Alpine Immune Science Seattle 201 Elliot Avenue West

PTC Therapeutics NJ 07080-2449 South Plainfield 100 Corpote Court

2C Tech Corporation, Inc. CA 92618 Irvine 15310 Barranca Parkway, Sui

2D Genomics Inc.

3-V Biosciences, Inc. CA 94025 Menlo Park 3715 Haven Ave. Suite 220
Praetego, Inc.‚‚ NC 27617 Raleigh 8311 Brier Creek Parkway, Su

Intellia Therapeutics MA 02139 Cambridge 40 Erie Street

Sangamo Therapeutics CA 94804 Richmond 501 Canal Blvd

Bioverativ, a Sanofi company MA 02451 Waltham 225 Second Avenue
Humanigen, Inc. (HGEN) CA 94005-1878 Brisbane 1000 Marina Boulevard, Suite 250

CRISPR Therapeutics AG MA 02139 Cambridge 610 Main Street

23andMe CA 94041 Mountain View, 899 W Evelyn

Teva PA 19454 North Wales 1090 Horsham Road

 CA
Amgen Inc. 91320-1799 Thousand Oaks One Amgen Center Drive
Dicerna Pharmaceuticals MA 02140 Cambridge, 87 Cambridgepark Drive

NY United States
Acorda Therapeutics 10502 Ardsley 420 Saw Mill River Road
Tempus IL 60654 Chicago 600 West Chicago Ave. Ste 510

Pittsburgh Cytogenetics LaboratoPA 15213 Pittsburgh 300 Halket St., Rm. 1225
Caris molecular intelligence Az 85040 Phoenix 4610 South 44th Place
Caris molecular intelligence TX 75039 Irving 750 West John Carpenter Fre
ACCC DC 20001 Washington 900 Seventh Street, NW Suite

DDC Clinic
Molecular Diagnostics
Laboratory OH 44062 Middlefield 14567 Madison Rd.

NCEE Labs NE 68521 Lincoln 4740 Discovery Dr.

 500 W Office Center Drive
Aurinia Pharmaceuticals Inc. PA 19034 Fort Washington Suite 400

Envision Genomics AL 35806 Huntsville 601 Genome Way

LBT Innovations SA 5000 Adelaide Level 8, 44 Waymouth Street

BCR Diagnostics AZ 85226 Chandler 145 S 79th St. Ste 13,

Fry Laboratories AZ 85260 Scottsdale 14807 N. 73rd Street Suite #1

Iron Horse Diagnostics AZ 85255 Scottsdale 21053 N 75th Street

BC V5T 4T5
Augurex Life Sciences Canada Vancouver 887 Great Northern Way, Sui
 Suite #204 Donald Rix
BC Canada Building
Contextual Genomics V6T 1Z3 Vancouver 2389 Health Sciences Mall

BC, Canada
Response Biomedical V6P 6P2 Vancouver 1781 – 75th Avenue W.

1000 Atlantic Avenue

Alveo Technologies California 94501 Alameda Suite 114
 1701 Harbor Bay Parkway,
Singulex CA 94502 Alameda Suite 200

Main
Silver Lake Research California 91702 Azusa 787

Exogen Bio CA 94710 Berkeley 820 Heinz Ave

Exogenesis MA 01821 Billerica, 20 Fortune Drive

Nodexus CA 94704 Berkeley 2150 Shattuck Ave. PH

Kite HQ CA 90404 Santa Monica 2400 Broadway

Kite El Segundo (Manufacturing) CA 90245 El Segundo 2355 Utah Ave.

Mammoth Biosciences CA 94107 San Francisco 953 Indiana St.

26 Landsdowne Street
Beam Therapeutics MA 02139 Cambridge 2nd Floor
Celsius Therapeutics MA 02142 Cambridge 215 First Street, Suite 401S

Casma Therapeutics MA 02139 Cambridge 38 Sidney Street, Suite 200

Cedilla Therapeutics MA 02139 Cambridge 38 Sidney Street, 2nd Floor

bluebird bio MA 02142 Cambridge 60 Binney St.

Moderna MA 02139 Cambridge 200 Technology Square

Versant Ventures CA 94104 San Francisco One Sansome, Suite 3630

 54 West 21st Street
Versant Ventures NY 10010 New York Suite 408

7800 Equitable Drive

Versant Ventures MN 55344 Eden Prairie Suite 150
 BC V5T 4T5, 887 Great Northern Way
Versant Ventures Canada Vancouver Suite 210

CODA Biotherapeutics, Inc. CA 94408 South San Francis329 Oyster Point Boulevard, 3rd Floor
Pipeline Therapeutics CA 92121 San Diego 10578 Science Center Driv

One Sansome
Street
Tempest Therapeutics CA 94104 Suite 3690
SNIPR Biome - A CRISPR Company
Integrated DNA Technologies, In Illinois 60076 Skokie 8180 N. McCormick Blvd.

GenScript NJ 08854 Piscataway GenScript 860 Centennial

GENEWIZ NJ 07080 South Plainfield 115 Corporate Boulevard

Admera Health NJ 07080 South Plainfield 126 Corporate Boulevard

9620 Medical Center

Drive
OriGene Technologies MD 20850 Rockville Suite 200

Abnova CA. 91788 Walnut PO Box 1697

Illumina CA 92122 San Diego 5200 Illumina Way

Illumina WI 53719 Madison 5602 Research Park Blvd.,

Illumina CA 94404 Foster City 200 Lincoln Centre Drive

Agios Pharmaceuticals MA 02139-4169 Cambridge 88 Sidney Street

Zymergen, Inc. CA 94608 Emeryville 5980 Horton Street, Suite 105

Molecular Devices CA 95134 San Jose 3860 N First Stree

Ohio

PerkinElmer, Inc. 44311 Akron 520 South Main St., Suite

Agilent Technologies CA 95051 Santa Clara 5301 Stevens Creek Blvd

Halo-Bio RNAi Therapeutics, Inc.Washington 98112 Seattle 4111 E. Madison, Box 140

300 Third Street

Alnylam Pharmaceuticals MA 02142 Cambridge 3rd Floor
 400 Dexter Avenue
North
Juno Therapeutics, Inc. WA 98109 Seattle Suite 1200

Arrowhead Pharmaceuticals CA 91101 Pasadena 225 South Lake Avenue, S

Regulus Therapeutics CA 92121 San Diego 10614 Science Center Dr.

Catalent Pharma Solutions IN 47403 Bloomington 1300 S. Patterson Dr.

La Jolla Pharmaceutical Compan California 92121 San Diego 4550 Towne Centre Court

Heron Therapeutics, Inc. CA 92121 San Diego 4242 Campus Point Court,
Heron Therapeutics, Inc. NJ 07302 Jersey City 101 Hudson Street, Suite

Translate Bio MA 02421 Lexington 29 Hartwell Ave

Repare Therapeutics MA 02142 Cambridge 1 Broadway, 14th Floor

Vividion Therapeutics CA 92121 San Diego 5820 Nancy Ridge Drive

Celera Corporation NJ 07094 Secaucus 500 Plaza Drive

 500 River Ridge Drive
Corbus Pharmaceuticals MA 02062 Norwood Second Floor

Constellation Pharmaceuticals MA 02142 Cambridge 215 First Street, Suite 200

 80 Guest Street
Proteostasis Therapeutics, Inc. ( MA 02135 Boston 5th Floor

Aragen Bioscience Inc CA 95037 Morgan Hill 380 Woodview Avenue

Allele Biotechnology & Pharmaceu
CA 92121 San Diego 6404 Nancy Ridge Drive

LakePharma, Inc. CA 94002 Belmont 520 Harbor Blvd

ElitechGroup UT 84321 Logan 370 West 1700 South

DiaSorin CA 90630 Cypress 11331 Valley View St.

Arcturus Therapeutics CA 92121 San Diego 10628 Science Center Driv

Savara Inc. TX, 78746 Austin 6836 Bee Cave Road, Build
A-Med Health Care CA 92647 Huntington Beach5302 Rancho Road

North Carolina 9121 Anson Way,

NovaBiotics Ltd 27615 Raleigh Suite 200,

Sanovas, Inc. CA 94901 San Rafael 2597 Kerner Boulevard

Nivalis Therapeutics, Inc. CO 80301 Boulder 3122 Sterling Circle, Ste 200
miRagen Therapeutics, Inc. CO 80301 Boulder 6200 Lookout Rd.

Eloxx Pharmaceuticals MA 02451 Waltham 950 Winter Street,

Respiratory Research, Inc. TX 78720 Austin PO Box 202108

SPYRYX Biosciences Inc. NC 27713 Durham 801-10 Capitola Drive

EnBiotix, Inc. MA 02118-3406 Boston 197 West Springfield Stre

Novoclem Therapeutics NC 27703 Durham 4222 Emporer Blvd. Suite

Progenesis CA 92037 La Jolla 4150 Regents Park Row, S
Progenity, Inc. MI 48108 Ann Arbor 5230 S. State Road

Progenity, Inc. CA 92122 San Diego 4330 La Jolla Village Drive Suite 200

AffloVest TX 78744 Austin 2101 E St Elmo Rd # 275

Curza UT 84108 Salt Lake City 630 Komas Drive, Suite 1
Curza MA 02142 Cambridge One Broadway, 14th floor

Chemistry Rx Compounding and PA 19107 Philadelphia 829 Spruce Street, Suite

FRD Specialty Pharmacy CA 91042 Los Angeles Address: 6253 Foothill Bl

 (Québec) H3C 2G9
Laurent Pharmaceuticals Canada Montréal 355 Peel, Suite 503

Talee Bio PA 19104 Philadelphia 3001 Market Street, Suite

Onspira Therapeutics, Inc. PA 19087 Wayne 640 Lee Road, Ste 117
ProclaRx LLC OH, 45701 Athens ProclaRx LLC, Suite 212, 3

Monitored Therapeutics, Inc. OH 43017 Dublin 6543 Commerce Pkwy., Su

CBS Labs Biobanking and ResearcFL 33010 Hialeah 2546 West 6th Ave
Synspira MA Boston

Quench Medical Minnesota 55116 St Paul 2136 Ford Pkwy

Copernicus Therapeutics, Inc. OH 44106 Cleveland 11000 Cedar Ave #145

Spirovation NC 27599 Chapel Hill 7107 Marsico Hall, CB# 7

Molecular Diagnostics Consulting,
CA 92121 San Diego 4010 Sorrento Valley Blvd #400

HTG Molecular Diagnostics AZ 85706 Tucson 3430 E. Global Loop

GenMark Diagnostics CA 92008 Carlsbad 5964 La Place Court

BioFire Diagnostics, LLC Utah 84108 Salt Lake City 515 Colorow Drive

Molecular Pathology Laboratory TN 37804 Maryville 250 E. Broadway

Molecular Image Inc. CA 94560 Newark 39655 Eureka Drive
 610 Main Street North
KSQ Therapeutics, Inc. MA, 02139 Cambridge 4th Floor
CZ Biohub CA 94158 San Francisco 499 Illinois St

Applied StemCell, Inc.

521 Cottonwood Dr.
Applied StemCell, Inc. California 95035 Milpitas Suite #111
Desktop Genetics MA 02139 Cambridge 210 Broadway # 201

Synthego Corporation CA 94063 Silicon Valley

610 Main Street

Casebia Therapeutics Massachusetts 02139Cambridge North Building, 5th Floor

455 Mission Bay

Boulevard South
California 94158 San Francisco 3rd Floor

Applied Biological Materials - a V6V 2J5 CANADA Richmond #1-3671 Viking Way
AUM BioTech PA 19104 Philadelphia 3711 Market Street, Suite 800

Locus Biosciences, Inc. NC 27713 Kit Creek Road Research Triangle Park
Excision BioTherapeutics Inc. PA 19104 Philadelphia 3624 Market Street, Office #514

Transnetyx TN 38016 Cordova 8110 Cordova Road, Suite

eGenesis, Inc. MA 02139 Cambridge 300 Technology Square, Suite 301

Dharmacon CO 80026 Lafayette 2650 Crescent Drive, #100

Eurofins Genomics KY 40299 Louisville 12701 Plantside Dr.

Recombinetics, Inc. MN 55104 Saint Paul

Exonics Therapeutics MA 02111 Boston 75 Kneeland Street, 14th Floor

California 94720-
Innovative Genomics Institute 3370 Berkeley 2151 Berkeley Way
GeneCopoeia Maryland 20850 Rockville 9620 Medical Center Dr.,

Solentim PA 19087 Wayne 987 Old Eagle School Road

KromaTiD™ Inc. CO 80523-0922 Fort Collins 200 W. Lake St #922 (INU

iNfinitesimal IL 60077 Skokie 8025 Lamon Ave., Suite 7

Nextbiotics California 94110 San Francisco

Avectas MA 02142 Cambridge 245 First Street, Suite 1800

2600 Hilltop Drive

ALSTEM, INC CA 94806 Richmond Building B, Suite C328

Mycroarray MI 48105 Ann Arbor 5840 Interface Dr, Suite 1

Namocell CA 94043 Mountain View 2483 Old Middlefield Way,

Mirimus Inc. NY 11226 Brooklyn 760 Parkside Avenue, Sui

GenEdit CA 94720 Berkeley 130 Stanley

VectorBuilder TX 77384 Shenandoah 150 Pine Forest Drive, Sui

VectorBuilder CA 95050 Santa Clara 2255 Martin Avenue, Suit

APSIS Therapeutics, LTD. NY 12084-0954 Guilderland PO Box 954

Legomics NY 10152 New York City 375 Park Avenue, Suite 2607
The ODIN California 94607 Oakland 335 Henry St

Kytopen Corp. MA 02139-4018 Cambridge 501 Massachusetts Avenue

Somatic Biosciences California 92832 Fullerton Glenwood Ave.

 104 T. W. Alexander
Drive,
LifeEDIT NC 27709 Research Triangle Building 1

Arbele WA 98052 Redmond, 4032 148th Ave NE

TriPhos Therapeutics, Inc. CA 92124 San Diego Robusto Road

Biocodon Technologies KS 66201 Broadmoor 1006 Mission

 Massachusetts
Hunterian Medicine 02139 Cambridge 100 Pacific St,

Evolve Biotechnologies California Berkeley 2151 Berkeley Way

GENeuver California 94305 Stanford San Francisco Ct

Newlife BioChemEx LLC MD 20817 Bethesda 10411 Motor City Drive

720 Westview Dr SW
Gene Edit Biolab GA 30310 Atlanta Building C, Suite C257
Akonni Biosystems MD 21701 Frederick 400 Sagner Ave., Suite 30

9000 Virginia Manor

Road
BioServe MD 20705 Beltsville Suite 207
 27 Drydock Ave.
ORIG3N MA 02210 Boston 3rd Floor

World Trade Center East

2211 Elliott Ave., Suite
Stratos Genomics WA 98121 Seattle #210

GENeuver California 94305 Stanford San Francisco Ct

Newlife BioChemEx LLC
phone number web address e-mail
360-693-8850 https://moleculartestinglabs.com/

(520) 547-2827 https://www.htgmolecular.com/info@htgmolecular.com

1 800-242-3233 https://www.healthcare.siemens.com/molecular-diagnostics
ir.team@siemens-healthineers.com

510-982-6030 | https://cariboubio.com/ info@cariboubio.com

1-201-825-0186 https://www.admdiag.com/ info@GeneIDLab.com

1 206-598-5735 http://depts.washington.edu/molmicdx/
molmicdx@uw.edu

1-443-602-8833 http://www.personalgenome.com/
blindheim@bllbiopartners.com

8,445,224,263 http://icmdiagnostics.com/

1 678-225-0222 https://mnglabs.com/ hhuerta@mnglabs.com

1 510-839-5600 https://www.machaondiagnostics.com/
info@machaondiagnostics.com
(212) 431-4200 http://spectrumdiagnostics.com/
info@spectrumdiagnostics.com
212 972 0077 http://acuamarkdx.com/ info@acuamarkdx.com

1-512-381-4397 https://www.luminexcorp.com/cvalle@luminexcorp.com
1-408-541-4191 http://www.cepheid.com/us/ ordermanagement@cepheid.com

212-583-0100 http://enzo.com/ information@enzo.com

978-338-3045 https://www.launchworksml.com/
sales@launchworksml.com

(608) 274-4330 https://worldwide.promega.com/

techserv@promega.com

1 (858) 224-6600 https://www.invivoscribe.com/

646-699-7855 https://azurrx.com/ info@azurrx.com

1 301-496-3245 https://www.nhlbi.nih.gov/

1 949-900-5500 https://www.ambrygen.com/ info@ambrygen.com

1 (970) 987-2654 https://aridispharma.com/cystic-fibrosis/

 https://volitionrx.com/

646-685-4419 https://chimeron.com/ contact@chimeronbio.com

1 844-627-7246 https://www.massivebio.com/ support@massbio.io

(212) 489-2100 http://delcath.com/ investorrelations@delcath.com

212-461-2315 https://www.tymeinc.com/home/default.aspx
investorrelations@tymeinc.com

1-212-398-9726 http://www.toyobousa.com/index.html
info@toyobousa.com
1 (347) 915 5410 https://www.basepairtech.com/info@basepairtech.com

(650) 574-3000 http://www.gilead.com/ public_affairs@gilead.com

1 (862) 261-7000 https://www.allergan.com/home

http://www.cfcoc.com/

407 898 4427 https://hhcs.com/ care@hhcs.com

855 237 4669 http://cfri.org/ cfri@cfri.org

1 516 665 8200 http://ait-pharm.com/

800-255-5162 https://www.abbvie.com/

800-255-5162 https://www.abbvie.com/

800-255-5162 https://www.abbvie.com/

650-454-1000 https://www.abbvie.com/

650-454-1000 https://www.abbvie.com/

650-454-1000 https://www.abbvie.com/

650-454-1000 https://www.abbvie.com/

https://www.abbvie.com/
 https://www.abbvie.com/

https://www.abbvie.com/

http://www.glpg.com/ admin_bos@glpg.com

(760) 231-2440 https://www.gene.com/ https://www.gene.com/contact-us/email-us

(707) 454-1000 https://www.gene.com/ https://www.gene.com/contact-us/email-us

(650) 225-1000 https://www.gene.com/ https://www.gene.com/contact-us/email-us

(503) 992-3600 https://www.gene.com/ https://www.gene.com/contact-us/email-us

6 1796 30100 https://www.corbuspharma.com/
info@corbuspharma.com

1 (855) 328 3500 https://www.extedo.com/ info@extedo.com

781-357-2333 http://www.pulmatrix.com/index.php
info@pulmatrix.com

31 88 166 7000 http://www.proqr.com/ info@proqr.com

617-431-3600 http://www.alcresta.com/ info@alcresta.com

1 647 428 7031 http://archbiopartners.com/ info@archbiopartners.com

1 647 428 7031 http://archbiopartners.com/ info@archbiopartners.com

1 (646) 617 30 88 http://tgv-inhalonix.com/ tets@tgvlabs.com

800 793 1261 https://www.respirtech.com/

(617) 225-0096 http://www.proteostasis.com/

1-224-383-3000 https://www.horizonpharma.com/

1-224-383-3000 https://www.horizonpharma.com/

1-415-903-1400 https://www.horizonpharma.com/

1-800-236-9933 https://www.astrazeneca-us.com/
USMediateam@astrazeneca.com
 1-800-236-9933 https://www.astrazeneca-us.com/

1-800-236-9933 https://www.astrazeneca-us.com/

617-714-6500 https://www.modernatx.com/ info@modernatx.com

acturing Facility https://www.modernatx.com/ info@modernatx.com

617 401 9000 https://www.editasmedicine.com/

info@editasmed.com

1 (908) 517 7330 https://www.cyclacel.com/

(919) 313-1180 http://www.parion.com/

1 510 856 5600 http://www.anthera.com/ info@anthera.com

 http://curxpharma.com/ info@curxpharma

http://www.celtaxsys.com/ medical@celtaxsys.com

781 860 0045 https://www.concertpharma.com/

info@concertpharma.com

206 788 4545 https://www.alpineimmunesciences.com/

@AlpineImmuneSci
908-222-7000 https://www.ptcbio.com/en/ info@ptcbio.com

949-382-1308 http://www.2ctechcorp.com/ info@2ctechcorp.com

https://www.2dgenomics.com/

(650) 561-8600 http://www.3vbio.com/ businessdevelopment@3vbio.com

(919) 610-5950

857-285-6200 https://www.intelliatx.com/ bd@intelliatx.com

https://www.sangamo.com/
781-663-4400 www.bioverativ.com
ulevard, Suite 250 https://www.humanigen.com/

617-315-4600 http://www.crisprtx.com/index.php
1 650-938-6300 https://www.23andme.com/?myg=true

888-838-2872 https://www.tevausa.com/
1 805-447-1000 amgenmediarelations@amgen.com
(617) 621-8097 https://dicerna.com/

1-800-367-5109 http://www.acorda.com/ acordamc@dlss.com

go Ave. Ste 510 https://www.tempus.com/ support@tempus.com

(412)641-5558/55 http://pittgenetics.com/ PittCytogenetics@mail.magee.edu

888 979 8669 https://www.carismolecularintelligence.com/
MIclientservices@carisls.com
866 771 8946 https://www.carismolecularintelligence.com/
MIclientservices@carisls.com
1 800 892 1400 https://www.aacc.org/

440-632-5532 http://www.ddccliniclab.org/ lab@ddcclinic.org

402 323 6233 https://nceelabs.com/ info@nceelabs.com

1 (250) 744-2487 https://www.auriniapharma.com/
clinicaltrials@auriniapharma.com

http://envisiongenomics.com/ info@envisiongenomics.com
61 (03) 9620 3333 https://www.lbtinnovations.com/
info@lbtinnovations.com

(480) 809-6158 http://www.bcrbiotech.com/ info@bcrbiotech.com

1 866 92 78075 https://frylabs.com/ info@frylabs.com

602-810-0812 http://ironhorsedx.com/ manager@IronHorseDx.com

604-637-3280 http://augurex.com/
778 379 2931 https://contextualgenomics.com/
info@contextualgenomics.com

1-888-591-5577 http://responsebio.com/ customersupport@responsebio.com

510-749-4895
https://alveotechnologies.com/info@alveotechnologies.com
510 995 9000 https://www.singulex.com/

626 359 8441 https://silverlakeresearch.com/info@silverlakeresearch.com

http://www.exogenbio.com/
978-439-0120 https://www.exogenesis.us/ jdavis@exogenesis.us

510-646-1142 http://www.nodexus.com/ info@nodexus.com

(310) 824-9999 https://www.kitepharma.com/

https://www.kitepharma.com/
https://mammoth.bio/

https://beamtx.com/ info@beamtx.com
857-776-7400 http://celsiustx.com/ info@celsiustx.com

https://www.casmatx.com/ contact@casmatx.com
 https://www.cedillatx.com/ contactus@cedillatx.com

339-499-9300 https://www.bluebirdbio.com/ info@bluebirdbio.com

200 Technology Sq https://www.modernatx.com/ info@modernatx.com

(415) 801-8100 https://www.versantventures.com/

(646) 357-1286 https://www.versantventures.com/

(612) 254-1170 https://www.versantventures.com/

 (604) 424-9913 https://www.versantventures.com/

int Boulevard, 3rd Floor https://www.codabiotherapeutics.com/

ealcamo@codabiotherapeutics.com
18,583,335,280 http://www.pipelinetherapeutics.com/

https://www.tempesttx.com/# partnering@tempesttx.com
https://www.sniprbiome.com/ cg@sniprbiome.com
1 847 745 1700 http://www.idtdna.com/pages custcare@idtdna.com

1-732-885-9188 https://www.genscript.com/ gene@genscript.com

1-908-222-0711 https://www.genewiz.com/en-GB/
service.europe@genewiz.com
908-222-0533 https://www.admerahealth.com/

1-888-267-4436 https://www.origene.com/

1-909-264-1399 http://www.abnova.com/
1 858 202 4500 https://www.illumina.com/ info@illumina.com

1 800 284 8474 https://www.illumina.com/ info@illumina.com

 1 6503 769000 https://www.illumina.com/ info@illumina.com

617-649-8600 http://www.agios.com/ holly.manning@agios.com

Street, Suite 105 https://www.zymergen.com/ info@zymergen.com

1 800-635-5577 https://www.moleculardevices.com/

1-800-321-9632 http://www.perkinelmer.com/
1 877-424-4536 https://www.agilent.com/ contact_us@agilent.com

1-(206)-254-0300 http://www.halo-bio.com/ thauser@halo-bio.com

617 551 8200 http://www.alnylam.com/ medinfo@alnylam.com

206-582-1600 https://www.junotherapeutics.com/

626-304-3400 https://arrowheadpharma.com/info@arrowheadpharma.com

1-888-REGULUS (734-http://regulusrx.com/
812-355-6746 https://www.catalent.com/index.php
FOLLOW.US@CATALENTPHARMA

(858) 207-4264 http://lajollapharmaceutical.com/

info@ljpc.com

858-251-4400 https://www.herontx.com/careers-main
info@herontx.com
201-633-6473 https://www.herontx.com/careers-main
info@herontx.com

1 (617) 945-7361 https://translate.bio/

http://www.reparerx.com/ info@reparerx.com
858 345 4690 http://www.vividion.com/ information@vividion.com

973-520-2700 http://questdiagnostics.com/home/about/brands/products
617 963 0100 https://www.corbuspharma.com/about/careers
info@corbuspharma.com

1 781-235-3060 https://www.constellationpharma.com/
info@constellationpharma.com
(617) 225-0096 http://www.proteostasis.com/

408 779 1700 info@aragenbio.com

858-587-6645 http://www.allelebiotech.com/ info@allelebiotech.com

650-288-4891 https://lakepharma.com/ inquiries@lakepharma.com

435 22 .1422 https://www.elitechgroup.com/a.warren@elitechgroup.com

1 562 240 6500 http://www.diasorin.com/en/company
CS.molecular@diasorin.com

(858) 900-2660 https://arcturusrx.com/ info@ArcturusRx.com

1 (512) 961-1891 https://savarapharma.com/ ir@savarapharma.com

 http://www.a-med.com

1 919 578 4216 https://www.novabiotics.co.uk/

(415) 729-9391 https://sanovas.com/ info@sanovas.com

Circle, Ste 200 http://www.nivalis.com/

720 643 5200 http://www.miragen.com/ info@miragenrx.com

1-781-577-5300 http://www.eloxxpharma.com/matt.hazlehurst@eloxxpharma.com
(++1) 512 587-7141 http://respiratoryresearch.com/

919 899 9399 http://spyryxbio.com/

508-400-1856 http://www.enbiotix.com/

919 321 1375 https://www.novoclem.com/ info@vasttherapeutics.com

 1-858-257-2122 https://progenesis.com/ info@progenesis.com
https://www.progenity.com/

Village Drive Suite 200 https://www.progenity.com/

512-326-3244 http://www.afflovest.com/ info@biophysicscorp.com

 (801) 396-3590 http://www.curza.com/Home
y, 14th floor http://www.curza.com/Home

855-790-0100 http://chemistryrx.com/ info@chemistryrx.com

(855) 373-2580 http://www.frdspecialtyrx.com/

 http://www.laurentpharma.com/
info@laurentpharma.com

215 239 6271 http://taleebio.com/ info@taleebio.com

https://www.onspiratx.com/
614-915-0865 http://proclarx.com/ info@proclarx.com

614 761 3555 http://monitoredrx.net/ info@MonitoredRX.com

(305) 882-1051 http://cbslaboratory.com/

(781) 235-3060 https://www.synspira.com/ info@synspira.com

http://quenchmedical.net/ beverlin@quenchmedical.net
1 (216) 534-6164 http://cgsys.com/ rmoen@cgsys.com

919 452 1631 http://www.spirovation.com/ tony.church@spirovation.com

o Valley Blvd #400 http://moleculardiagnosticsconsulting.com/about-us.php

(877) 507-3259 https://www.htgmolecular.com/support@htgmolecular.com

1 760.448.4300 https://www.genmarkdx.com/ info@genmarkdx.com

1-801-736-6354 https://www.biofiredx.com/ info@biofiredx.com

865 380 9746 http://www.mplnet.com/ services@mplnet.com

http://www.molecularimage.com
617-674-9150 https://ksqtx.com/ info@ksqtx.com
 https://www.czbiohub.org/ info@czbiohub.org

1-866-497-4180 https://www.appliedstemcell.com/
 https://www.deskgen.com/landing/
info@deskgen.com

https://www.synthego.com/

857-270-5100 https://casebia.com/

650-410-3071 https://casebia.com/

1-866-757-2414 https://www.abmgood.com/ info@abmGood.com

Street, Suite 800 http://www.aumbiotech.com/ customercare@aumbiotech.com

(919) 313-9648 https://www.locus-bio.com/ info@locus-bio.com

Street, Office #514 https://excisionbio.com/ info@excisionbio.com

888-321-2113 http://www.transnetyx.com/
gy Square, Suite 301 https://www.egenesisbio.com/ info@egenesisbio.com

800-235-9880 (Optionhttps://dharmacon.horizondiscovery.com/
cs.dharmacon@horizondiscovery.com
1-800-688-2248 https://www.eurofinsgenomics.com/en/home/
GenomicsSupport@eurofins.com

651-757-0427 http://www.recombinetics.com/kris.huson@recombinetics.com
treet, 14th Floor http://exonicstx.com/ Info@ExonicsTx.com

https://innovativegenomics.org/igi-info@berkeley.edu
1-301-762-0888 https://www.genecopoeia.com/support@genecopoeia.com

617-715-6927 https://www.solentim.com/ support@solentim.com

303-775-1512 http://www.kromatid.com/ info@kromatid.com

(224) 251-8192 http://infinitesimal-llc.com/ infinitesimal@infinitesimal-llc.com

https://www.next-biotics.com/ info@next-biotics.com
et, Suite 1800 https://www.avectas.com/

(510) 708-0096 http://www.alstembio.com/ info@alstembio.com

1 734-998-0751 http://www.mycroarray.com/ info@arborbiosci.com

(650) 386-6878 https://www.namocell.com/ info@namocell.com

(929) 377-3744 https://www.mirimus.com/ info@mirimus.com

http://www.genedit.com/ info@genedit.com
 408-649-5280 https://en.vectorbuilder.com/ service@vectorbuilder.com

(800) 517-2189 https://en.vectorbuilder.com/ service@vectorbuilder.com

http://www.apsisglobal.com/ info@apsisglobal.com

nue, Suite 2607 http://www.legomics.com/

 (707) 879-8635 http://www.the-odin.com/

usetts Avenue https://kytopen.com/ team@kytopen.com

(847)-445-2231 https://www.somaticbiosciences.com/
 http://lifeeditinc.com/ http://lifeeditinc.com/contact/

(452) 628 - 2800 http://www.arbele.org/ info@arbele.org

8587408336 http://www.triphosthera.com/ Scott@TriPhosThera.com

http://www.biocodon.com/ info@biocodon.com
 https://www.hunterian.com/ info@hunterian.com

https://www.evolvebiotech.com/
ShakkedHalperin@gmail.com

http://www.geneuver.com

http://www.nlbiochemex.com/

1-800-398-8514 http://geneeditbiolab.com/ service@geneeditbiolab.com

(301) 698-0101 https://akonni.com/ info@akonni.com

1-800-405-3 (3362) https://www.bioserve.com/ info@bioserve.com

 8,009,136,351 https://orig3n.com/

(206) 448-7961 x103 https://www.stratosgenomics.com/

info@stratosgenomics.com

http://www.geneuver.com/
activitiy c.suite leaders and titles1 c.suite leaders and titles2

pharmacogenetic, toxicology, and infectious diDave DeLong | Head of Finance | HMegan Callahan | General Co

Shaun D. McMeans
Vice President of Finance,
Timothy (TJ) B. Johnson Administration and Chief
a provider of instruments, reagents, and servicChief Executive Officer Financial Officer

enables precision medicine, with molecular tesDr. Bernd Montag CEO Dr. Jochen Schmitz CFO

Rachel Haurwitz, Ph.D. Barbara McClung, J.D.

President and Chief Executive Chief Legal Officer and
CRISPR-Cas genome editing Officer Corporate Secretary

Dr. Pablo Umansky Dr. Daniel Cohen

provides the highest quality molecular testing Chief Executive Officer Laboratory Director

Brad T. Cookson M.D., Ph.D Karen Stephens Ph.D

provide highly accurate, rapid and sensitive Director Associate Director,

developing a portfolio of regulated tissue-bas Dr. Samuel Angiuoli CIO Megan Bailey VP

Dr. Adnan Khan is the medical Dr. Thomas Huebner is a

director of Integrated Cellular and board-certified, fellowship-
provides comprehensive anatomic, clinical, an Molecular Diagnostics trained pathologist

Terry Conrad Peter L. Nagy, MD, PhD

offers a comprehensive selection of complex biPresident/Chief Executive Officer Chief Medical Officer

Brad Lewis, MD
Michael Ero Dr. Lewis is the Medical
Mr. Ero is the president and CEO of Director of Machaon
clinical reference laboratory, specializing in Machaon Diagnostics Diagnostics

provide medical practitioners with the analytical tools and information needed to administer superior treatment options
 BERNARD PEPERSTRAETE
FOUNDER & CHIEF
FRANCIS BARANY EXECUTIVE
develops technology which allows for highly acFOUNDER & LEAD INVENTOR President/CEO;

Harriss T. Currie
Nachum “Homi” Shamir Chief Financial Officer,
President and Chief Executive Senior Vice President,
Technologies serve a wide range of clinical applOfficer Finance and Treasurer

improve patient outcomes by enabling access to molecular diagnostic testing

Barry W. Weiner
Elazar Rabbani, Ph.D. President, Chief Financial
Chairman of the Board of Directors Officer, Principal Accounting
& Chief Executive Officer Officer and Director
focused on harnessing genetic processes to de

A Molecular Diagnostics CMO -

Assays to measure apoptosis, viability,

cytotoxicity and inflammation

PCR
Reagents and kits for PCR, qPCR and RT-qPCR

Genetic Identity
Complete solutions for DNA typing, from
sample prep to STR amplification

Scientific Articles
Read about the latest technologies and
product applications

DNA Purification and Quantitation

Adaptable purification chemistries for many
sample types and throughput needs

JEFFREY EDWARD MILLER, PH.D.

Founder, Chief Scientific Officer, MEGHNA BHATNAGAR
developing and manufacturing diagnostic pro Chief Executive Officer & Chairman Chief Financial Officer
 Thijs Spoor Daniel Dupret
focused on the development of recombinant pro
President PhD, Chief Scientific Officer

Understand normal biological function and

resilience
Investigate newly discovered pathobiological
mechanisms important to the onset and
progression of HLBS diseases
Investigate factors that account for
differences in health among populations
Identify factors that account for individual
differences in pathobiology and in responses
to treatments
Develop and optimize novel diagnostic and
therapeutic strategies to prevent, treat, and
cure HLBS diseases
Optimize clinical and implementation
research to improve health and reduce
disease
Leverage emerging opportunities in data
science to open new frontiers in HLBS
research
Further develop, diversify, and sustain a Robert S. Balaban, Ph.D.
scientific workforce capable of accomplishing Gary H. Gibbons Division of Intramural
the NHLBI’s mission NHLBI DIRECTOR Research (DIR)
2012 - Present Director, 2013 - Present

Kiyotaka Fujii
President, Global Healthcare,
Konica Minolta & Chairman, AARON ELLIOTT, PH.D.
give healthcare providers the most advanced te
Ambry Genetics Chief Executive Officer

Vu L. Truong, Ph.D. Wolfgang Dummer, M.D.,

Founder, Chief Executive Officer Ph.D.
a biopharmaceutical company focused on the and
de Director Chief Medical Officer
 Jake Micallef
Jake is an experienced
Cameron Reynolds scientist with expertise in
Cameron is an experienced research and development
entrepreneurial executive, with and in the management of
expertise in biotechnology early stage biotechnical
As cancer screening programs become more and
companies.
mo companies.

Jolly Mazumdar, Ph.D.,

Jolly Mazumdar, Ph.D., M.B.A. M.B.A.
Chimeron Bio is committed to discovering and Chief Executive Officer Chief Executive Officer

Dr. Arturo Loaiza-Bonilla

Selin Kurnaz, PhD Co-founder and Chief
provide customized, evidence-based cancer treLead-founder and CEO Medical Advisor

John Purpura

Executive Vice President - Global Alexander M. M. Eggermont,

Delcath Systems, Inc. is a specialty pharmace Operations MD, PhD

STEVEN HOFFMAN Co-Founder, MICHAEL DEMURJIAN Co-

Chief Executive, and Chief Science Founder and Chief Operating
Tyme Inc. is a clinical-stage biotechnology co Officer Officer

Toyobo is a leading manufacturer of enzymes aChairman- Ryuzo Sakamoto President - Seiji Narahara
 Josh Setton
Amit Sinha, PhD Business Development
Founder
Josh is a biotech major and
Amit is a computational biologist excels at driving growth at
with a decade of expertise. Before early-stage startups. He
starting Basepair he was an leads the business
Instructor at Harvard Medical development, customer
Basepair develops SaaS to manage, analyze and
School. success and support.

John F. Milligan, PhD

President and Chief Executive Gregg H. Alton
Gilead Sciences, Inc. is a research-based bio Officer Chief Patient Officer

CHAIRMAN, PRESIDENT AND

CEO, ALLERGAN
Brenton L. Saunders
Brent Saunders is Chairman,
President and Chief
Executive Officer of Allergan
plc. Mr. Saunders has served
as a Director, CEO and
Allergan plc (NYSE: AGN) is a bold, global ph https://www.allergan.com/home President since July 2014.

CFCOC works with healthcare providers, facilities, and businesses to develop products, services, programs, and training that he

Lois Adams, founder, president

and CEO of Cystic Fibrosis
Pharmacy, Freedom Pharmacy and
fill outpatient prescriptions, plus scripts for HHCS Health Group, Inc

Jessica Martens, Board Vice

Cystic fibrosis (CF) is a rare genetic, chronic Bill Hult, Board President President

Amir Avniel
Steve Lisi President and Chief
In 2011, Advanced Inhalation Therapies (AIT) wCEO and Chairman of the Board Operating Officer
 Laura J. Schumacher
Executive Vice President,
Richard A. Gonzalez External Affairs, General
Chairman of the Board and Chief Counsel and Corporate
We target specific difficult-to-cure diseases w Executive Officer Secretary

Laura J. Schumacher
Executive Vice President,
Richard A. Gonzalez External Affairs, General
Chairman of the Board and Chief Counsel and Corporate
We target specific difficult-to-cure diseases w Executive Officer Secretary

Laura J. Schumacher
Executive Vice President,
Richard A. Gonzalez External Affairs, General
Chairman of the Board and Chief Counsel and Corporate
We target specific difficult-to-cure diseases w Executive Officer Secretary

Laura J. Schumacher
Executive Vice President,
Richard A. Gonzalez External Affairs, General
Chairman of the Board and Chief Counsel and Corporate
We target specific difficult-to-cure diseases w Executive Officer Secretary

Laura J. Schumacher
Executive Vice President,
Richard A. Gonzalez External Affairs, General
Chairman of the Board and Chief Counsel and Corporate
We target specific difficult-to-cure diseases w Executive Officer Secretary

Laura J. Schumacher
Executive Vice President,
Richard A. Gonzalez External Affairs, General
Chairman of the Board and Chief Counsel and Corporate
We target specific difficult-to-cure diseases w Executive Officer Secretary

Laura J. Schumacher
Executive Vice President,
Richard A. Gonzalez External Affairs, General
Chairman of the Board and Chief Counsel and Corporate
We target specific difficult-to-cure diseases w Executive Officer Secretary

Laura J. Schumacher
Executive Vice President,
Richard A. Gonzalez External Affairs, General
Chairman of the Board and Chief Counsel and Corporate
We target specific difficult-to-cure diseases w Executive Officer Secretary
 Laura J. Schumacher
Executive Vice President,
Richard A. Gonzalez External Affairs, General
Chairman of the Board and Chief Counsel and Corporate
We target specific difficult-to-cure diseases w Executive Officer Secretary

Laura J. Schumacher
Executive Vice President,
Richard A. Gonzalez External Affairs, General
Chairman of the Board and Chief Counsel and Corporate
We target specific difficult-to-cure diseases w Executive Officer Secretary

Onno van de Stolpe - Chief Piet Wigerinck, Ph.D. - Chief

Galapagos (Euronext & NASDAQ: GLPG) is a clini
Executive Officer Scientific Officer

Sandra J. Horning, M.D.

Executive Vice President,
Bill Anderson Global Development and
Genentech engages in research, development,Chief
m Executive Officer Chief Medical Officer

Sandra J. Horning, M.D.

Executive Vice President,
Bill Anderson Global Development and
Genentech engages in research, development,Chief
m Executive Officer Chief Medical Officer

Sandra J. Horning, M.D.

Executive Vice President,
Bill Anderson Global Development and
Genentech engages in research, development,Chief
m Executive Officer Chief Medical Officer

Sandra J. Horning, M.D.

Executive Vice President,
Bill Anderson Global Development and
Genentech engages in research, development,Chief
m Executive Officer Chief Medical Officer
 Mark A. Tepper, Ph.D.
President & Chief Scientific
Officer
Mark A. Tepper, Ph.D., co-
founded the Company in
2009. He has more than
Yuval Cohen, Ph.D. twenty years of leadership
Chief Executive Officer, Director experience in
Yuval Cohen, Ph.D., joined Corbus pharmaceutical R&D and his
in July 2013 as Chief Executive past roles include leadership
Officer. Prior to joining Corbus, he positions at Bristol Myers
was the President and co-founder Squibb, Serono, CytRx, RXi
of Celsus Therapeutics (Nasdaq Pharmaceuticals and NKT
Corbus Pharmaceuticals Holdings, Inc. is a PhaCLTX) from 2005 to June 2013. Therapeutics.

Maximilian Munte,
Managing Director
Maximilian Munte joined
Martin Schmid, Managing Director EXTEDO in February 2013 as
Martin Schmid joined EXTEDO in Managing Director. He
October 2010 as Managing shares the global
Director to head the global management responsibilities
The EXTEDOsuite supports the critical relation Marketing and Sales Department. with Martin Schmid.

Robert Clarke, PhD David Hava, PhD

At Pulmatrix, we are developing innovative inhChief Executive Officer Chief Scientific Officer

ProQR, a company on a mission to create

new medicines for patients in need. We focus Daniel de Boer is our founding
on a group of diseases called rare diseases, Chief Executive Officer since our René Beukema is our Chief
with a very high need for new medicines. Out incorporation in 2012. Daniel is a Corporate Development
of the approximately 7,000 rare diseases, less passionate and driven Officer and General Counsel.
than 400 have a treatment, and we intend to entrepreneur and advocate for CF René joined us in September
change that. To treat these diseases we use patients, and has assembled an 2013 and is a seasoned in-
RNA therapies, a technology that allows us to experienced team of successful house corporate lawyer in
address inherited diseases that are caused by biotech executives as co-founders the Dutch biotechnology
a genetic defect. and early investors. arena.
 Eric R. First, M.D.
Daniel Tassé Chief Scientific Officer
Chairman and Chief Executive
Officer Eric R. First, M.D., is Chief
Scientific Officer at Alcresta
Daniel Tassé is Chairman and CEO Therapeutics. He has over
Alcresta Therapeutics is dedicated to helping of Alcresta Therapeutics. An 20 years of executive
patients, caregivers, practitioners, and other accomplished healthcare experience across the
stakeholders fulfill their potential. executive, Daniel has built and led pharmaceutical,
businesses with global footprints biotechnology, consumer
We each bring unique experiences and in the fields of bio- health, medical device, and
expertise, but we all share a set of values pharmaceuticals, medical devices, food & nutrition industries.
that define our company: diagnostics, and health services Across these sectors,

Andrew Bishop
Acting Chief Financial
Officer, Director
Mr. Bishop is a Partner and
Richard Muruve Co-Founder of Bingley
CEO, Director, Co-founder Capital Inc., and brings over
Mr. Muruve co-founded Arch 20 years of experience in
Biotech Inc. with the Arch advising biotech and health
Arch Biopartners Inc. is focused on the developInflammation team in 2006. care companies

Andrew Bishop
Acting Chief Financial
Officer, Director
Mr. Bishop is a Partner and
Richard Muruve Co-Founder of Bingley
CEO, Director, Co-founder Capital Inc., and brings over
Mr. Muruve co-founded Arch 20 years of experience in
Biotech Inc. with the Arch advising biotech and health
Arch Biopartners Inc. is focused on the developInflammation team in 2006. care companies
The TGV-inhalonix is a biopharmaceutical
company that is focused on the development
of a first-in-classantibiotic to address unmet
needs in lung infectious disease in cystic
fibrosis patients in particular.

In addition to our drug development

programs focused on cystic fibrosis, TGV- Victor Tetz, MD, Ph.D George Tetz, MD, Ph.D
inhalonix has ongoing research programs Dr. Tetz serves as Scientific Advisor Dr. George Tetz serves as a
aimed at other life-threatening respiratory and is responsible for the strategic CEO and Senior Director
infections. planning for TGV-inhalonix. Clinical Development

dedicated to improving the quality of life for

those living with respiratory complications.
It’s our singular focus, and a commitment
shared by each of us at RespirTech. That
same commitment and vision inspired
Warren Warwick, M.D., and Lee Hansen,
MPH, to develop the technology for children
with Cystic Fibrosis at the University of Dr. Jim Ehlen Dr.
Minnesota. Jim Ehlen is CEO of RespirTech

Marija Zecevic, Ph.D.

Chief Operating Officer

Meenu Chhabra Dr. Zecevic has been serving

President and Chief Executive as our Chief Operating
Officer Officer since February 2018,
Proteostasis Therapeutics is an innovative having served previously as
biopharmaceutical company committed to Ms. Chhabra has been serving as Chief Business Officer
the discovery and development of novel our President and Chief Executive (March 2017 to February
therapeutics to treat diseases caused by an Officer and a member of our 2018) and Vice President of
imbalance in the Proteostasis Network (PN). board of directors since May 2014. Business Development
 Timothy P. Walbert
Chairman, President and Chief
Executive Officer Robert F. Carey
Tim joined Horizon Pharma in June Executive Vice President,
2008 as president and chief Chief Business Officer
executive officer and has served as Bob joined Horizon Pharma
chairman of our board of directors in March 2014 as chief
build a growing pipeline and explore all potentsince 2010. business officer.

Timothy P. Walbert
Chairman, President and Chief
Executive Officer Robert F. Carey
Tim joined Horizon Pharma in June Executive Vice President,
2008 as president and chief Chief Business Officer
executive officer and has served as Bob joined Horizon Pharma
chairman of our board of directors in March 2014 as chief
build a growing pipeline and explore all potentsince 2010. business officer.

Timothy P. Walbert
Chairman, President and Chief
Executive Officer Robert F. Carey
Tim joined Horizon Pharma in June Executive Vice President,
2008 as president and chief Chief Business Officer
executive officer and has served as Bob joined Horizon Pharma
chairman of our board of directors in March 2014 as chief
build a growing pipeline and explore all potentsince 2010. business officer.

Ruud Dobber, Ph.D President, Christie Bloomquist Vice

AstraZeneca US and Executive Vice President, Corporate Affairs,
President, Government Affairs
industry-leading innovation across our main North America North America
 Ruud Dobber, Ph.D President, Christie Bloomquist Vice
AstraZeneca US and Executive Vice President, Corporate Affairs,
President, Government Affairs
industry-leading innovation across our main North America North America

Ruud Dobber, Ph.D President, Christie Bloomquist Vice

AstraZeneca US and Executive Vice President, Corporate Affairs,
President, Government Affairs
industry-leading innovation across our main North America North America

Stéphane Bancel, Chief Executive Stephen Hoge, M.D.,

We are pioneering a new class of medicines ma
Officer President

Stéphane Bancel, Chief Executive Stephen Hoge, M.D.,

We are pioneering a new class of medicines ma
Officer President

What if we could repair broken genes?

What if we could address the root cause of
diseases caused by mutations in our DNA?
That’s what the team at Editas Medicine is Katrine Bosley Charles Albright, Ph.D.
striving to achieve Chief Executive Officer Chief Scientific Officer

Paul McBarron
Spiro Rombotis Executive Vice President,
President and Chief Executive Finance and Chief Operating
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC,Officer Officer and Secretary

Paul Boucher, MBA, President & Karl Donn PhD, VP

Parion Sciences is a development stage compan
CEO Pulmonary Development

May Liu • Senior Vice President,

Finance and Administration Paul F. Truex • Executive
May joined Anthera in April 2007 Chairman
as the Director of Finance, Mr. Truex currently serves as
assumed the role of Corporate the Executive Chairman of
Controller in October 2007, the Board. Previously, he
became Vice President of Finance served as Director and Chief
in January 2011, and is currently Executive Officer since the
Senior Vice President of Finance inception of Anthera in 2004
Anthera Pharmaceuticals is a biopharmaceuticsince May 2015. through 2016
 Patrick Flume, MD Felix Ratjen, MD, FRCP(C)

Professor of Medicine and Division Chief Respiratory

Pediatrics and Director of the and HE Sellers Chair in Cystic
Cystic Fibrosis Center, Medical Fibrosis, Hospital for Sick
University of South Carolina, Children, University of
CURx Pharmaceuticals is a specialty pharmaceCharleston Toronto, Toronto

Eric Springman
Greg Duncan Chief Scientific Officer
President and CEO Dr. Springman joined
Greg Duncan is the President and Celtaxsys in 2009 from Locus
Chief Executive Officer of Pharmaceuticals, where he
Celtaxsys, Inc. He was most held several positions of
recently Executive Vice President increasing responsibility
and President of North American including Head of Discovery
Operations for Brussels based and Technologies and Head
Celtaxsys is a clinical-stage pharmaceutical de specialty pharma UCB. of Development.

Roger Tung, Ph.D.

Co-Founder, President and CEO
Roger D. Tung, Ph.D. is our co-
founder and has served as our
President and Chief Executive Marc Becker
Officer and as a member of our Chief Financial Officer
board of directors since April Mr. Becker has served as our
2006. Chief Financial Officer since
At Concert Pharmaceuticals, we are pioneeringCo-Founder, President and CEO January 2018.
PTC is a science-led, global
biopharmaceutical company focused on the
discovery, development and
commercialization of clinically-differentiated
medicines that provide benefits to patients Neil Almstead, Ph.D. |
with rare disorders. Founded 20 years ago, Executive Vice President,
PTC Therapeutics has successfully launched Research, Pharmaceutical
two rare disorder products and has a global Operations & Technology
commercial footprint. This success is the Stuart W. Peltz, Ph.D. founded PTC Neil Almstead, Ph.D.
foundation that drives investment in a robust Therapeutics, Inc. in 1998 and has In his role as Executive Vice
pipeline of transformative medicines and served as Chief Executive Officer President, Neil Almstead,
PTC's mission to provide access to best-in- and a member of the board of Ph.D. is responsible for all
class treatments for patients who have an directors since the company's the discovery research to
unmet medical need. inception. fuel PTC’s robust pipeline.

Jim Taylor Robert Armstrong

2C Tech intends to validate and develop the poChief Executive Officer Chief Financial Officer

PRANAV PATEL AREK BIBILLO

CEO, President and Co-Founder CTO and Co-Founder
Pranav has served as Chief Arek is a CTO and co-
Executive Officer and President of founder of 2D Genomics. He
2D Genomics since its founding in has more than 20 years of
Fundamentally NEW Platform Based on 2Dzyme:
2016. experience in NGS industry.

William McCulloch, MB,

George Kemble, PhD ChB, FRCP, FFPM
Chief Executive Officer, Chief Chief Medical Officer
Scientific Officer Dr. McCulloch (Bill) practiced
Dr. Kemble joined 3-V Biosciences medicine for seven years in
in August 2011 as its Chief the U.K., including post-
Scientific Officer and was graduate training in Internal
promoted to Chief Executive Medicine, Hematology and
Officer in October 2015. Oncology, before joining the
Chief Executive Officer, Chief international pharmaceutical
We are a clinical-stage pharmaceutical company
Scientific Officer industry in 1984.
Praeteo is developing prophylactic therapies
for surgical and critical care patients. Its lead
candidate is an intravenous formulation to
protect against the development of acute
kidney injury (AKI) following cardiac surgery.

John Leonard, M.D. Thomas Barnes, Ph.D.

President and Chief Executive Senior Vice President,
Developing curative genome editing treatments
Officer
t Innovative Sciences

STÉPHANE BOISSEL
SANDY MACRAE, M.B., CH.B., Executive Vice President,
PH.D. Corporate Strategy
Chief Executive Officer CLOSE
CLOSE Mr. Boissel is an experienced
Sandy Macrae, M.B., Ch.B., Ph.D., biotech professional who
has served as Sangamo’s President brings over 25 years of
and Chief Executive Officer and as leadership experience across
a member of the Board of corporate finance, strategy
Accelerating toward the future of new genomicDirectors since June 2016. and business development.

At Bioverativ, a Sanofi company, we are dedicated to transforming the lives of people with hemophilia, cold agglutinin disease a
 Tarek Sahmoud, MD, PhD

Chief Medical Officer

25+ years oncology drug

development, medical,
regulatory affairs experience
Novartis CAR-T clinical
Greg Jester development consultant;
former Novartis VP, Senior
Chief Financial Officer Global Clinical Program
Head (oncology); senior
Decades of financial, operational development roles at
and entrepreneurial experience in Celgene, Bristol-Myers
life sciences Squibb and Boehringer-
Vice president, finance, for Ingelheim
privately held Tris Pharma, Inc Registered Arimidex,
CFO roles at private and publicly Afinitor; responsibility for
owned pharmaceutical companies, Kymriah, Yervoy, Abraxane,
Humanigen is repositioning and developing itsincluding Alvogen and Innovive marizomib, dasatinib

DR. RODGER NOVAK

Co-founder and President
Dr. Rodger Novak co-
founded CRISPR
DR. SAMARTH KULKARNI Therapeutics together with
Chief Executive Officer Emmanuelle Charpentier
and Shaun Foy. He is an
Dr. Samarth Kulkarni has experienced pharmaceutical
significant expertise in strategy and biotechnology executive
and operations in biotech and a and former University
wide range of related cutting-edge Professor at the Vienna
CRISPR Therapeutics is focused on the developtherapeutic technologies Biocenter in Austria.
You are made of cells. And the cells in your
body have 23 pairs of chromosomes. Your
chromosomes are made of DNA, which can
tell you a lot about you. Explore your 23 pairs
today.

Find out what your 23 pairs of chromosomes

can tell you.

Kåre Schultz
President & CEO Iris Beck-Codner
Share on Facebook Share on Executive Vice President,
LinkedIn Share on Twitter Global Brand &
Communications
Kåre Schultz Share on Facebook Share
on LinkedIn Share on
Twitter
Kåre Schultz became Teva's
President and CEO on November Iris Beck-Codner
1, 2017. Mr. Schultz, 56, is a
seasoned veteran in the
healthcare industry who has Ms. Beck-Codner became
distinguished himself through his Executive Vice President,
experience leading financial and Global Brand &
restructuring initiatives at global Communications in
Teva is working every day to make quality healcompanies. November 2017.
 Robert A. Bradway
Chairman and Chief
Executive Officer
Victoria H. Blatter Robert A. Bradway is
Senior Vice President, U.S. Amgen's chairman and chief
Government Affairs executive officer. Bradway
As senior vice president, U.S. became chairman in January
Government Affairs, Victoria H. 2013 and chief executive
Blatter is responsible for federal officer in May 2012.
and state legislative issues and Bradway served as the
managing relationships with U.S. company's president and
agencies, legislatures, and chief operating officer from
governmental administrations. She May 2010 to May 2012, and
is also responsible for international was appointed to the Amgen
lobbying and diplomacy in Board of Directors in
At Amgen, we believe in a “biology first” appr Washington, D.C. October 2011.
 DOUGLAS M. FAMBROUGH III,
PH.D. BOB D. BROWN, PH.D.
President and Chief Executive Chief Scientific Officer,
Officer Senior Vice President
Douglas M. Fambrough, Ph.D., co- Bob Brown, Ph.D., joined
founded Dicerna in 2007 and has Dicerna as senior vice
served as the Company’s chief president, research in 2008.
executive officer since 2010. Prior Prior to joining Dicerna, he
to joining Dicerna as CEO, Doug had a long career at Genta,
specialized in financing innovative where he was vice
life science technology companies president, research and
as a general partner with Oxford technology and had more
Bioscience Partners, a Boston- than 75 issued patents and
Dicerna is working to improve the lives of peopbased venture capital firm. patent applications.

its simplest, biotechnology is technology

based on biology - biotechnology harnesses
cellular and biomolecular processes to
develop technologies and products that help
improve our lives and the health of our
planet. We have used the biological
processes of microorganisms for more than
6,000 years to make useful food products,
such as bread and cheese, and to preserve
dairy products. Ron Cohen, M.D. Burkhard Blank, M.D.
President & Chief Executive Officer Chief Medical Officer
 ERIC LEFKOFSKY KEVIN WHITE, PHD

Founder & CEO President

Eric Lefkofsky is the founder and Dr. Kevin White serves as

CEO at Tempus, a leading provider President at Tempus, where
of technology enabled precision he oversees the scientific
Tempus is a technology company that has builtmedicine
t solutions. operation.

PRENATAL TESTING
chromosome analysis
FISH Analysis
microarray analysis
Preimplantation Genetic Screening
POSTNATAL AND ADULT TESTING
chromosome analysis
FISH Analysis
microarray analysis
PRODUCTS OF CONCEPTION TESTING
chromosome analysis
FISH analysis
microarray analysis
ONCOLOGY TESTING
Testing for Hematology Disorders
chromosome analysis
FISH analysis
microarray analysis
disease-specific testing approaches
Testing for Solid Tumors Svetlana A. Yatsenko, MD
SPECIMEN REQUIREMENT Aleksandar Rajkovic, M.D., Ph.D. Director of the Pittsburgh
CYTOGENETICS REQUISITION FORMS Medical Director of the Cytogenetics Laboratory
constitutional analysis Cytogenetics Laboratory Associate Professor of
oncology analysis Professor of OB/GYN & Pathology, OB/GYN &
RESIDENT AND FELLOW TRAINING Reproductive Sciences Reproductive Sciences

Personalize treatment options and uncover novel molecular insights through comprehensive interrogation of important DNA, R
Personalize treatment options and uncover
novel molecular insights through
comprehensive interrogation of important
DNA, RNA and Proteins. Research studies
continue to demonstrate the clinically utility
and actionability of multi-platform profiling
with Caris Molecular Intelligence. Enhance
R&D innovation and maximize commercial
value with advanced and comprehensive
molecular insights that can be customized to
your needs.

The American Association for Clinical Chemistry (AACC) is a global scientific and medical professional organization dedicated to

Baozhong (Bao) Xin, PhD,

Technical Director

Heng Wang, MD, PhD, Laboratory Dr. Xin has a PhD in

Director molecular biology from the
University of Hong Kong. He
Dr. Wang serves as Medical completed his post-doctoral
an internationally recognized leader for Director of DDC Clinic and fellowship in Cancer
diagnosis, treatment and research of many Laboratory Director of DDC Clinic Genetics at Case Western
complex disorders. Molecular Diagnostic Laboratory. Reserve University.

Pre-Compliance Pre-Scans EMC Testing

EMC Compliance Testing
Product Safety Testing
Environmental Testing AARON STEGGS
Non-Destructive X-ray Testing STEVE CASS ENVIRONMENTAL TEST
Product Certification GENERAL MANAGER MANAGER
Aurinia is a clinical stage biopharmaceutical
company focused on developing and
commercializing therapies in disease areas of
high unmet medical need. We are currently
developing voclosporin, an investigational Richard M. Glickman, L.L.D. (Hon) Neil Solomons, M.D.
drug, for the treatment of lupus nephritis CEO & Chairman of the Board Chief Medical Officer
(LN) and focal segmental glomerularsclerosis
(FSGS). Additionally, we are advancing Richard M. Glickman, L.L.D. (Hon) Neil Solomons, M.D.
voclosporin ophthalmic solution (VOS), a Dr. Glickman presently serves as Neil co-founded privately-
topic formulation, for the treatment of dry the Company’s CEO and Chairman held Aurinia
eye syndrome (DES). of the Board. Pharmaceuticals in 2012.

Help clinicians and healthcare providers Jill Tapper, MHA, CG

diagnose rare disease, end diagnostic (ASCP)CM
odysseys or reverse misdiagnoses through Founder | Chief Operating
integration of the practice of genomic Grace Terrell MD, MMM Officer & Vice President of
medicine when and how they need it. President & CEO Medical Genomics
Provide partner organizations with the
clinical end-to-end expertise, infrastructure Dr. Grace Terrell is CEO of Envision Ms. Tapper has over 15
and resources necessary to implement and Genomics, a company helping years of experience directing
deploy cutting edge, market differentiating clinicians diagnose rare disease the operations of clinical
clinical genomic services. through the integration of genetics laboratories and
Support practicing preventative care. genomic data into clinical care. programs.
Following the success of MicroStreak, LBT
has developed a second breakthrough
technology that automates the next stage of
the microbiology workflow: the reading of
culture plates after incubation. The
Automated Plate Assessment System CATHERINE COSTELLO
(APAS®), which performs image capture, BRENT BARNES CHAIRMAN
analysis and interpretation of culture plates, CHIEF EXECUTIVE OFFICER AND Kate Costello was in
has attracted broad interest from diagnostic MANAGING DIRECTOR management with a
companies and microbiologists around the After beginning his career with commercial law firm before
world. The technology is currently being global defence contractor Thales, establishing Governance
commercialised in a joint venture with Brent spent 11 years gaining broad Matters, a management
Zurich-based Hettich AG Switzerland, with Senior Executive experience in a consultancy firm specialising
commercial manufacturing of the first plate- variety of roles with Australian in corporate governance
reading instrument due to commence in medical device manufacturer practices and board
2016. Cochlea... performance.

Boris Rotman, Ph.D. Chief

Scientific Officer
Founder of BCR Diagnostics, Inc.,
The BCR-30-min BI™ is the first rapid BI that Dr. Rotman has done basic and Daniel J. Sussman, Ph.D.
perfectly matches CDC’s definition of an ideal applied research in the fields of Dr. Sussman joined BCR
monitoring system. Simple Technology Biochemistry, Cellular Diagnostics in December,
Could Reduce Cost of Fluorescence-based Immunology, and Molecular 2011 as Vice President for
Instrumentation by More than Five-fold Biology. Research and Development.

STEPHEN E. FRY, M.S., M.D. – THE

FOUNDER
In addition to being the Founder,
Director, and Principal Investigator
of our laboratory, Stephen E. Fry,
M.S., M.D., was previously a
We are committed to understanding chronic General Practitioner based in
diseases and contributing to their cure Scottsdale. Dr. Fry first became
through advancements in diagnostics and interested in autoimmune diseases
basic science research with emphasis on in 1992, after seeing the
chronic inflammatory diseases, vector-borne debilitating effects that these
diseases, and their intersection diseases can have on patients.
 Gerry Shaw, Ph.D.
ALS DIAGNOSTIC Co-Founder and VP of
ALS is currently clinically diagnosed by ruling Product Development
out all other diseases that may cause Dr. Shaw is also Founder and
symptoms similar to those presented by the President of EnCor
patient. Iron Horse is developing the first Biotechnology Inc., a
diagnostic test for ALS that will rapidly Robert Bowser, Ph.D. successful company that
determine if someone has the disease. Iron President specializes in the generation
Horse is also developing markers of disease Dr. Bowser developed the protein and sale of antibodies for
progression that will be useful to monitor signatures for both the ALS research purposes to
disease progression and drug treatments diagnostic test and the ALS scientific investigators and
during clinical trials prognostic test. many other companies

Douglas B. Buchanan, B.Sc.,

M.Sc., MBA, Director,
LifeLabs Medical Laboratory
Services
Augurex is a collaboration-driven, biomarker-
evidence based biotechnology company. Douglas Buchanan Following
Privately held, we began our research the purchase of BC
programs in 2008 focused on the 14-3-3η Norma K. Biln, B.Sc., MBA, Chief Biomedical by LifeLabs
protein, a novel biomarker involved in the Executive Officer Medical Laboratory Services,
joint damage process, with current Doug Buchanan joined the
applications in rheumatoid arthritis (RA). Norma Biln leadership team of the new
From this initial basic research, a portfolio of Norma Biln is a leading figure in combined organization and
14-3-3η-centric clinical programs emerged, the Canadian Biotechnology sector holds the position of Vice
that is unveiling the potential of this recently recognized as one of President & Senior
previously unfamiliar factor in autoimmunity, Canada’s Most Powerful Women: Integration Officer at
and transforming the management of RA. Top 100 Award Winner in 2017. LifeLabs.
 CELIA COURCHENE
PRESIDENT
The tests Contextual Genomics engineer Ms. Courchene has more than 30
detect mutations in cancer, and have been years of experience as a business
designed to be medically necessary, clinical and legal executive, initially in SOHRAB SHAH PHD
grade (CAP, CLIA validated), and cost private law practice with a leading CHIEF INFORMATICS
effective. Our tests are embedded with Canadian law firm and for the past OFFICER
leading, proprietary molecular quality 20 years as a corporate affairs, Sohrab Shah is the Chief of
assurance tools, enabling laboratory partners business development and legal Computational Oncology at
to effectively support their cancer physicians executive in the life sciences Memorial Sloan Kettering
and patients. industry. Cancer Center.

The RAMP® Platform is a lateral flow

immunoassay platform that provides
accurate and precise diagnostic information Dr. Barbara Kinnaird, Ph.D. nastasios Tsonis, CPA, CA
in minutes. Response applications include Chief Executive Officer Director of Finance
Cardiovascular and Infectious Disease tests Dr. Barbara Kinnaird has over 25 Anastasios Tsonis is a
that provide lab quality results quickly. The years of research and business Chartered Accountant with
RAMP® Platform also supports Biodefense experience primarily in the fields nine years of experience in
and Environmental testing applications with of point of care (POC) testing and finance, accounting, and
the same speed, precision and accuracy. in vitro diagnostics. assurance.

Alveo Technologies is changing the world by

applying cutting edge advances in sensing,
microfluidics, and bioassays to create the
next-generation of disease and personal care MIKE AICHER, MBA
diagnostic devices. Founder and President

Our innovative products connect and RON CHIARELLO, PHD Mike is the President and a
empower consumers, healthcare Founder and CEO Founder of Alveo
professionals and treatment providers with Technologies. Prior to Alveo,
the ability to know sooner, act faster, and Ron is the Chief Executive Officer, Mike co-founded and served
make better-informed decisions. Advanced a Founder, and a member of the as National Genetics
diagnostics clear the path to more Board of Directors of Alveo Institute's (NGI) CEO from
personalized medicine and better outcomes. Technologies. 1991 to 2012.
 John Todd, Ph.D.
Chief Scientific Officer

John Todd joined Singulex in

Guido Baechler 2007 and has championed
President and Chief Executive Singulex’s clinical programs
Officer to demonstrate the clinical
utility of SMC™ for
Guido Baechler has served as cardiovascular disease risk
President and Chief Executive prediction and patient
Singulex is an immunodiagnostics company at Officer
t of Singulex since 2013 management.

The EAP™ (Enhanced Affinity Platform)

System is a conceptually unique
immunization scheme, modeled on the rapid
and powerful immune response to viral
antigens. Unlike the antibody responses used
in traditional approaches, antiviral responses
happen in days, not weeks, and give rise to
high-affinity antibodies targeting a broad
range of epitopes, not just a few
immunodominant ones. A major benefit of
the EAP™ System is its ability to induce high-
specificity antibodies to the smallest
determinants, including single-atom
differences.

Exogen Bio is a company providing DNA

damage and repair research to healthcare
organizations and other research institutions.
DNA DamageDNA Repair MechanismDNA
Replication ProcessDNA MutationsDNA
Repair EnzymesDNA TestsDNA Collection Kit
 Dmitry Shashkov, Ph. D., President Sean Kirkpatrick, Director of
and CEO Applications
Dmitry joined the company in Prior to joining Exogenesis in
February 2018 after 25-year career 2007, Sean had 20 years of
in advanced materials. Prior to experience with Epion Corp.
Exogenesis, he was the President in the development and
and CEO of H. C. Starck Fabricated application of a variety of
Products, a leading global surface coating and
The Exogenesis technology has the unique manufacturer of refractory metals treatment technologies
ability to produce important atomic level serving aerospace, defense, including plasma, ion
surface modification effects without coatings medical, electronic and industrial implantation and gas cluster
or additives. markets. ion beam processing

Scientists and researchers lack systems to

reliably and accurately isolate individual cells
from transfected or cultured cell suspensions
or even heterogeneous samples such as
whole blood. There is a growing need to
study complex cell systems using next-gen
approaches for rapidly emerging market
segments including stem cell biology, genetic
engineering (e.g. CRISPR/Cas9), tumor Anand Kesavaraju
heterogeneity, drug discovery, precision Karthik Balakrishnan, PhD Founder/Chief Strategy
agriculture, and more. Founder/CEO Officer

For the past three decades, members of our

team have been at the forefront of cancer
immunotherapy. Today, we are a leader in
engineered T cell therapy, changing the
paradigm of cancer treatment with what is
potentially the biggest breakthrough since
the introduction of combination
chemotherapy more than 60 years ago.
Mammoth’s vision is to provide a CRISPR-
based platform on which an infinite number
of tests can be built by both ourselves and
our partners - democratizing access to an
endless variety of tests for bio sensing in
healthcare, as well as across industries such
as agriculture, manufacturing, forensics, and Trevor Martin Ashley Tehranchi
more. Co-founder, CEO Co-founder, CTO

J. Keith Joung, M.D., Ph.D.

Co-Founder
J. Keith Joung is a leading
innovator in the field of
genome editing. He is
Beam Therapeutics is developing precision currently Desmond and Ann
genetic medicines for serious diseases. Co- Heathwood Research
founded by scientific pioneers known for Scholar, Pathologist, and
advancing CRISPR gene editing, we’re the Associate Chief of Pathology
first company to pursue development of new David R. Liu, Ph.D. for Research at
therapies using CRISPR base editing Co-Founder Massachusetts General
technology. We aim to use these David R. Liu is the Richard Merkin Hospital (MGH) and is
technologies to generate a broad pipeline of Professor and Vice-Chair of the Professor of Pathology at
precision genetic medicines that repair Faculty at the Broad Institute of Harvard Medical School. He
disease-causing point mutations, write in Harvard and MIT, Professor of is also a member of the
protective genetic variations, or modulate Chemistry and Chemical Biology at Center for Cancer Research
the expression or function of disease-causing Harvard University, and Howard and the Center for
genes. Hughes Medical Institute Computational and
Investigator. Integrative Biology at MGH.
 Maya Said, Sc.D.
CHIEF OPERATING OFFICER

Maya is an entrepreneur,
founder, and healthcare
passionate. An engineer and
Susan O’Connor scientist by training, she
Our target identification screens and drug CHIEF PEOPLE OFFICER strongly believes that
discovery programs represent the potential technology combined with
of identifying and developing precision Susan has dedicated her entire biological insight can
therapeutics. We are tackling multiple career to creating and shaping revolutionize how diseases
diseases through new in-depth clinically companies in the life sciences and are treated and managed. At
focused screens and advance novel targets biotechnology industries. At Celsius, she oversees
identified through single-cell RNA sequencing Celsius, Susan is focused on talent, operations, finance and
analysis to rapid drug discovery. organization and culture. strategy.

Frank Gentile, Ph.D.

Frank Gentile, Ph.D.
Interim Chief Operating
Officer
Frank Gentile joined Third
Rock Ventures in 2015 to
focus on research and
Our health depends on the careful development opportunities
movement of millions of protein molecules throughout the portfolio. He
around each cell in the human body. Keith Dionne, Ph.D. brings nearly 25 years of
Autophagy is the natural process that Keith Dionne, Ph.D. experience working with
facilitates this orderly trafficking and is also Chief Executive Officer pharmaceutical and
essential for recycling old proteins and Keith Dionne is an industry veteran biotechnology companies,
mitochondria. Although the human body with 20+ years of experience including spending 12 years
boosts autophagy in response to exercise or leading U.S. and international with Tekla Capital
reduced nutrient intake, only recently have biotechnology companies. Most Management LLC, formerly
we begun to understand how in certain recently, he was president and Hambrecht & Quist Capital
diseases this quality control process goes CEO of Constellation Management LLC, where he
awry and is detrimental. Pharmaceuticals – an oncology most recently served as
focused epigenetics company. senior vice president.
 Andres Tellez, Ph.D.
Senior Director of Business
Development and Strategy
Andres Tellez comes to Cedilla C. Eric Schwartz, Ph.D.
We founded Cedilla at a time of fundamental from Syros Pharmaceuticals, Vice President, Drug
and rapidly growing insight into the where he served as senior director Discovery
mechanisms underlying protein stability. of business development and Eric Schwartz brings more
Small molecules that degrade or stabilize helped secure the company’s than two decades of
target proteins are precedented, but have partnerships with Incyte and experience in drug discovery
been discovered serendipitously Johnson and Johnson and development to Cedilla.

bluebird bio is a clinical-stage company

committed to developing potentially Jason F. Cole, Esq.
transformative gene therapies for severe Derek Adams, Ph.D.
genetic diseases and T cell-based Chief Legal Officer
immunotherapies. Our objective is to Chief Technology and
develop and bring to market the most Manufacturing Officer Jason Cole has served as our
advanced products based on the chief legal officer since
transformative potential of gene therapy to Derek Adams, Ph.D., joined us in March 2016 after serving as
provide patients hope for a better life in the March 2017 as our chief our senior vice president,
face of limited or no long-term safe and technology and manufacturing general counsel for two
effective treatment options. officer. years.
 Stephen Hoge, M.D.
President

Moderna is a leader in the discovery and Stéphane Bancel As President of Moderna, Dr.
development of messenger RNA (mRNA) Chief Executive Officer Stephen Hoge leads drug
therapeutics and vaccines, an entirely new discovery, preclinical
class of medicines that directs the body’s development, and platform
cells to produce intracellular or secreted R&D, including chemistry,
proteins that can have a therapeutic or Mr. Stéphane Bancel joined biology, formulation, and
preventive benefit for both patients and Moderna in the summer of 2011 early stage technical
healthy individuals. With its breakthrough when it was a one employee development. Dr. Hoge
platform, Moderna is creating mRNA company. He has assembled a joined Moderna in 2012,
medicines for a wide range of diseases and world-class team and raised nearly and as a leader from the
conditions, in many cases by addressing $2 billion between equity earliest days of the company
currently undruggable targets or underserved financing and upfront from has had a wide range of
areas of medical need. licensing collaborations. responsibilities.

CLARE OZAWA, PHD

Clare became a Versant

managing director in
January 2017 and leads
investments in San Diego
Versant Ventures is a leading healthcare BRADLEY BOLZON, PHD and the Bay Area. Clare
investment firm committed to helping Brad Bolzon, Ph.D., is a Managing currently is responsible for
exceptional entrepreneurs build the next Director and chairman of the strategic business
generation of great companies. The firm investment team at Versant. Brad development, operations
invests across the healthcare sector and at all combines 13 years of global and finance for the
stages of company development, with an pharmaceutical industry Inception Sciences research
emphasis on the discovery and development experience and a similar tenure as sites in San Diego,
of novel therapeutics. a venture capitalist. Vancouver and Montreal.
 CLARE OZAWA, PHD

Clare became a Versant

managing director in
January 2017 and leads
investments in San Diego
Versant Ventures is a leading healthcare BRADLEY BOLZON, PHD and the Bay Area. Clare
investment firm committed to helping Brad Bolzon, Ph.D., is a Managing currently is responsible for
exceptional entrepreneurs build the next Director and chairman of the strategic business
generation of great companies. The firm investment team at Versant. Brad development, operations
invests across the healthcare sector and at all combines 13 years of global and finance for the
stages of company development, with an pharmaceutical industry Inception Sciences research
emphasis on the discovery and development experience and a similar tenure as sites in San Diego,
of novel therapeutics. a venture capitalist. Vancouver and Montreal.

CLARE OZAWA, PHD

Clare became a Versant

managing director in
January 2017 and leads
investments in San Diego
Versant Ventures is a leading healthcare BRADLEY BOLZON, PHD and the Bay Area. Clare
investment firm committed to helping Brad Bolzon, Ph.D., is a Managing currently is responsible for
exceptional entrepreneurs build the next Director and chairman of the strategic business
generation of great companies. The firm investment team at Versant. Brad development, operations
invests across the healthcare sector and at all combines 13 years of global and finance for the
stages of company development, with an pharmaceutical industry Inception Sciences research
emphasis on the discovery and development experience and a similar tenure as sites in San Diego,
of novel therapeutics. a venture capitalist. Vancouver and Montreal.
 CLARE OZAWA, PHD

Clare became a Versant

managing director in
January 2017 and leads
investments in San Diego
Versant Ventures is a leading healthcare BRADLEY BOLZON, PHD and the Bay Area. Clare
investment firm committed to helping Brad Bolzon, Ph.D., is a Managing currently is responsible for
exceptional entrepreneurs build the next Director and chairman of the strategic business
generation of great companies. The firm investment team at Versant. Brad development, operations
invests across the healthcare sector and at all combines 13 years of global and finance for the
stages of company development, with an pharmaceutical industry Inception Sciences research
emphasis on the discovery and development experience and a similar tenure as sites in San Diego,
of novel therapeutics. a venture capitalist. Vancouver and Montreal.

Elizabeth Alcamo, PhD

Vice President, Corporate
Strategy and Business
Operations
CODA Biotherapeutics’ revolutionary
chemogenetic platform aims to control the
activity of cells to treat disease. With Michael Narachi, MBA
chemogenetics, the goal is to modify a target President & Chief Executive Officer Elizabeth (Liz) Alcamo is an
cell population using gene therapy to express experienced corporate
a tunable “switch” protein. Cells modified strategy professional who
with the “switch” can be activated or has spent the past four years
inactivated in a dose-dependent manner by a Mike Narachi is CODA’s President working in gene therapy
subsequently administered small molecule and CEO. Prior to joining CODA, companies focused on
therapeutic, an effect that should only occur Mike served as CEO and director at bringing AAV-based
in the modified cells. Orexigen Therapeutics. therapeutics to the clinic.
Pipeline is using innovative research
strategies to develop novel drugs for the Jonah Chan, PhD is Professor of
treatment of MS and other demyelinated Neurology at UCSF. He received his
diseases by enhancing the functional PhD in Neuroscience from the
restoration of the affected nerves. University of Illinois at Urbana- Ari Green, MD, MCR is
Champaign and completed a Professor of Neurology and
Damage to myelin in multiple sclerosis (MS) postdoctoral fellowship in the Ophthalmology at UCSF. He
and other demyelinating diseases results in Department of Neurobiology at received his MD from Duke
the disruption of the nerve signal that is Stanford University with Professor University and spent 2 years
essential for neuronal functions of the brain Eric Shooter. Jonah is currently the as a Howard Hughes
and spinal cord. This is accompanied by Debbie and Andy Rachleff Predoctoral Fellow during
nerve degeneration, ultimately leading to Distinguished Professor of this time. He completed
chronic disability. In order to effectively treat Neurology IV, Vice Chief for the medical internship and
this devastating condition, it is essential that Division of Neuroinflammation Neurology residency
we develop novel methodologies and and Glial Biology and Co-Director followed by fellowship
medications to promote remyelination and of the Innovation Program for training in
repair of the affected nerve cells. To date, Repair and Remyelination. He is Neuroimmunology and
there are no effective restorative therapies the recipient of the NMSS Career Neuroophthalmology at
and they remain one of the greatest unmet Transition Award, Baxter UCSF before joining the
needs for people living with MS. Foundation Scholar Award, faculty.

Tempest has a balanced and deep pipeline

consisting of first-in-class and best-in-class
small molecule therapeutics, which modulate
distinct immune response pathways relevant
to mounting an effective anti-tumor
response. The molecules were developed by Tom Dubensky Ginna G. Laport
Inception Sciences, a Versant Ventures PRESIDENT & CHIEF EXECUTIVE CHIEF MEDICAL OFFICER
affiliated drug discovery engine. Tempest has OFFICER
assembled a highly experienced team of Dr. Ginna Laport is Chief
small molecule and immuno-oncology drug Thomas W. Dubensky Jr., Ph.D. has Medical Officer and brings
developers to advance these programs to the served as the President & CEO of significant expertise in
clinic across diverse cancers representing Tempest Therapeutics since joining Hematology/Oncology and
significant unmet medical need the company in 2017 clinical drug development.
Christian Grøndahl, CEO
DNA & RNA
CRISPR genome editing
Next generation sequencing
Genes & gene fragments
qPCR & PCR
Functional genomics
Reagents and kits
GMP, OEM & integrations
Optional services
IDT OligoCard

After almost two decades of fast growth in

developing biological reagents, the company
has expanded its business into
immunotherapy, CDMO, laboratory
equipment, and microbial industry to further
fulfill its mission in making people and nature
healthier through biotechnology. For
example, GenScript’s subsidiary company,
Nanjing Legend Biotech, has accumulated a
series of pipelines for immunotherapy, of
which the leading CAR-T product (LCAR- Dr. Jay Keasling
B38M for multiple myeloma) has received
IND clearance from both FDA and CFDA. Dr. Jay Keasling is the Hubbard Jon Stonehouse
GenScript has also established open and Howe Jr. Distinguished Professor of
innovative technology-driven platforms and Biochemical Engineering at the Jon Stonehouse, a
GMP facilities for pre-clinical drugs discovery University of California, Berkeley in pharmaceutical executive for
and pharmaceutical products development the Department of Bioengineering more than 20 years, has
along with a completed industrial microbial and the Department of Chemical strong commercialization,
research, development and industrialization and Biomolecular Engineering, financial transaction,
platform for enzyme screening, genetic senior faculty scientist at Lawrence business development and
engineering, protein engineering, and Berkeley National Laboratory, and management expertise. He
fermentation process optimization and Chief Executive Officer of the Joint joined BioCryst as President
research application. BioEnergy Institute (JBEI). and CEO in January 2007.

Standard Gene Synthesis (PriorityGENE)

TurboGENE™
FragmentGENE
Synthetic DNA Libraries
CRISPR Construct Synthesis
Single-Stranded DNA Synthesis New
 Brady Millican
Vice President, Business
Development
Brady Millican is the Vice
President of Business
Development at Admera
Health. Prior to joining
Admera Health, Mr. Millican
gained over 18 years of
experience in the diagnostic
Guanghui Hu, Ph.D. laboratory industry at
President & CEO companies including Dianon
Dr. Guanghui Hu is the President (since acquired by LabCorp),
and co-founder of Admera Health. AmeriPath (since acquired
Pharmacogenomics (PGx) combines the Previously, Dr. Hu served as Vice by Quest Diagnostics),
study of genetics with the science of President and Global Business Bostwick Laboratories, and
drug delivery. Testing can help predict how Leader of Translational Genomics Pathology Service Associates
a patient may respond to drug therapy at GENEWIZ, Inc. Prior to joining (since acquired by
based on their DNA. GENEWIZ, Inc. McKesson).

Custom Cloning
cDNA Clone Set
Custom Lentivirus
Custom shRNA
Custom Protein Service
CRISPR Cloning Service
Custom sgRNA
Antibody Development
Antibody Specificity Service
Assay Development

After the completion of human genomic

project, most human expressed genes have
been identified, and full-length cDNA of
these genes have become publicly available.
In the emerging proteomics era, proteins act
as the key players in the unveiling of these
genes. In order to effectively decipher the
mystery of these proteins, antibodies with
their inherent sensitivity and specificity thus
become the most versatile tools for providing
one-to-one relationship with their target
proteins.
Health Garret Hampton, PhD
Advances in genetic analysis tools for Executive Vice President,
molecular diagnostics are revolutionizing the Clinical Genomics
practice of medicine, improving prenatal and Garret Hampton joined
reproductive care, enabling earlier disease Illumina in 2017 and leads
detection, and advancing treatment of the company’s Clinical
heritable disease. Novel assays based on Genomics Group, which
next-generation sequencing and microarray Francis deSouza President & Chief includes the Reproductive
technologies are being developed, helping us Executive Officer and Genetic Health and
unlock the power of the genome. When Francis deSouza was appointed Oncology Businesses,
laboratories begin to take advantage of these President & CEO of Illumina in Regulatory, Clinical and
tools, we will see changes in health care in 2016 and is responsible for Medical Affairs, CLIA Labs,
ways never before imagined, ultimately directing all aspects of company and the Chief Medical
paving the way to improving human health. strategy, planning, and operations. Officer’s organization.

Health Garret Hampton, PhD

Advances in genetic analysis tools for Executive Vice President,
molecular diagnostics are revolutionizing the Clinical Genomics
practice of medicine, improving prenatal and Garret Hampton joined
reproductive care, enabling earlier disease Illumina in 2017 and leads
detection, and advancing treatment of Francis deSouza President & Chief the company’s Clinical
heritable disease. Novel assays based on Executive Officer Genomics Group, which
next-generation sequencing and microarray Francis deSouza was appointed includes the Reproductive
technologies are being developed, helping us President & CEO of Illumina in and Genetic Health and
unlock the power of the genome. When 2016 and is responsible for Oncology Businesses,
laboratories begin to take advantage of these directing all aspects of company Regulatory, Clinical and
tools, we will see changes in health care in strategy, planning, and operations. Medical Affairs, CLIA Labs,
ways never before imagined, ultimately Francis deSouza President & Chief and the Chief Medical
paving the way to improving human health. Executive Officer Officer’s organization.
Health Garret Hampton, PhD
Advances in genetic analysis tools for Executive Vice President,
molecular diagnostics are revolutionizing the Clinical Genomics
practice of medicine, improving prenatal and Garret Hampton joined
reproductive care, enabling earlier disease Illumina in 2017 and leads
detection, and advancing treatment of Francis deSouza President & Chief the company’s Clinical
heritable disease. Novel assays based on Executive Officer Genomics Group, which
next-generation sequencing and microarray Francis deSouza was appointed includes the Reproductive
technologies are being developed, helping us President & CEO of Illumina in and Genetic Health and
unlock the power of the genome. When 2016 and is responsible for Oncology Businesses,
laboratories begin to take advantage of these directing all aspects of company Regulatory, Clinical and
tools, we will see changes in health care in strategy, planning, and operations. Medical Affairs, CLIA Labs,
ways never before imagined, ultimately Francis deSouza President & Chief and the Chief Medical
paving the way to improving human health. Executive Officer Officer’s organization.

At our core, Agios is a science-driven

research organization. We have built a
discovery platform upon our expertise in the
fields of cellular metabolism and precision
medicine across three major focus areas:
cancer metabolism, rare genetic diseases and
metabolic immuno-oncology. We take a David Schenkein, M.D. Scott Biller, Ph.D.
systems biology approach to deeply Chief Executive Officer Chief Scientific Officer
understand disease states, drive the Dr. Schenkein joined Agios in Dr. Biller joined Agios as
discovery and validation of novel therapeutic August 2009 as the chief executive chief scientific officer in
targets, and define patient selection officer and a member of our board September 2010, with more
strategies, thereby increasing the probability of directors and has been a than 25 years of drug
that our experimental medicines will have hematologist and medical discovery and development
the desired therapeutic effect. oncologist for more than 20 years experience.

Our platform integrates automation, machine Zach Serber

learning, and genomics to rapidly accelerate Chief Science Officer and VP
the pace of scientific advancement. This of Development
atheoretic approach leverages machine
learning to navigate the genomic search At Zymergen, Zach is
space to make discoveries far beyond the Joshua Hoffman responsible for our overall
capacity of human intuition Chief Executive Officer scientific direction.
We provide our customers with innovative
bioanalytical solutions for protein and cell
biology in life science research,
pharmaceutical and biotherapeutic Martyn Ansell
development. Chief Financial Officer and
Vice President, Finance
With over 140,000 placements in Martyn joined Molecular
laboratories around the world, our Devices in June 2012 as Vice
instruments have contributed to remarkable President, Finance. Prior to
scientific research described in over 150,000 joining Molecular Devices he
peer reviewed publications. Included within a was Chief Financial Officer of
broad product portfolio are platforms for Vistec Semiconductor
high-throughput screening, genomic and Greg Milosevich Systems, a global leader in
cellular analysis, colony selection and President the development and
microplate detection. We are over 1,100 Greg was appointed President of manufacture of electron-
associates strong with rich domain Molecular Devices in January 2015 beam lithography
knowledge to support scientific and has been with the firm since equipment for the
breakthroughs April of 2006. semiconductor industry.

Studies have suggested that up to 15% of

disease-causing variants may be found in the
non-coding regions of the genome, which are
not covered by exome sequencing tests. The
PCR-free sequencing methods used in Whole Jason Priar
Genome Sequencing (WGS) provide for more Head of Global Sales and
uniform coverage across both coding and Madhuri Hegde, Ph.D., FACMG Marketing
non-coding regions of DNA. The more VP and Chief Scientific Officer Jason brings more than 12
uniform coverage offered through WGS can Dr. Hegde is a medical geneticist, a years of clinical and
in fact provide better coverage of some board certified diplomat in clinical commercial experience
regions of the exome than traditional exome molecular genetics by the holding genetic sales
sequencing, increasing the possibility of American Board of Medical leadership positions with
finding a disease causing mutation. Genetics, and an ACMG Fellow. major laboratories.
 Henrik Ancher-Jensen
Senior Vice President,
Agilent is helping researchers answer some Agilent
of the most ground-breaking biological President, Order Fulfillment
questions - all with cellular metabolism. Mike McMullen and Supply Chain
Cellular metabolism is the set of chemical President and Chief Executive Henrik Ancher-Jensen
reactions that take place within a cell. These Officer, Agilent Henrik Ancher-Jensen is
reactions sustain life, allowing cells to grow, Mike McMullen senior vice president,
divide and respond to their environment, Mike McMullen was appointed Agilent, and president,
making metabolism a central aspect of Agilent CEO in March 2015, Order Fulfillment and Supply
biology. replacing William (Bill) Sullivan. Chain (OFS).

The Multivalent RNA molecule (MV-RNA)

represent a new RNAi trigger for the
treatment of disease. The non-canonical
structure utilizes the same RISC pathway as
siRNA, but expands gene targeting,
eliminates sense-strand off-target effects,
and introduces the first 'junction containing'
structure to RNAi. With an exlusive IP
position and novel technical characteristics,
Halo-Bio is working to release Multivalent
RNAi based products that utilize MV-RNA's
unique capabilities

lnylam is leading the translation of RNA

interference (RNAi) into a whole new class of
innovative medicines with the potential to
transform the lives of patients who have
limited or inadequate treatment options.
Based on Nobel Prize-winning science, RNAi
therapeutics represent a powerful, clinically
validated approach for the treatment of a KAREN ANDERSON
wide range of debilitating diseases with high SVP CHIEF HUMAN RESOURCES BARRY GREENE
unmet medical need. Alnylam was founded OFFICER PRESIDENT
in 2002 on a bold vision to turn scientific Karen Anderson joined Alnylam in Barry Greene joined Alnylam
possibility into reality, which is now marked 2014 from Biogen Idec where she in 2003 and has more than
by its robust discovery platform and deep served as Vice President, Human 25 years of experience in
pipeline of investigational medicines, Resources for Research & Design healthcare, pharmaceutical,
including 4 programs in late-stage clinical (R&D) and Corporate and biotechnology
development. Development. industries.
Juno is developing autologous cellular
biologics as an answer to overcoming tumor
evasion and potentially eradicating cancer
cells. We believe the type of engineered T
cell we put in the body matters, and we have
developed the capability to manipulate and
control the type of cells a patient receives,
allowing us to develop potential “best-in-
class” products that could deliver optimal
therapeutic impact.

Arrowhead Pharmaceuticals develops

medicines that treat intractable diseases by
silencing the genes that cause them. Using a
broad portfolio of RNA chemistries and
efficient modes of delivery, Arrowhead
therapies trigger the RNA interference
mechanism to induce rapid, deep and
durable knockdown of target genes. RNA
interference, or RNAi, is a mechanism
present in living cells that inhibits the
expression of a specific gene, thereby
affecting the production of a specific protein.
Arrowhead’s RNAi-based therapeutics Christopher Anzalone, Ph.D
leverage this natural pathway of gene President and Chief Executive Bruce Given, M.D.
silencing. Officer Chief Operating Officer

JOSEPH “JAY” HAGAN TIMOTHY M. WRIGHT, M.D.

President and Chief Executive tim wright
Dysregulated microRNA expression is a key Officer Dr. Wright joins Regulus
factor in many complex multi-factorial Jay Hagan from California Institute for
diseases, including inflammatory disease, Joseph P. “Jay” Hagan joined Biomedical Research
fibrosis, metabolic disease and cancer. Regulus in January 2016 as Chief (Calibr), a not-for-profit
microRNA therapeutics are oligonucleotides Operating Officer, Principal translational research
that modulate the function of microRNAs, Financial Officer and Principal institute, where he was
correcting the imbalance of gene expression Accounting Officer and was Executive Vice President of
and associated cellular pathways to treat a appointed to President and Chief Translational Sciences since
broad range of human disease. Executive Officer in May 2017. February 2015.
Catalyst + Talent. Our name combines these
ideas. From drug and biologic development
services to delivery technologies to supply
solutions, we are the catalyst for your
success. With over 80 years of experience,
we have the deepest expertise, the broadest WETTENY JOSEPH
offerings, and the most innovative JOHN CHIMINSKI SENIOR VICE PRESIDENT &
technologies to help you get more molecules CHAIR & CHIEF EXECUTIVE CHIEF FINANCIAL OFFICER
to market faster, enhance product OFFICER Wetteny Joseph was named
performance and provide superior, reliable John Chiminski was named Chief Senior Vice President &
manufacturing and packaging results. Executive Officer of Catalent Chief Financial Officer in
Pharma Solutions in March 2009. February 2018.

Lakhmir S. Chawla, MD |
Chief Medical Officer
Dr. Chawla joined La Jolla as
Chief Medical Officer,
effective July 1, 2015.
George F. Tidmarsh, MD, PhD | Previously, Dr. Chawla was a
President, Chief Executive Officer Professor of Medicine at the
and Secretary George Washington
Dr. Tidmarsh has been President, University, where he had
La Jolla Pharmaceutical Company is a Chief Executive Officer, Secretary dual appointments in the
biopharmaceutical company focused on the and a Director of La Jolla since Department of
discovery, development and January 2012. Dr. Tidmarsh has Anesthesiology and Critical
commercialization of innovative therapies over 25 years of experience in Care Medicine and in the
intended to significantly improve outcomes biotechnology, including the Department of Medicine,
in patients suffering from life-threatening successful clinical development of Division of Renal Diseases
diseases. three FDA-approved drugs. and Hypertension.

Our mission is to improve the lives of

patients by developing novel, best-in-class
treatments to address some of the most
important unmet patient needs. We aim to
develop patient-focused solutions by Barry D. Quart, Pharm.D.
applying our innovative science and Chief Executive Officer and Robert H. Rosen
technologies with well-known pharmacology. Director President and Director
Our mission is to improve the lives of
patients by developing novel, best-in-class
treatments to address some of the most
important unmet patient needs. We aim to
develop patient-focused solutions by Barry D. Quart, Pharm.D.
applying our innovative science and Chief Executive Officer and Robert H. Rosen
technologies with well-known pharmacology. Director President and Director

Ann Barbier, M.D., Ph.D.

Chief Medical Officer
Dr. Barbier joined Translate
Bio in 2017 as chief medical
Ronald C. Renaud, Jr. officer. Prior to joining
Chief Executive Officer Translate Bio, Dr. Barbier was
Ron has served as our chief vice president of clinical
executive officer since 2014. development, rare genetic
Formerly, Ron was at Idenix diseases, at Agios
We are a leading mRNA therapeutics Pharmaceuticals (2007-2014), Pharmaceuticals, where she
company developing a new class of where he served as chief financial led the development
potentially transformative medicines to treat officer, chief business officer and program of a small molecule
diseases caused by protein or gene finally, president and chief in rare benign hematological
dysfunction. executive officer. diseases.

Repare Therapeutics is developing new, Lloyd M. Segal

precision oncology drugs for patients that President & CEO
target specific vulnerabilities of tumor cells.
Its approach integrates insights from several Cameron Black Lloyd is an Entrepreneur-in-
fields of cell biology including DNA repair and VP, Discovery residence at Versant
synthetic lethality. Repare’s platform Ventures, and from 2010-
combines a proprietary, high throughput, Cameron joined Repare 2016 was a Managing
CRISPR-enabled gene editing target discovery Therapeutics in mid-2016 to lead Partner at Persistence
method with high-resolution protein the drug discovery efforts on Capital Partners, a leading
crystallography, computational biology and newly identified synthetic lethal Healthcare private equity
clinical informatics. targets investor.
 Fred Aslan
President and Chief Business
Officer
Vividion is a next generation biotechnology Diego Miralles X
company focused on expanding the CEO Fred joined the Vividion
therapeutic potential of small molecules. We X team in September 2018 as
are applying our pioneering synthetic Diego comes from an extensive President and Chief Business
chemistry and chemoproteomic platforms to background in leading and Officer. He was the founder
reveal druggable opportunities across the developing innovative businesses. and CEO of Adavium
entire proteome, much of it previously He was previously President of Medical, which he built into
considered undruggable. Our goal is to create Adaptive Therapeutics, where he the leading Brazilian medical
life-changing therapeutics for diseases and built a therapeutics program device company, raising over
pathways not adequately addressed by leveraging Adaptive US$50 million from
existing treatments. immunosequencing platform. institutional investors.

Stephen H. Rusckowski Everett Cunningham

Chairman, President and Chief Senior Vice President,
We are the world’s leading provider of Executive Officer Commercial
diagnostic testing, information and services
that patients and doctors need to make Steve Rusckowski is Chairman, Everett Cunningham is
better healthcare decisions. Our services President and Chief Executive Senior Vice President,
range from routine blood tests — such as Officer of Quest Diagnostics. Since Commercial for Quest
total cholesterol, Pap testing and white blood joining Quest Diagnostics as Diagnostics. He is
cell count — to complex, gene-based and President and Chief Executive responsible for commercial
molecular testing. Officer in May 2012, sales and marketing.
 Mark A. Tepper, Ph.D.
President & Chief Scientific
Officer
Mark A. Tepper, Ph.D., co-
founded the Company in
2009. He has more than
Yuval Cohen, Ph.D. twenty years of leadership
Chief Executive Officer, Director experience in
Yuval Cohen, Ph.D., joined Corbus pharmaceutical R&D and his
in July 2013 as Chief Executive past roles include leadership
Officer. Prior to joining Corbus, he positions at Bristol Myers
was the President and co-founder Squibb, Serono, CytRx, RXi
of Celsus Therapeutics (Nasdaq Pharmaceuticals and NKT
Corbus Pharmaceuticals is a Phase 3 clinical-stage
CLTX)pharmaceutical
from 2005 to June
company
2013.focused
Therapeutics.
on the development and commercializatio

Constellation Pharmaceuticals is a clinical-

stage biopharmaceutical company using
expertise in epigenetics to discover and
develop novel therapeutics that address
serious unmet medical needs in patients with
cancers associated with abnormal gene
expression.
Our integrated epigenetics platform enables
us to validate targets and generate small
molecules against these targets that
selectively modulate gene expression in
tumor and immune cells to drive anti-tumor
activity. Our integrated epigenetics platform
includes a deep understanding of the
biological context in which epigenetic
regulatory proteins, or epigenetic regulators,
Jigar Raythatha
operate, the development of small-molecule President and Chief Executive
product candidates that selectively modulate Officer
their activity and the design of clinical Jigar Raythatha has spent nearly Emma Reeve
development programs supported by novel 20 years in the biotechnology Chief Financial Officer
biomarker strategies. industry in a variety of business Emma Reeve is a global
functions. He rejoined finance executive who has
We are able to target a broad variety of Constellation in March 2017 as the worked in healthcare for
epigenetic regulators using our platform and company’s chief executive officer over 20 years across
have generated development candidates from Jounce Therapeutics, where pharmaceutical, medical
acting against distinct classes of those he held the role of chief business device and bio-pharma
regulators. officer. companies.
Proteostasis Therapeutics, Inc. is a clinical
stage biopharmaceutical company Marija Zecevic, Ph.D.
developing small molecule therapeutics to Chief Operating Officer
treat cystic fibrosis and other diseases caused
by dysfunctional protein processing. Dr. Zecevic has been serving
Headquartered in Boston, MA, the as our Chief Operating
Proteostasis Therapeutics team focuses on Meenu Chhabra Officer since February 2018,
identifying therapies that restore protein President and Chief Executive having served previously as
function. In addition to its multiple programs Officer Chief Business Officer
in cystic fibrosis, Proteostasis Therapeutics (March 2017 to February
has formed a collaboration with Astellas Ms. Chhabra has been serving as 2018) and Vice President of
Pharma, Inc. to research and identify our President and Chief Executive Business Development
therapies targeting the Unfolded Protein Officer and a member of our (August 2016 to March
Response (UPR) pathway. board of directors since May 2014. 2017).

Virginie Menard Rose, Ph.D.,

Clearly, robust and accurate diagnostic tools Director of Cell Line
are required to aid and inform physicians Development and Upstream
diagnosis of many disease states. Many of Process Development
these diagnostic tools require protein (e.g. Malavika Ghosh, Ph.D., Vice
monoclonal antibody) components for their President, In Vivo Services Dr. Menard Rose has over 20
readout. As such, they require biological years of experience in Cell
manufacturing systems to make those Dr. Ghosh has extensive expertise Line and Process
reagents. However, when compared to the in molecular and cell biology Development. She obtained
protein requirements for therapeutics studies ranging from discovery of her Ph.D in Biological and
applications, diagnostic products have a novel disease related genes, gene Medical Engineering from
significantly lower demand in terms of expression profiling, functional the University of Paris XIII,
scalability and absolute amount of protein. studies on therapeutic targets to where she worked with
However, they still require the robustness translation studies on animal Pasteur Merieux and Rhone-
and reproducibility. models. Poulenc.
Allele Biotechnology and Pharmaceuticals,
Inc. is a private, San Diego-based company
that explores the mechanisms of biological
processes to develop technologies and
products for biomedical researchers. The
company was founded by scientists and
other professionals with the goal of
advancing discovery and innovation.

Our mission is to increase accessibility to

innovative molecular biology research tools
by offering cutting edge products at a
reasonable cost, and providing excellent
customer service in addition to the technical
knowledge needed to facilitate their use. Our
knowledgeable scientists and technicians are
available to answer questions regarding any
of our products.

Douglas Demian, M.S.

LakePharma is the leading US-based biologics David Boyle Director, Pharma Assay
company specializing in antibody Chief Financial Officer Development and Screening
engineering, antibody discovery, molecular David Boyle was appointed to (MA)
engineering, protein chemistry, Chief Financial Officer in 2018. He Doug serves as Director, of
bioexpression, biofunction, bioprocessing, has vast experience in financial LakePharma’s Assays Group
bioanalytics and µBIOMANUFACTURING℠ leadership at technology, in Worcester and is
biologics manufacturing services for Phase 1 biotechnology and pharmaceutical responsible for oversight of
clinical trials. companies. the Pharma Assay Portfolio.

We are addressing laboratories that provide a

service closer to the patient (Physician Office
Labs, smaller “BenchTop” laboratories
Worldwide, transplant laboratories dedicated
to specific patients, sweat testing in Cystic
Fibrosis Centers and Clinics, simple single-use
Mycoplasma kits, mini-sed rate tests for small
labs).
For over 40 years the Company has been
developing, producing and commercializing
worldwide reagent kits for the In Vitro
Diagnostics market, in particular for the
Immunodiagnostics and Molecular
Diagnostics segments.

We have a number of mRNA medicine

development programs that leverage our
proprietary LUNAR delivery system and
mRNA design and production capabilities.
We have a partnership with Cystic Fibrosis
Foundation Therapeutics, Inc. to develop Joseph E. Payne, President & CEO,
novel mRNA therapeutic candidates to treat Director of the Board
cystic fibrosis and a strategic collaboration Joseph E. Payne, is the President Padmanabh Chivukula, CSO
with CureVac AG to jointly discover, develop and Chief Executive Officer of & COO
and commercialize mRNA therapeutic Arcturus Therapeutics Ltd. He Pad Chivukula, Ph.D., is the
candidates to treat ornithine serves on Arcturus’s Board since Chief Scientific Officer and
transcarbamylase (OTC) deficiency and other March 2013. He brings with him Chief Operating Officer of
diseases. We have also partnered with an exceptional track record of Arcturus Therapeutics. Dr.
Ultragenyx to develop up to ten mRNA ushering novel therapeutics to the Chivukula has an exceptional
therapeutic candidates for rare disease clinic including targeted RNA and technically solid
targets. The first disclosed indication is medicines utilizing lipid-mediated foundation in nanoparticle
Glycogen Storage Disease type III. delivery technologies. technology.

Savara's pipeline comprises: Molgradex, an

inhaled granulocyte-macrophage colony-
stimulating factor, or GM-CSF, in Phase 3 Rob Neville Taneli Jouhikainen
development for PAP, and in Phase 2a CEO COO
development for NTM lung infection; and Robert Neville has served as Dr. Taneli Jouhikainen is a
AeroVanc, a Phase 3 stage inhaled Savara’s CEO and Chairman since co-founder of Savara, has
vancomycin for treatment of MRSA infection he co-founded the company in served as Chief Operating
in cystic fibrosis. June 2008. Officer since October 200...
A-Med Health Care is a specialty pharmacy
providing advanced medications, infusions,
supplies, and services to patients living with
complex conditions. We provide support for
patients suffering from conditions such as
Cystic Fibrosis, HIV/AIDS,

NovaBiotics is also developing NM001

(Lynovex®), an orphan drug treatment for
cystic fibrosis. NM001 has a unique dual Mr Bryan Bodek
antibacterial-mucoactive mode of action that Chairman of the Board
kills bacteria, disables biofilms and disrupts
excess mucous produced in the airways of Dr. Deborah O'Neil Mr Bryan Bodek joined
patients with cystic fibrosis (and other Chief Executive Officer and NovaBiotics Board in 2009.
chronic respiratory diseases). NM001 is being Scientific Officer He is Chairman of Trenchard
evaluated in Phase IIa clinical trials as an oral Aviation and brings more
treatment for cystic fibrosis and is also being A biotechnologist with over two than 30 years experience of
formulated for inhalation to enable longer decades of experience in the field advising public and private
term, more targeted delivery of the drug. of anti-infectives research & drug companies in all aspects of
development. their business.

Larry Gerrans - President & CEO

Larry Gerrans began his medical
device career as a Total Joint
Replacement Specialist for Depuy
The company is initially targeting the Orthopedics (Johnson & Johnson),
pulmonary market, which includes treatment where he worked with many of
of lung cancer, COPD, asthma and cystic the world's premier orthopedic Steve Goldsmith - VP,
fibrosis. Future addressable markets include surgeons in the education and Marketing
treatment of diseases and disorders of the six intra-operative consultation of 30+ years experience in
major organ systems of the tubular anatomy. primary and revision total joint Marketing, Sales, and
arthroplasty. Advertising.

As part of this evolution, we changed our

company name to Nivalis, a name that
communicates the commitment, passion,
and energy we are bringing to the Cystic
Fibrosis community as we strive to discover
and develop innovative solutions that
improve and extend the lives of people
managing CF.
miRagen’s areas of focus include
hematological malignancies, pathological
fibrosis, neuro-degeneration, and JASON A. LEVERONE, C.P.A.
cardiovascular disease. In 2011, the company CHIEF FINANCIAL OFFICER
formed a strategic partnership with Servier, a WILLIAM S. MARSHALL, PH.D. BOARD OF DIRECTORS
privately-run, French research-based BOARD OF DIRECTORS MEMBER, MEMBER, CO-FOUNDER,
pharmaceutical company, to advance miRNA- CO-FOUNDER, PRESIDENT AND PRESIDENT AND CHIEF
targeting drug candidates for the treatment CHIEF EXECUTIVE OFFICER, EXECUTIVE OFFICER,
of cardiovascular disease. MIRAGEN THERAPEUTICS MIRAGEN THERAPEUTICS

Gregory Weaver, M.B.A.,

Bob Ward, Chairman of the Board CFO
and CEO Mr. Weaver is a seasoned
Mr. Robert (Bob) E. Ward is the financial executive with
Chairman of the Board and Chief more than 30 years of
Executive Officer of Eloxx experience in leading
Pharmaceuticals, Inc. (“Eloxx”). He business and financial
Eloxx’s lead product candidate, ELX-02, is a previously served as the Chief operations for private and
small molecule drug candidate designed to Executive Officer and President at public companies, including
restore production of full-length functional Radius Health, Inc. (NASDAQ: financing transactions,
proteins. ELX-02 is in the early stages of RDUS) successfully completing the strategic planning, investor
clinical development focusing on cystic initial public offering that became relations, and business
fibrosis and cystinosis. the top performing IPO; development initiatives.
Respiratory Research, Inc. develops A. Rafi Baddour, P.E. John W. Vaughan
proprietary medical devices and diagnostics General Manager Secretary
supporting the study of Cystic Fibrosis,
Asthma, Lung Cancer and Infectious Disease Mr. Baddour currently serves as Mr. Vaughan fills several
worldwide. Our RTube™ Exhaled Breath General Manager of Respiratory supporting roles with
Condensate Collector has been trusted over Research. He manages all day-to- Respiratory Research
200,000 times to capture exhaled biomarkers day activities including Sales, leveraging his detailed
in academic, pharmaceutical, and Support, Manufacturing, knowledge of the respiratory
government research studies worldwide Engineering, Quality, and therapeutic and diagnostics
since 2005. Regulatory. markets.

Spyryx Biosciences is a biopharmaceutical

company developing inhaled therapeutics for
severe respiratory diseases, with Cystic
Fibrosis (CF) as the first target indication.
Our development efforts are based on novel
peptides that reduce the airway surface Timm Crowder, PhD
density of epithelial sodium channels (ENaC) SVP, Technical Operations
via ligand-mediated internalization. This Tim Shannon, MD Timm’s responsibilities
mechanism has a robust and durable effect Chair include Spyryx’s technology
on enhancing airway and mucus hydration to Dr. Shannon is a board-certified and preclinical product
promote mucociliary clearance. We believe pulmonologist with development efforts, the
the mechanism of our investigational multidisciplined experience in manufacturing supply chain
peptides has the potential to provide research, strategic drug and quality system for
disease-modification for the dehydration development, and medical and Spyryx’s product candidates,
associated lung disease that is a feature of clinical affairs, including prior roles and oversight of Spyryx’s
CF, as well as having utility in multiple other in industry, academia, and clinical intellectual property
pulmonary and non-pulmonary indications. practice. portfolio.
On the systems-biology side, EBX-001 is Jeffrey Wager, M.D.
EnBiotix’s tobramycin-potentiator Chairman & CEO
combination aimed at treatment of chronic Executive Assistant:
Pseudomonas aerugiosa infections in anna.rabinovych(at)enbiotix-dot- Michael Garrett
patients with cystic fibrosis (CF), where the com Chief Business Officer
company has demonstrated dramatic Jeffrey Wager has 23 years of Mike.Garrett(at)EnBiotix-
enhancement of tobramycin’s effectiveness senior operating experience in the dot-com
in killing the bacteria both in vitro and in life sciences, beginning his career Mr. Garrett is responsible for
vivo. According to the CDC, exacerbations of with a unit of the Bank of Tokyo, formulation and execution
pulmonary infection from chronic advising Japanese pharma of corporate and strategic
colonization of microbes in the respiratory companies on the design and development at EnBiotix, in
tract is the major cause of disease and death conduct of international clinical addition to managing the
in patients with CF. trials and strategic alliances legal group.

Novoclem is an agile, innovative preclinical

stage pharmaceutical company focused on
helping patients suffering from severe
respiratory diseases breath better and live
the life they desire. We are currently in the
pre-clinical stage and are focused on the
development and commercialization of Mark Schoenfisch, PhD
therapeutics to treat rare respiratory Neal Hunter President and Chief
diseases. Chief Executive Officer Scientific Officer
Neal was the founding investor of A Professor of Chemistry at
Novoclem's lead product enables the Novan, Inc. and served as the the University of North
controlled and local delivery of Nitric Oxide Company’s Chairman for eight Carolina at Chapel Hill where
via macromolecules for the treatment of years, personally orchestrating the he has developed a dynamic
severe respiratory infections in patients with fund raising of over $100M in research program in the field
Cystic Fibrosis. private financing of nitric oxide.
 CEO
Dr. Nabil Arrach has 20 years of
Progenesis is the first company in the US to research experience in molecular
introduce Next Generation Sequencing (NGS) genetics, both in preclinical and
for Preimplantation Genetic Screening (PGS) clinical settings. He has worked at
and Preimplantation Genetic Diagnosis several prestigious research
(PGD), offering the most accurate testing in centers, including the University of
the IVF field. We offer embryo screening for California, Berkeley, Sanford-
many common diseases including cystic Burnham Medical Research
fibrosis, Fragile X syndrome, sickle cell Institute and the University of
disease, and Tay-Sachs disease. We have California, Irvine, and has
introduced the most accurate test in the IVF numerous high impact
field for 24-chromosome aneuploidy publications and a successful
screening and single gene disorder record in grant funding.

Using our highly-complex molecular

diagnostic testing, healthcare providers can
access the most advanced genomic Jeana DaRe, PhD, FACMG, Senior John Tazelaar, MD, Senior
technology to guide patient care at critical Laboratory Director, Director of Medical Director, Laboratory
life stages. Laboratory Affairs Director

The AffloVest is a fully mobile High

Frequency Chest Wall Oscillation (HFCWO)
airway clearance device. The AffloVest
pioneered mechanical oscillation airway
clearance therapy for patients with severe
respiratory diseases such as bronchiectasis,
cystic fibrosis and other neuromuscular
diseases.
 Ryan Davies – Chief Executive
Officer Todd Kinard – Executive Vice
Ryan Davies has had a long and President
Curza is a small molecule therapeutics successful career as an Todd specializes in
development company. Curza has developed entrepreneur, business executive intellectual property law
a new class of antibiotics that are active and and public servant. Ryan founded with technology expertise in
selective against Gram-negative pathogens. and served as CEO for a renewable the fields of biotechnology,
Specialties energy development company chemical & chemical
Antibiotic resistance, Biofilms, Antibiotics, that built, owned and operated processes, medical devices,
Small Molecules, Bacteria, antimicrobial, wind and solar projects toxicology, genetics,
tuberculosis, cystic fibrosis, and lyme disease throughout the United States microbiology and virology

Lars Brichta, PharmD, PhD

COO AND DIRECTOR OF
CLINICAL AND SCIENTIFIC
Amany Mansour-Awad, RPh, MBA AFFAIRS
Specialties PRESIDENT AND FOUNDER Lars graduated from
Pediatric dermatology, Otolaryngology, Amany has over 20 years of pharmacy school at the
Colorectal surgery, Infectious disease and experience working in Martin Luther University in
antibiotic optimization, Cosmetic science, pharmaceutical manufacturing, Halle, Germany and received
Pediatric neurology and epilepsy, Oncology, pharmaceutical regulatory affairs, his PhD in Neurogenetics
Dermatology, Men and Women's Health, and hospital/clinical pharmacies, and from the Universities of
Cystic Fibrosis specialty pharmacies. Bonn and Cologne.

Specialties
Oncology, HIV/AIDS, Hepatitis, Transplant,
Cystic Fibrosis, Multiple Sclerosis (MS),,
Rheumatology, Nephrology, Dermatology,
Crohns, Enteral Nutrition, Fertility,
Gastroenterology, Growth Hormone,
Ophthalmology, and Urology
Laurent Pharmaceuticals is a Montréal-based Jean-Marie Houle, Ph.D.
private biopharmaceutical company. Laurent Pharm - Vice President,
has a clinical stage lead program focusing on Clinical Development
LAU-7b, a once-a-day oral therapy addressing Jean-Marie Houle, Ph.D.
the persistent unresolved inflammation, a Pharm, brings a unique
leading cause of lung tissue destruction in Radu Pislariu, M.D. - President and blend of strong
patients with Cystic Fibrosis (CF).The CEO development leadership
underlying technology was developed at the Radu Pislariu, M.D., is an together with outstanding
Research Institute of the McGill University experienced healthcare management skills exercised
Health Centre (RI-MUHC) and received an entrepreneur and investor, with in the pharma, biotech and
Orphan Drug Designation from the U.S. Food extensive medical and drug contract research sectors of
and Drug Administration. development expertise. industry.

Talee Bio has two gene therapy product

candidates to treat cystic fibrosis. The major
hurdles of gene therapy for cystic fibrosis are
poor efficacy (i.e., transduction efficiency,
expression persistence, packaging capacity,
avoidance of immunogenicity), low safety
and tolerability (including genotoxicity for
those vectors that result in genomic Jane H. Hollingsworth
integration), and inability to manufacture Joan Lau, PhD, MBA Executive Chair
sufficient vector. Chief Executive Officer Eric Yuen, MD

Roy Clifford Levitt, MD Jeff Edelson

Onspira Therapeutics is focused on the
development of life-changing medicines to Chief Scientific Officer MD FRCPC MHSc.
bring hope to patients suffering from rare
pulmonary diseases. Our lead program is a Chief Medical Officer
novel, inhaled IL-1 (beta) antagonist protein
being advanced for the treatment of Roy Levitt, MD, has more than 35
bronchiolitis obliterans syndrome (BOS) in years of experience as a physician-
post-lung transplant patients. BOS is a scientist and 22 years in Jeff Edelson, MD, is a
significant, often fatal condition affecting pharmaceuticals development pulmonologist with more
thousands of patients around the world. including leadership in than 30 years of clinical
Additional programs will address interstitial development stage and global practice, research and
pulmonary fibrosis and cystic fibrosis. commercial biopharmaceuticals. management experience.
 Nick Henderson, MBA
ProclaRx's lead program, a broad spectrum Chairman of the Board
therapeutic antibody, is being developed for
indications such as chronic and recurrent Nick Henderson is Managing Joseph D. Kittle Jr., Ph.D.
otitis media, sinusitis and cystic fibrosis Partner of Applied Bio Ventures. Chief Executive Officer
related pulmonary infections. The Prior to that, he was CEO of
compounds for sinusitis and otitis media Applied Biomolecular Joseph D. Kittle Jr., Ph.D. has
have been validated in animal models. Technologies, a technology over 20 years of experience
development company focused on in the world of
commercializing technology. biotechnology.

Chief Executive Officer

Chief Operating Officer
Michael Taylor is a senior medical
device professional with over 18 Jim Kamnikar has over 20
years of public and private years of experience in
Monitored Therapeutics Inc. (MTI) is company experience in many operations, ecommerce,
Respiratory Telehealthcare Company focused aspects of business including product development,
on COPD, Asthma, Lung Transplant, and strategic planning, business digital marketing, and
Cystic Fibrosis with three proprietary development, product business strategy. He was
products - GoSpiro® Home Spirometer, management, project CEO of GoAntiques, Inc. until
GoHome™ Patient Health Monitor and the management, clinical services, its acquisition by Worthpoint
MTI CarePortal™. marketing and customer care. Corporation in 2008.

Biobanking, Anatomic Pathology,

Cytopathology, Molecular Diagnostics,
Myeloid Tests, Solid Tumor, BRCA1 & BRCA2,
Cystic Fibrosis, verifi® (NIPT) by CBS Labs,
Pharmacognetics, Women's Health,
Research, Clinical Trials, and PD-L1 Erick Martinez, MD – President Alex Morales, MD – Chief
Immunohistochemistry and CEO Operating Officer
 Tim Peters
Synspira is developing a new class of Director of Clinical
glycopolymer-based therapeutics that have Shenda Baker, Ph.D. Operations
the potential to address a major unmet need Chief Executive Officer Mr. Peters has 19 years of
associated with pulmonary disorders- the Dr. Shenda Baker is Chief Executive diverse pharmaceutical
chronic infection and related mucus Officer of Synspira (interim). Dr. research management
accumulation and inflammation which often Baker has more than 25 years of experience working in R&D
lead to exacerbations, hospitalizations and experience in polymer chemistry Program Management,
ultimately irreversible lung function decline and materials science and in Clinical Information
in diseases including cystic fibrosis, chronic leading, funding, and directing Systems/IT, Clinical Data
obstructive pulmonary disease (COPD), and scientific research and Management and Clinical
pneumonia. development Trial Operations.

Quench Medical is developing a novel

aerosol platform technology to deliver
medicine into deep areas of the lung with
unprecedented efficiency to greatly increase
efficacy in treating pulmonary airway Nancy Ness, Acting CFO
diseases. The primary application of this Nancy Ness is a financial
technology is an inhaled chemotherapy professional with extensive
medication to treat lung cancer by directly Bryce Beverlin II, Ph.D. Founder & experience in biomedical
targeting lung tumors and minimizing CEO company development who
systemic toxicity. The platform technology is Bryce Beverlin II founded Quench is an expert in shaping
being extended with further pipeline Medical to solve crucial problems rounds of financing in
medications to treat additional lung diseases in respiratory drug delivery for addition to controllership
such as COPD, asthma, and cystic fibrosis. treating lung diseases. and treasury duties.
Copernicus Therapeutics, Inc. (CTI) is a
clinical stage biopharmaceutical company
and a leader in the emerging field of
precision medicine and gene therapy.
Through their proprietary, non-viral, nucleic
acid nanoparticle platform, they are able to
achieve robust gene transfer in several
tissues without the immune response and
limited treatment window of AAV. Combined Mark J. Cooper, MD
with world-class intellectual property in Robert C. Moen, MD, PhD Senior Vice President,
plasmid design for long-term and controlled President & Chief Executive Officer Science and Medical Affairs
expression, CTI is poised to become a leader | Board Member As one of Copernicus’
in the 21st century pharmaceutical industry. Dr. Moen has served as academic founders and the
Copernicus‘ President and CEO current Senior VP of Science
Current programs include: since 1998, bringing his scientific, and Medical Affairs, Dr.
manufacturing, clinical, and Cooper is actively involved in
Cystic Fibrosis (Phase I/II Complete) regulatory expertise to drive the the clinical development of
Eye (Pre-clinical) company’s nanoparticle gene our nanoparticle gene
Brain (Pre-clinical) therapy technologies forward. therapy technologies.

RAY PICKLES, PHD

TONY D. CHURCH Internal Scientific Adviser
CEO
Specialties Ray is an associate professor
Contract research organization, Respiratory Tony has a wealth of experience in of microbiology and
disease, Cystic Fibrosis, COPD, Asthma, and research and in project immunology at the UNC
Respiratory drug discovery management. School of Medicine
 About the Team

Our Molecular Diagnostics

Consulting team has over 30
years of professional
experience in molecular
About the Founder diagnostic product
development. Our
Sylvia NormanSylvia A. Norman, combined expertise covers
PhD, PMP is the Founder of all aspects of product
Molecular Diagnostics Consulting. development from project
planning to product launch.
Dr. Norman has 20 years of Staffed by experienced
Diagnostics Project Planning, Project experience in developing products industry veterans, you can
Management, Diagnostics Assay Design, for the molecular diagnostic trust Molecular Diagnostics
Clinical Specimen Sourcing, Regulatory market. She specializes in Consulting with your
Compliance Guidance, Generating/Editing designing, developing, and diagnostic product
Documents, Social Media Marketing, and validating molecular diagnostic development out-sourcing
New Lab Set-Up assays. needs.

John L. Lubniewski
President, Chief Operating
Timothy (TJ) B. Johnson Officer
Chief Executive Officer Mr. Lubniewski has served as
Mr. Johnson has served as the our President and Chief
company’s Chief Executive Officer Operating Officer since April
and as a member of our board of 2018. He previously served
directors since January 2008. He as our Chief Business Officer
also served as the company’s from April 2011 until April
President from January 2008 until 2018. Mr. Lubniewski joined
April 2018. Mr. Johnson joined us us from Ventana, a medical
from LVC Consulting, a consulting diagnostics company and
company, where he was a partner member of the Roche Group
from April 2007 to January 2008. and global headquarters of
Prior to April 2007, Mr. Johnson Roche Tissue Diagnostics, or
spent five years in leadership roles RTD, where he served in
RNA Analysis, Companion Diagnostics, at Ventana Medical Systems, Inc. leadership roles for nine
Molecular Diagnostics, Pharma Services, or Ventana, a medical diagnostics years both before and after
mRNA, miRNA, Sequencing, and Gene company, prior to its acquisition by the acquisition of Ventana
Expression Roche Holdings, Inc., or Roche. by Roche in March 2008.
 HANY MASSARANY
President and Chief Executive
Officer
Mr. Massarany has served as SCOTT MENDEL
President and Chief Executive Chief Financial Officer
Multiplex Molecular Diagnostics, Medical Officer and Director since May Mr. Mendel has served as
Devices, Infectious Diseases, Syndromic 2011. Mr. Massarany has over 25 Chief Financial Officer since
Testing, Electrochemical Detection, In Vitro years of healthcare, life sciences, May 2014. Mr. Mendel has
Diagnostics, Random and Continuous Access, and diagnostics experience and over 25 years of financial
Multiplex PCR, eSensor, IVD, Patient Centered has held various global leadership leadership experience and
Care, True Sample-to-Answer Workflow, positions with Ventana, Roche has held various leadership
Patient Safety, Long Term Partner, and Data Diagnostics, Bayer Diagnostics, and positions with The Active
Management Chiron Diagnostics Network and GE Healthcare

Infectious Disease Diagnostics, Multiplex

PCR, Real-time PCR Instruments and
Reagents, Hi-Res Melting Instruments and
Kits, Molecular Diagnostics, and Syndromic
Testing

Molecular Diagnostics, Flow Cytometry,

Genomic Solutions, Oncology,
Hematopathology, Infectious Diseases, and
Medical Genetics
Molecular Image is pioneering the development of predictive molecular diagnostics using proprietary software techn
 Frank Stegmeier, PhD, Chief
Scientific Officer
David Meeker, MD, Chief Executive
Officer Frank Stegmeier is an
Dr. Meeker is the President & CEO industry-leading expert in
of KSQ, a biotech company with a genetics, cancer biology and
proprietary CRISPRomics drug functional genomics who
discovery engine. Utilizing this has led the industrialized
engine, KSQ is advancing a application of functional
pipeline of oncology and immuno- genomics for oncology drug
Functional Genomics, Drug Discovery, oncology drug development discovery in the
CRISPR, Immuno-Oncology, and Therapeutics programs. pharmaceutical industry.
 STEVE QUAKE, D.PHIL.
Co-President
Dr. Stephen Quake’s
research is at the nexus of
biology, physics and
technology development. He
JOE DERISI, PH.D. has invented many
Co-President measurement tools for
Dr. Joseph DeRisi is infusing biology, including new DNA
biomedical research with an sequencing technologies
inventor’s flair. He led the that have enabled rapid
development of a new diagnostic analysis of the human
Biochemistry, Bioengineering, Bioinformatics, tool called the Virochip that genome and microfluidic
Biomedical Research, Biophysics, Cell Atlas, contains DNA from every known automation that allows
CRISPR, Dengue, Ebola, Genetics, Genome virus that can quickly scan blood scientists to efficiently
Sequencing, Genomics, Infectious Disease, or spinal fluid for evidence of isolate individual cells and
MERS, Recombinant DNA, and Zika infection. decipher their genetic code.

Ruby Yanru Chen-Tsai, Ph.D.,

Co-founder and CSO
uhong Jiang, Ph.D., Co-founder, Dr. Chen-Tsai received her
President and CEO PhD from Cornell University.
Most recently, Dr. Jiang has served She has been working with
Genome Editing, Mouse Rat Model as General Manager of China embryonic stem cells and
Generation, Cell Line Models, iPSC Disease Operations at MicuRx genetic animal models for
Modeling, iPSC Differentiation, iPSC Tox Pharmaceuticals (a California- over 18 years. Prior to
Study, iPSC Generation, Reference Standards, based novel drug discovery joining ASC, Dr. Chen-Tsai
Isogenic Cell Lines, Phonetype Screening, company). Dr. Jiang received a worked at Stanford
FFPE , Contract Research, Stem Cell Culture, Ph.D. degree in the U.S. He has University for 19 years as
Bioproduction, CRISPR/Cas9, Cancer more than twenty-five years of the Director of the
Research, Neuro Disease Research, experience in life science research, Transgenic Research Center
Genomics, Virus Packaging, Safe Harbor and more than 12 years of product and Associate Director of
Locus, antibody production, Antibody development and management the Stanford Cancer
screening, antibody discovery, and experience in several biotech Institute, overseeing nine
Bioproduction companies. research support labs.
 Riley Doyle As a biochemist turned Victor Dillard A former
software engineer, Riley chemical engineer keen on
recognized the enormous seeing personalized
untapped potential for software treatment realized, Victor
innovation in the life sciences. An has spent the past five years
Synthetic Biology, Genome Engineering, alum of Genentech, he brings ten leading Desktop Genetics’
Genome Editing, Functional genomics, years of laboratory-based genetic business development and
Biotechnology, CRISPR, Cell Line Engineering, engineering experience to Desktop CRISPR genome editing
Drug Discovery, Bioinformatics, Screening, Genetics initiatives.
Artificial Intelligence, and Machine Learning CEO and Founder COO and Founder

Founded by former SpaceX engineers,

Synthego is a leading provider of genome
engineering solutions. The company’s
flagship product, CRISPRevolution, is a
portfolio of synthetic RNA designed for
CRISPR genome editing and research.

Scientific Innovation, Medical Breakthroughs,

Gene-editing technology, Protein
Engineering, Breakthrough Human
Therapeutics, CRISPR-Cas9 gene editing
technology, Patient Focused, Hematology,
Ophthalmology, Genetic Diseases, and Rare
Disease

Jim Burns, Ph.D. ndy Scharenberg, M.D.

President and CEO Chief Scientific Officer

Applied Biological Materials (abm) provides

quality research reagents and custom
services at incredible prices. We have an
extensive product range to make abm your
one-stop supplier for all your research needs:
PCR, RT-PCR, qPCR, antibodies, siRNA,
miRNA, CRISPR, stable cell lines,
immortalized cell lines, growth factors, and
various viral expression systems (adenovirus,
lentivirus, AAV).
RNA silencing, miRNA inhibition, lncRNA
knockdown, CRISPR Alternatives, mRNA
Knockdown, miRNA mimics, Cell Biology,
Cancer Research, Neuroscience, Functional
Genomics, and Antagomirs

Paul Garofolo
Co-Founder, Chief Executive
Officer, & Chairman Dave Ousterout, PhD
Paul has been a member of Co-Founder & Chief
multiple Executive Management Technology Officer
teams of both publicly traded Dr. Dave Ousterout is a co-
multi-national corporations and founder and Chief
successful startup opportunities. Technology Officer for Locus
He currently serves as the CEO of Biosciences. Dave’s expertise
Locus Biosciences, an emerging is in protein engineering and
CRISPR, Bacterial Infections, Antibiotic biotech focused on the discovery early stage applications of
Resistance, Biotechnology, Microbiome, and and development of a novel class new technologies to treat
Targeted Therapeutics of CRISPR/Cas Antimicrobials. human diseases.
 Kamel Khalili, Ph.D.
Professor and Chair,
Department of
Neuroscience and Director,
Center for Neurovirology
Temple University Lewis Katz
School of Medicine

Dr. Khalili joined Temple

University in 1999 as
Director for the Center of
Neurovirology and Cancer
Thomas Malcolm, Ph.D. Biology, as well as Professor
President & CEO in the Department of
Biology. During his tenure,
Dr. Khalili defined many of
Dr. Thomas Malcolm is a founder the biochemical and genetic
of Excision BioTherapeutics and mechanisms of activation
currently serves as CEO and associated with the Human
President. Prior to founding Immunodeficiency Virus
Excision, Thomas served as the (HIV), JC virus and its related
CEO of Criterion BioScience condition Progressive
Our mission is to advance gene editing Research Group, a life sciences Multifocal
therapeutics for our indications into safe and consulting group based in New Leukoencephalopathy, and
efficacious medicines that will greatly York, NY that specialized in Herpes Simplex Virus (HSV).
improve the lives of infected individuals. analyzing and advising on Dr. Khalili currently serves as
biotechnologies. In addition to his Professor and Chair of the
The company was founded in 2015 and has current position, Thomas serves as Department of
already produced a considerable intellectual a scientific officer and board Neuroscience, as well as the
property portfolio covering the use of the member for BioMark Diagnostics Director for the Center for
CRISPR and other gene editing tools in Inc., a company developing Neurovirology at Temple
relation to our targeted pipeline of industry-disruptive metabolomic University School of
indications. diagnostics for cancers. Medicine.

Founded in 2000 and headquartered in

Memphis, Tenn., Transnetyx launched the
world’s first fully-automated genotyping
system for detecting transgenic, knockout,
knock-in, SNP and CRISPR mutations in
animal research models.
 LUHAN YANG, Ph.D., Co-
Founder and Chief Scientific
Officer
Dr. Luhan Yang co-founded
eGenesis in 2015, and is
currently leading the
scientific strategies and
efforts at eGenesis as chief
scientific officer. She
previously developed the
highly programmable
ULIE SUNDERLAND, Interim CEO genome-engineering tool,
Ms. Julie Sunderland was CRISPR/Cas9, for use in
appointed interim CEO of eGenesis mammalian cells, and
in December 2017, and is also pioneered the first isogenic
Managing Director at Biomatics human stem cell lines to
Capital Partners. Prior to co- model human diseases at
founding Biomatics in 2016, Ms. the tissue level. She was
Sunderland was director of recently honored in the
Program Related Investments for Bloomberg 50 (2017),
the Bill & Melinda Gates named “Young Global
Foundation, where she led the Leader” by the World
foundation’s $1.5 billion strategic Economic Forum (2017), was
eGenesis is a life sciences company focused investment pool focusing on global among “30 Under 30” in
on leveraging CRISPR technology to deliver health, global development and Science and Healthcare by
safe and effective human transplantable education. In this role, she funded Forbes Magazine (2014) and
cells, tissues and organs to the hundreds of 50 investments, including 30 in was a laureate of the “Young
thousands of patients worldwide who are in health care, and built a team of 10 Entrepreneur Initiative”
dire need. investment professionals. competition (2014).

Today, our gene modulation research tools

have expanded to include CRISPR-Cas9 gene
editing reagents. We launched the very first
synthetic CRISPR-Cas9 guide RNAs, and now
offer one of the most comprehensive CRISPR
gene editing portfolios in the industry,
including the first arrayed synthetic CRISPR
RNA whole human genome library. Our gene
editing products include predesigned
genome-wide lentiviral and synthetic guide
RNA reagents designed by a validated
algorithm, Cas9 nucleases, and design tools
& kits for homology-directed repair.
The CRISPR/Cas9 system is one of the latest
developments in the field of genetic
engineering. Using CRISPR technology time it
is possible to perform easy and cost efficient
editing of a cells´ genome - as demonstrated
in every organism studied so far!

Eurofins Genomics offers a comprehensive

product portfolio to guide your CRISPR/Cas9
experiment to success.

David Aberle, MBA

Chief Financial Officer & Vice
President of Finance
Aberle comes to
Recombinetics with 20 years
of experience in financial
and strategic management
including six years in the
Recombinetics is a global leader in Tammy Lee medical device industry at
proprietary gene repair and gene-editing President & Chief Executive Officer AGA Medical Corporation
technology. Our breakthrough scientific Lee has more than 15 years of (now part of St. Jude
research and development of TALEN and executive leadership in corporate, Medical) where he served as
CRISPR (Cas9) gene editing technologies has government and regulatory affairs; Interim Chief Financial
resulted in breakthroughs in the regenerative marketing and communications; Officer, Corporate Controller,
medicine, disease research and animal fundraising; and human resource Treasurer and other key
agriculture. functions. financial leadership roles.
Exonics is initially focused on repairing the
most frequent mutations that cause
Duchenne muscular dystrophy, for which
there is currently no cure. Preclinical data ERIC OLSON, PHD Founder and JOHN RIPPLE Chief Executive
suggest Exonics’ novel SingleCut CRISPR gene Chief Science Advisor Officer
editing has the potential to treat a large Eric Olson, PhD, is Professor and John Ripple joined Exonics
proportion of boys who suffer from Chair of the Department of Therapeutics as Chief
Duchenne. This is achieved by repairing Molecular Biology at the Executive Officer in 2017.
errors in the DNA sequence that causes University of Texas Southwestern Prior to Exonics, John served
mutations of dystrophin, the protein missing Medical Center in Dallas, where he as CEO of Ensemble
in boys with Duchenne. also holds the Robert A. Welch Therapeutics, Permeon
Though our primary focus is on Duchenne, Distinguished Chair in Science, the Biologics, Virdante
we plan to expand our therapeutic focus to Annie and Willie Nelson Pharmaceuticals (acquired
include other related neuromuscular Professorship in Stem Cell by Momenta
diseases where our proprietary SingleCut Research, and the Pogue Pharmaceuticals), and
CRISPR gene editing may provide a significant Distinguished Chair in Research on Syntonix Pharmaceuticals
clinical benefit. Cardiac Birth Defects. (acquired by Biogen).

Jonathan Weissman, Ph.D.

Co-director
Jonathan Weissman is a
Professor of Cellular and
Molecular Pharmacology at
Jennifer Doudna, Ph.D. the University of California,
Executive Director San Francisco. The
Jennifer Doudna is a Professor of Weissman lab combines
The Innovative Genomics Institute (IGI) is Molecular and Cell Biology and large-scale approaches and
composed of diverse researchers with a Chemistry at the University of mechanistic investigations to
powerful combined expertise. After the California, Berkeley. The Doudna understand fundamental
development of the CRISPR-Cas9 system for lab pursues a mechanistic biological processes
rewriting DNA, we saw the potential of understanding of fundamental including gene expression,
applying this technology to solve some of biological processes involving RNA translation, and protein
humanity’s greatest problems. molecules. folding.
GeneCopoeia, Inc. is a leading provider and
manufacture of genomics and proteomics
products and services worldwide.
GeneCopoeia has developed a series of
cutting edge research tools, including the
largest collection of expression-ready clones
(ORF cDNA, Promoter, shRNA, miRNA),
comprehensive genome-editing tools (CRISPR
and TALEN), as well as highly efficient viral
delivery systems (Lentivirus and AAV).

Instrumentation for Cell Line Development,

Cell documentation for proof of clonality,
Single cell cloning, Gene editing, CRISPR, and
single cell printing

DNA Mutation Detection, Chromosome

Analysis, Custom DNA Probes, Chromatid and
Chromosome Paint Products, Biomedical
Applications, Gene Editing Quality Control,
CRISPR Analysis, Genetic Disease Diagnosis,
Gene Editing Off-Target Effects, Gene Editing
Process Optimization, Undiagnosed Disease
Discovery, Genetic Disease Discovery, and
Genetic Disease Screening http://www.kromatid.com/about-us/leadership-team/

Specialties
Single Cell Transfection, Electroporation,
CRISPR/Cas9, and Cell Line Generation

Specialties
Biotech, CRISPR, and Digital Biology
 Dr. Michael Maguire
Founder & Director, CEO
Dr. Maguire is President and CEO Dr. Shirley O'Dea
of Avectas, which he has led since Founder & Director, CSO
its inception in 2012. He has 20 Dr. O’Dea co-founded
years of experience in the life Avectas in 2012 and is the
sciences industry, serving as a company’s CSO. She is
founder, investor, director and charged with overseeing
business leader. Dr. Maguire scientific programs. Dr.
Specialties graduated from Trinity College, O’Dea’s basic research
Cell Engineering, Transfection, Cell Therapy, Dublin, as a biomedical engineer provides a strong pipeline of
CAR-T, Gene Editing, Gene Therapy, and and completed his PhD on local applications for Avectas
CRISPR delivery to the lung. technology.

Specialties
iPS Cells, Virus Packaging, Gene Editing
CRISPR/Cas9, and Cell Immortalization

Dr. Erdogan Gulari – Co-

Founder & Managing
Partner
Custom Oligonucleotides, Nucleic Acid Dr. Jean-Marie Rouillard – Co- In addition to his roles at
Synthesis, Gene Synthesis, NGS Target Founder & Chief Scientific Officer Arbor Biosciences, Dr. Gulari
Enrichment, Synthetic Biology, Probes, Dr. Rouillard co-founded is the Donald L. Katz
CRISPR/Cas9, In vitro Gene Expression, NGS MYcroarray in 2006 after spending Collegiate Chair, Professor in
Sequencing Service, Next Generation time as a research investigator in the Chemical Engineering
Sequencing, DNA Synthesis, and Dr. Gulari’s lab at the University of Department at the
Hybridization Capture Michigan. University for Michigan

Gentle to the cell, effortless, compact, and

cost-effective; it is designed to empower a
variety of single cell applications, including
cell line development, CRISPR, monoclonal
antibody development, single cell genomics,
circulating tumor cell (CTC) and circulating
fetal cell isolation.
We also aim to remain at the cutting edge of
biomedical research, incorporating the latest
emerging technologies, including
CRISPR/Cas9 genome editing, and
engineering the most advanced research
tools for high impact screening assays and
sophisticated disease model creation. With
our rapid and cost-effective approaches, we
have pioneered the way for systematic
production of large cohorts of preclinical
subjects, designed to more precisely model
human disease and ready to evaluate
therapeutic potential of specific gene targets. Chia-Lin Wang, PhD
By synergizing CRISPR/Cas9 and RNAi Prem Premsrirut PhD, MD Director of Genetic
technologies, our next generation Founder and President/CEO, Engineering Services,
CRISPR/Cas9-RNAi mouse models will serve Mirimus Inc. Mirimus Inc
to transform preclinical drug discovery
research and drive the development of Research Assistant Professor, Cell Research Assistant Professor,
effective and safe candidate therapies to Biology, SUNY Downstate Medical Cell Biology, SUNY
combat human disease. Center Downstate Medical Center

RISPR/Cas9 is a powerful genome editing tool

that makes therapeutic gene editing possible.
It is easier to use, faster, and more accurate
than previous gene editing techniques and
thus has the potential for a wide range of
therapeutic applications. In particular,
CRISPR/Cas9 gene editing has the potential
to treat a variety of incurable genetic
diseases. However, current CRISPR delivery
methods rely on viruses and are problematic
due to viral-induced toxicity and prolonged
Cas9 exposure, increasing off-target effects. A
non-viral CRISPR/Cas9 delivery method is
needed. In addition, low efficiency levels Kunwoo Lee, Hyo Min Park,
achieved make it impossible to target certain Ph.D. UC Berkeley Ph.D. UC Berkeley
diseases. CEO and Co-founder CTO and Co-founder
Specialties
Cloning, Virus Packaging, Vector
Construction, BAC Recombineering,
Lentivirus, Adenovirus, Adeno-associated
virus, shRNA libraries, CRISPR, shRNA, and
Gene synthesis

Specialties
Cloning, Virus Packaging, Vector
Construction, BAC Recombineering,
Lentivirus, Adenovirus, Adeno-associated
virus, shRNA libraries, CRISPR, shRNA, and
Gene synthesis

APSIS Therapeutics, LTD. is an enterprise

developing new chemical entities of
therapeutic importance with its focus on
novel nucleosides, nucleotide prodrugs, and
modified CRISPR/Cas9 (lgRNA/Cas9). APSIS is
dedicated to discovering, developing and
commercializing cures for patients suffering
from chronic viral infections, diseases caused
by retrovirus (HIV) and DNA virus (HSV, HBV) Sheri Lin, CEO

E-mail: sheri.lin@apsisglobal.com

Specialties
Synthetic Biology, CRISPR, and Gene Editing
 George Church, Ph.D.,
Business and Science
Advisor
George Church is Professor
of Genetics at Harvard
Medical School and Director
of PersonalGenomes.org,
which provides the world's
only open-access
information on human
Genomic, Environmental &
Josiah Zayner, Ph.D., CEO Founder, Trait data (GET). His 1984
case@the-odin.com, Harvard PhD included the
@4LovofScience first methods for direct
I started the company in 2013 working nights Dr. Josiah Zayner is a global leader genome sequencing,
and weekends to fulfill orders and working as in the BioHacker movement, molecular multiplexing &
a Synthetic Biology fellow at NASA during the constantly pushing the boundaries barcoding. These led to the
day. In late 2014 I decided to make a DIY of Science outside traditional first genome sequence
Bacterial genome engineering CRISPR environments. He started (pathogen, Helicobacter
kit(http://www.the-odin.com/diy-bacterial- BioHacking during his Ph.D. in pylori) in 1994 . His
gene-engineering-crispr-kit/) and raised Molecular Biophysics at the innovations have
~$70k through crowdfunding. In 2015 we University of Chicago, creating The contributed to nearly all
made around $200k and this year we are Chromochord in his apartment, "next generation" DNA
projected to make near $500k. We are the world’s first musical sequencing methods and
growing at 10% or more month over month instrument that uses engineered companies (CGI-BGI, Life,
since August 2016. protein nanotechnology. Illumina, Nanopore).

CULLEN R. BUIE, PH.D.

Co-Founder
Cullen R. Buie, Ph.D. is a
Transfection, Immunotherapy, Cell PAULO A. GARCIA, PH.D. Tenured Professor of
engineering, Mechanical engineering, CEO & Co-Founder Mechanical Engineering at
Genetic engineering, Mammalian cells, Dr. Paulo A. Garcia co-invented the MIT and co-inventor of the
Bacterial cells, Manufacturing, Immunology, Flowfect™ technology while he high-throughput genetic
CRISPR, and CAR T-cell was a Research Scientist at MIT. modification technology.

Specialties
IVF, Livestock Cloning, Embryo Transfer, and
CRISPR/CAS9
 Tedd Elich - CSO
Tedd has worked in the ag
biotech industry for over 20
years. Prior to joining
Proprietary bioinformatic analyses AgBiome/LifeEDIT he was
demonstrate that there are thousands of the Gene Expression
novel CRISPR-Cas gene editing systems in this Technology Lead at
collection. LifeEDIT is prioritizing and Mark Moore - CEO Monsanto Co. where he led
investigating these systems in order to Mark was involved in early multidisciplinary efforts to
develop novel gene editing tools with diverse discovery projects for Herceptin develop and implement
PAM requirements, higher fidelity, novel and Avastin at Genentech. He was technology for regulating
functionality, reduced immune response risk, a Founder and CSO of Deltagen, a transgene expression in
and smaller size for easier delivery. functional genomics company. crops.

Our mission is to deliver innovative and cost-

effective therapeutics to treat diseases of
unmet needs. We focus on antibody-based
therapeutic platforms, including chimeric
antigen receptor (CAR)-T and Bi-specific
antibody technology, while leveraging new
technology on CRISPR genome editing. http://www.arbele.org/senior-management/

Eric Nilson
Chief Technology Officer,
Board Member & Corporate
Secretary

Eric Nilson is a Partner at

QED Dynamics Inc., a
Southern California-based
consulting firm which
specializes in leveraging
informatics for
biopharmaceutical and
Specialties Scott Petersen, Ph.D. molecular diagnostic
siRNA Delivery, Antisense, CRISPR, and RNAi The President and CEO companies.

Specialties
Gene Editing , Gene Cloning, CRISPR, Protein
Synthesis, Expression Systems, Custom
Antibody , Custom Peptide or gene synthesis,
Antibody Phase Display , and Technology
Transfer
Hunterian Medicine LLC is a gene-editing
company working to cure genetic diseases by
correcting DNA mutations using its innovative
CRISPR delivery technology. The company’s
patented technology solves the problem of
CRISPR delivery with a “2-for-1” genetic
element that enables delivery via a single
adeno-associated virus (AAV).

Stealth-mode startup accelerating drug

development using a proprietary CRISPR-
based evolution platform

Our algorithms also allow researchers to

narrow down choices of target sequences
with predictable outcomes. We believe our
approach significantly reduce the time, cost
and effort necessary for gene editing using
CRISPR.

Tired with low efficiency of RNAi mediated

knockdown?
* Worries about never ending validation from
CRISPR/Cas9 genome editing?
* Do you know easy, fast, and accurate
genome editing approach with FastTALE
TELAN techonolgy?
* Curious about SuperFast qPCR protocol
which will be done in 20 min/reaction?
* Interest in one-step Reverse Transcription
for RT-PCR?

You name a gene, we deliver your mice! We

generate mouse models for you using gene
targeting (knock-out/knock-in), transgenic
(including BAC) as well as CRISPR/Cas9
technologies.
 Charles Daitch, PhD
CEO & Founder
Dr. Daitch is the Founder of Akonni
and has served as the CEO and
Board member since its inception
in 2003. He has 26 years of Lawrence Firestone
product development experience Executive Vice President &
in integrated biosensors Chief Financial Officer
encompassing a broad range of Lawrence Firestone joined
Akonni Biosystems is a molecular diagnostics disciplines including chemistry, Akonni as the Executive Vice
company that develops, manufactures, and biology, biomaterials, engineering, President and Chief Financial
will market sophisticated genetic testing and chemical/biological defense. Officer in April of 2018. Mr.
devices for complex infectious and human He manages and leads Firestone draws on over 35
health diseases, like Methicillin-resistant multidisciplinary teams of years of executive
Staphylococcus aureus (MRSA), multi-drug- scientists and engineers focused management experience in
resistant tuberculosis (MDR-TB), and on the development of next- both public and private
influenza sub-typing with oseltamivir- generation in-vitro diagnostic technology companies as a
resistance detection devices. C-level executive.

TERRI LEHMAN, PH.D.

RAMA MODALI Dr. Lehman has served as

BioServe’s Chief Technical
Rama Modali is the founder and Officer since 1993. Terri is
president of BioServe. Since responsible for development
Specialties BioServe’s 1989 inception, Rama and maintenance of all
Human Biospecimen Provider, Custom spearheaded our efforts to standard operating
Biospecimen Collections, Pre-Clinical develop and provide advanced procedures (SOPs) for all
Molecular Srevices, DNA and RNA Extraction, molecular biology services to research work, as well as
Genotyping, Real-Time PCR, and DNA pharmaceutical, academic and quality control across all
Synthesis government institutions. products and services.
Regenerative Medicine, Tissue Engineering,
Stem Cell Research, Pluripotent Stem Cells,
iPSC, Biotechnology, Personalized Medicine,
Molecular Biology, DNA,

Stratos Genomics' goal is to establish the Mark Kokoris

next gold standard of DNA sequencing with President, CEO and Board Member
its “Sequencing by Expansion™” (SBX) 20+ years of experience working Bob McRuer, Ph.D.
method. SBX is a simple, elegant, single- on the cutting edge of CTO and Board Member
molecule detection process that circumvents biotechnology. Mr. Kokoris’s 25+ years of instrumentation
the limitations of competing technologies, passion is to conceive and develop design, optics/electro optics
allowing accurate, ultra-low-cost whole- innovative and transformative and project management
genome sequencing. technologies. experience.

Our algorithms also allow researchers to

narrow down choices of target sequences
with predictable outcomes. We believe our
approach significantly reduce the time, cost
and effort necessary for gene editing using
CRISPR.
 c.suite leaders and titles3 c.suite leaders and titles4 c.suite leaders and titles5

Teresa D. Dodd | Sr. Director, Revenue Cycle

Sam M. Rua, Jr.

Vice President of Regulatory
Affairs and Quality Systems

Michael Reitermann - Member of the Managing Board

Timothy Herpin, Ph.D., M.B.A. Steven Kanner, Ph.D. Chris Fuller, Ph.D.
Chief Business Officer Chief Scientific Officer Vice President of Informatics

David Gruber Dr. Amalia Abut

VP Sales and Business Chief
Development Financial Officer

Daniel Hoogestraat
MB(ASCP)
Stephen J. Salipante, M.D., Ph.D Dhruba J. SenGupta Ph.D Medical Laboratory Scientist
Assistant Director Senior Research Scientist Lead

Dr. Maria Chan VP Jay Foust SVP Dr. Sian Jones VP

Dr. Amin Khan is a board-

Dr. Layla Alizadeh is a board- Fralmer Nierva is a senior certified
certified, fellowship-trained executive holding the position gastroenterologist/hepatolog
pathologist of Laboratory Director ist

KEITH HYLAND, PhD Ralph Nelson Steve Nelson

Executive Vice President Chief Financial Office Chief Information Officer

Alexander Joyner, PhD

Yamini Bynagari, PhD Jamey Kain, PhD Dr. Alexander Joyner is a
Dr. Yamini Bynagari is Director Dr. Jamey Kain is Director of Senior Clinical Bioinformatics
of Clinical Research at Machaon Genetic Innovation at Scientist at Machaon
Diagnostic Machaon Diagnostic Diagnostics

or treatment options
Todd C. Bennett Charles J. Collins, PhD Nancy M. Fairchild, SPHR
Senior Vice President, Global Senior Vice President, Senior Vice President,
Sales and Customer Operations Research and Development Human Resources

James M. O'Brien
Executive Vice President, Dieter Schapfel, MD Paul C. O'Brien
Finance Chief Medical Director for Vice President of Global
Enzo Clinical Labs Human Resources

PAUL MCMULLIN
MICHAEL VISHNEVETSKY, PH.D. Head of Global Sales & DR. BRADLEY PATAY, M.D.
Head of Business Development Marketing Chief Medical Officer
Maged Shenouda James Pennington Luc Lebreton
Chief Financial Officer MD, Chief Medical Officer PhD, R&D, Programs Director

Nakela Cook, M.D., M.P.H.,

F.A.C.C. David C. Goff, M.D., Ph.D. W. Keith Hoots, M.D.
Immediate Office of the Division of Cardiovascular Division of Blood Diseases
Director (IOD) Sciences (DCVS) and Resources (DBDR)
Chief of Staff, 2008 - Present Director, 2016 - Present Director, 2013 - Present

LINH H. LE TOM SCHOENHERR MICHAEL MARTINSON

Chief Operating Officer Chief Commercial Officer Chief Financial Officer

Steven Chamow, Ph.D. Elizabeth Leininger, Ph.D.

Fred Kurland, J.D., M.B.A. Vice President of Research Vice President of Regulatory
Chief Financial Officer and Development Affairs
 Jason Terrell
Jason has expertise in clinical
medicine and in laboratory
diagnostics. He was educated
at Hardin-Simmon University Louise Day
Gaetan Michel (Biochemistry) where he Louise brings more than 20
Gaetan has over 10 years of graduated Summa Cum years of marketing, sales and
experience in production Laude, also receiving the leadership experience to her
management. Holland Medal of Honor. role at Volition.

Chiraag Patel, M.D., M.B.A. Jack M. Kaplan

Director Director Richard D. Carvajal, MD

Harry M. Buchman Dr. Belisario A. Arango Dr. Jason L. Freedman

Chief Business Officer Chief of Community Oncology Chief Pediatric Advisor

John Kaufman, MD
Gregory Gores, MD Oregon Health and Science Jonathan S. Zager, MD
Mayo Clinic Center Moffitt Cancer Center

BEN TAYLOR President, Chief GIUSEPPE DEL PRIORE, MD, JONATHAN ECKARD, PH.D.
Financial Officer MPH Chief Medical Officer Chief Scientific Affairs Officer

Directors - Masaru Watanabe

Shigeo Takenaka
Hitoshi Ueno
Shigeo Nishiyama
Taketoshi Oka*
Masaru Nakamura*
Takafumi Isogai*
 Brooke Greenstein Mukta Phatak, PhD
Bioinformatics Bioinformatics
Charles Murphy
Bioinformatics Brooke studies statistical Mukta is an early pioneer of
genomics at Cornell NGS technology; evaluating
Charles completed his PhD at University. She works on software, establishing
Cornell, working on NGS bioinformatics programming analysis best-practices and
analysis. and data visualizations. educating scientists.

Andrew Dickinson Laura Hamill

Executive Vice President, Executive Vice President, William A. Lee, PhD
Corporate Development and Worldwide Commercial Executive Vice President,
Strategy Operations Research

EVP & CHIEF COMMERCIAL EVP & CHIEF FINANCIAL EVP & CHIEF LEGAL OFFICER
OFFICER OFFICER AND CORPORATE SECRETARY
William Meury Matt Walsh A. Robert D. Bailey
Bill Meury is the Chief Mr. Walsh joined Allergan in Bob Bailey is the Chief Legal
Commercial Officer, and has February 2018 as Executive Officer and Corporate
served in this role since May Vice President and Chief Secretary, and has served in
2016. Financial Officer. this role since July 2014.

ograms, and training that help them better serve the Cystic Fibrosis community and the broader population of patients with respiratory and

Kristin Shelton, RRT, Board Oscar A. Flamenco, CPA, Board

Secretary Treasurer

Frederick Montgomery, PhD

Giora Davidai, MD Rhona Shanker Vice President of Medical
Chief Medical Officer Director of Regulatory Affairs Systems
 Michael E. Severino, M.D.
William J. Chase Carlos Alban Executive Vice President,
Executive Vice President and Executive Vice President, Research & Development
Chief Financial Officer Commercial Operations and Chief Scientific Officer

Michael E. Severino, M.D.

William J. Chase Carlos Alban Executive Vice President,
Executive Vice President and Executive Vice President, Research & Development
Chief Financial Officer Commercial Operations and Chief Scientific Officer

Michael E. Severino, M.D.

William J. Chase Carlos Alban Executive Vice President,
Executive Vice President and Executive Vice President, Research & Development
Chief Financial Officer Commercial Operations and Chief Scientific Officer

Michael E. Severino, M.D.

William J. Chase Carlos Alban Executive Vice President,
Executive Vice President and Executive Vice President, Research & Development
Chief Financial Officer Commercial Operations and Chief Scientific Officer

Michael E. Severino, M.D.

William J. Chase Carlos Alban Executive Vice President,
Executive Vice President and Executive Vice President, Research & Development
Chief Financial Officer Commercial Operations and Chief Scientific Officer

Michael E. Severino, M.D.

William J. Chase Carlos Alban Executive Vice President,
Executive Vice President and Executive Vice President, Research & Development
Chief Financial Officer Commercial Operations and Chief Scientific Officer

Michael E. Severino, M.D.

William J. Chase Carlos Alban Executive Vice President,
Executive Vice President and Executive Vice President, Research & Development
Chief Financial Officer Commercial Operations and Chief Scientific Officer

Michael E. Severino, M.D.

William J. Chase Carlos Alban Executive Vice President,
Executive Vice President and Executive Vice President, Research & Development
Chief Financial Officer Commercial Operations and Chief Scientific Officer
 Michael E. Severino, M.D.
William J. Chase Carlos Alban Executive Vice President,
Executive Vice President and Executive Vice President, Research & Development
Chief Financial Officer Commercial Operations and Chief Scientific Officer

Michael E. Severino, M.D.

William J. Chase Carlos Alban Executive Vice President,
Executive Vice President and Executive Vice President, Research & Development
Chief Financial Officer Commercial Operations and Chief Scientific Officer

Bart Filius, MBA - Chief

Operating Officer & Chief Andre Hoekema, Ph.D. - Chief Walid Abi-Saab, M.D. - Chief
Financial Officer Business Officer Medical Officer

Sean Johnston
Senior Vice President, General
Michael Varney, Ph.D. Counsel, Chief Compliance Kimball Hall
Executive Vice President, Officer, Corporate Secretary Senior Vice President,
Genentech Research & Early and Head of Legal Affairs, Manufacturing Biologics
Development Pharma North America Drug Substance

Sean Johnston
Senior Vice President, General
Michael Varney, Ph.D. Counsel, Chief Compliance Kimball Hall
Executive Vice President, Officer, Corporate Secretary Senior Vice President,
Genentech Research & Early and Head of Legal Affairs, Manufacturing Biologics
Development Pharma North America Drug Substance

Sean Johnston
Senior Vice President, General
Michael Varney, Ph.D. Counsel, Chief Compliance Kimball Hall
Executive Vice President, Officer, Corporate Secretary Senior Vice President,
Genentech Research & Early and Head of Legal Affairs, Manufacturing Biologics
Development Pharma North America Drug Substance

Sean Johnston
Senior Vice President, General
Michael Varney, Ph.D. Counsel, Chief Compliance Kimball Hall
Executive Vice President, Officer, Corporate Secretary Senior Vice President,
Genentech Research & Early and Head of Legal Affairs, Manufacturing Biologics
Development Pharma North America Drug Substance
Barbara White, M.D.
Chief Medical Officer Robert Discordia, Ph.D.
Barbara White, M.D., joined Sean Moran, CPA, MBA Vice President,
Corbus as Chief Medical Officer Chief Financial Officer Pharmaceutical
in June 2014. Dr. White's Sean Moran, CPA, joined Development &
industry experience includes Corbus in January 2014. He Manufacturing
Phase 1-4 clinical development has more than twenty years of Robert Discordia, Ph.D.,
experience in inflammatory and senior financial experience joined Corbus as Vice
autoimmune diseases, including with emerging biotechnology, President, Pharmaceutical
rheumatology, respiratory, and drug delivery and medical Development &
dermatology diseases. device companies. Manufacturing in May 2018.

Andreas Wastl, Vice

Christian Bohrmann, Vice Keith Wallace, Vice President President Innovations &
President Global Marketing & Customer Care Technology
Alliances Keith Wallace is Vice President Andreas Wastl is Vice
Christian Bohrmann is the of Customer Care of EXTEDO President Innovations &
Global Vice President for GmbH. Keith joined EXTEDO in Technology at EXTEDO
Marketing & Alliances at 2012. GmbH. Andreas joined
EXTEDO. He joined the EXTEDO in 2003 and since
company in 2006 to expand the He leads a global team of then has held different
Channel Management and highly skilled application positions within the
Partner Program support specialists company

William Duke, Jr. Ted Raad Jim Roach, M.D., FACP, FCCP
Chief Financial Officer Chief Business Officer Chief Medical Officer

David Rodman, M.D. is our

Smital Shah has served as our Executive Vice President of
Chief Financial Officer since Research & Development.
Gerard Platenburg has served October 2014. Smital has a David joined ProQR in 2017
as our Chief Innovation Officer 12-year track record of having previously served in
since February 2014. Gerard is a management and leadership leadership roles with
co-founder of our company and in biopharma companies and Novartis Institutes for
also served as the sole member investment banking, with Biomedical Research (NIBR),
of our supervisory board particular experience in Vertex Pharmaceuticals,
between August 2012 and financial strategy and capital miRagen Therapeutics and
December 2013 markets Nivalis Therapeutics.
Jim Gamgort
Chief Commercial Officer

Jim Gamgort is Chief Bill Scheinler

Commercial Officer of Alcresta Tasos Konidaris Chief Legal and Compliance
Therapeutics. Jim has over 25 Chief Financial Officer Officer and Secretary
years of commercial leadership
experience, launching multiple Tasos Konidaris is the Chief Bill Scheinler is Chief Legal
products and new indications in Financial Officer of Alcresta and Compliance Officer and
the medical device and Therapeutics. Prior to Alcresta Secretary at Alcresta
pharmaceutical industries. Therapeutics, Therapeutics.

Adrian Haigh
Director
Adrian Haigh was recently
Senior Vice President,
Patrick Vink Commercial Operations and
Director Chief Operating Officer of Claude Allary
Dr. Vink is a well-known and Gentium GmbH, playing a Director
active member of the European pivotal role in the sale of Claude Allary is in Paris
and North American life Gentium to Jazz Pharma for $1 working as an independent
sciences community. billion in December 2013 consultant in life sciences.

Adrian Haigh
Director
Adrian Haigh was recently
Senior Vice President,
Patrick Vink Commercial Operations and
Director Chief Operating Officer of Claude Allary
Dr. Vink is a well-known and Gentium GmbH, playing a Director
active member of the European pivotal role in the sale of Claude Allary is in Paris
and North American life Gentium to Jazz Pharma for $1 working as an independent
sciences community. billion in December 2013 consultant in life sciences.
 Sushant Kumar, MD, Ph.D
Jeffrey A. Gelfand, MD, Ph.D Dr Sushant is responsible for Michael Cynamon, MD, Ph.D
Dr. Jeffrey A. Gelfand, serves as the management of all Dr, Cynamon serves as a
a Chairman of the Scientific operational aspects and Member of Scientific
Advisory Board. investment. Advisory Board.

Po-Shun Lee, M.D. Ben Munoz, M.Sc., Ph.D.

Sheila Wilson, B.S.N., M.B.A. Executive Vice President, Chief Chief Scientific Officer
Senior Vice President, Clinical Medical Officer
Development Operations Dr. Munoz is currently se
 Barry J. Moze Brian K. Beeler
Executive Vice President, Chief Executive Vice President,
Paul W. Hoelscher Administrative Officer General Counsel
Executive Vice President, Chief Barry joined Horizon Pharma Brian joined Horizon Pharma
Financial Officer in June 2014 and in his in January 2013 and has
Paul joined Horizon Pharma in current role is responsible for more than 15 years of
June 2014 as executive vice all business operations and experience providing legal
president, finance and became project management, and counsel to businesses in
executive vice president, chief including human resources the healthcare and life
financial officer on Oct. 1, 2014. and information technology. sciences industries.

Barry J. Moze Brian K. Beeler

Executive Vice President, Chief Executive Vice President,
Paul W. Hoelscher Administrative Officer General Counsel
Executive Vice President, Chief Barry joined Horizon Pharma Brian joined Horizon Pharma
Financial Officer in June 2014 and in his in January 2013 and has
Paul joined Horizon Pharma in current role is responsible for more than 15 years of
June 2014 as executive vice all business operations and experience providing legal
president, finance and became project management, and counsel to businesses in
executive vice president, chief including human resources the healthcare and life
financial officer on Oct. 1, 2014. and information technology. sciences industries.

Barry J. Moze Brian K. Beeler

Executive Vice President, Chief Executive Vice President,
Paul W. Hoelscher Administrative Officer General Counsel
Executive Vice President, Chief Barry joined Horizon Pharma Brian joined Horizon Pharma
Financial Officer in June 2014 and in his in January 2013 and has
Paul joined Horizon Pharma in current role is responsible for more than 15 years of
June 2014 as executive vice all business operations and experience providing legal
president, finance and became project management, and counsel to businesses in
executive vice president, chief including human resources the healthcare and life
financial officer on Oct. 1, 2014. and information technology. sciences industries.

Jamie Freedman, MD, Ph.D

Tosh Butt Vice President, President, AstraZeneca Amy Jenner Vice President,
Respiratory Canada Inc. Commercial Operations
 Jamie Freedman, MD, Ph.D
Tosh Butt Vice President, President, AstraZeneca Amy Jenner Vice President,
Respiratory Canada Inc. Commercial Operations

Jamie Freedman, MD, Ph.D

Tosh Butt Vice President, President, AstraZeneca Amy Jenner Vice President,
Respiratory Canada Inc. Commercial Operations

Marcello Damiani, Chief

Juan Andres, Chief Technical Digital and Operational Annie Seibold Drapeau, Chief
Operations and Quality Officer Excellence Officer Human Resources Officer

Marcello Damiani, Chief

Juan Andres, Chief Technical Digital and Operational Annie Seibold Drapeau, Chief
Operations and Quality Officer Excellence Officer Human Resources Officer

Timothy D. Hunt, J.D.

Gerald Cox, M.D., Ph.D. Andrew Hack, M.D., Ph.D. Senior Vice President of
Chief Medical Officer Chief Financial Officer Corporate Affairs

Judy Chiao, M.D. Susan Davis, Ph.D.

Professor David Glover, Ph.D. Vice President, Clinical Senior Director, Business
FRS FRSE Development and Regulatory Development and Project
Chief Scientist Affairs Management

Brian Bray PhD, VP of

Jose Boyer PhD, VP Chemistry, Manufacturing
Ophthalmology Development Bill Thelin PhD, VP of Research and Control (CMC)

Christopher S. Henney, PhD •

Director Brian R. Mueller • Director
Craig Thompson • Chief Dr. Henney has served as the Brian R. Mueller is a senior
Executive Officer and Director Chairman of our board of financial executive with over
Craig joins Anthera with over 20 directors since August 2008 20 years of finance
years of experience in the and has been a member of experience, most of which is
pharmaceutical and healthcare our board of directors since in the biopharmaceutical
industries. April 2005 industry.
 Nicole Mayer Hamblett PhD

Associate Professor in the

Department of Pulmonary
John LiPuma MD Medicine at the Seattle
Children’s Hospital and Univ. D.R. (Dutch) VanDevanter,
Professor of Pediatrics of Washington School of PhD
(specialization in Cystic Medicine, Seattle and Co-
Fibrosis)Univ. of Michigan, Ann Director of the Cystic Fibrosis Case Western Reserve
Arbor, MI Therapeutic Network University School of
Coordinating Center Medicine, Cleveland, OH

Sanjeev Ahuja
Chief Medical Officer
Sanjeev has over 30 years of
experience as a physician Angela Walsh
including over 14 years in the Vice President, Finance
pharmaceutical/biotechnology Angela Walsh joined the
industry. He has training and Celtaxsys team in March 2016
clinical practice experience in from Green Circle Bio Energy,
obstetrics-gynecology and a renewable energy company
internal medicine. based in Cottondale, Florida.

Nancy Stuart
Chief Operating Officer
Lynette Herscha Ms. Nancy Stuart has served
General Counsel as our Chief Operating
Lynette Herscha has served as Officer since October 2007
James Cassella, Ph.D. our General Counsel and and was our Senior Vice
Chief Development Officer Secretary since June 2017 and President, Corporate
Dr. James Cassella has served as was our Vice President and Strategy and Operations
our Chief Development Officer Associate General Counsel from July 2006 to October
since February 2015. from July 2014 to June 2017. 2007.
 Mary Frances Harmon |
Mark E. Boulding | Executive Senior Vice President,
Vice President and Chief Legal Corporate Relations Mark J. Pykett, VMD, PhD |
Officer Mary Frances Harmon Chief Innovation Officer
Mark E. Boulding Ms. Harmon joined PTC in Mark J. Pykett, VMD, PhD
Mark Boulding has served as May 2015 with 30 years of Dr. Pykett joined PTC in
PTC's Executive Vice President experience in the August 2018 as Chief
and Chief Legal Officer since pharmaceutical industry Innovation Officer.
March 2012, and previously across a variety of functional Previously, he was the
served as Senior Vice President areas including sales, President and Chief
and General Counsel from April marketing, operations and Executive Officer of Agilis
2002 to February 2012. medical affairs Biotherapeutics.

Astrid Berthe
Vice President Regulatory
Charles Hagemeier, B.S. Affairs and Quality Assurance
Vice President Product Ramgopal Rao
Development Chairman of the Board

Douglas I Buckley, PhD

Vice President, Biology
Douglas I. Buckley, Ph.D. joined
3-V Biosciences as Vice
President, Biology in June 2012.
 Nishla Keiser Jennifer King, Ph.D. José Rivera
Senior Vice President, Deputy Senior Vice President, Executive Vice President,
General Counsel Business Development General Counsel

EDWARD REBAR, PH.D.

Chief Technology Officer
KATHY YI EDWARD CONNER, M.D. CLOSE
Chief Financial Officer Chief Medical Officer Dr. Rebar joined Sangamo in
CLOSE CLOSE 1998, and over the last 20
Kathy Yi has served as Senior Edward Conner, M.D. has years he has led the
Vice President and Chief served as Senior Vice development of the
Financial Officer since March President and Chief Medical Company's zinc finger
2017. Officer since November 2016. protein platform.

lia, cold agglutinin disease and other rare blood disorders. As an independent biopharmaceutical company spun out of Biogen’s hemophilia
CAMERON DURRANT MD, MBA
Dr. Cameron Durrant is the
Chairman and Chief Executive TIMOTHY MORRIS
Officer of Humanigen, since Timothy Morris currently
March 1, 2016. He was elevated serves as the chief financial
to that position after serving on RONALD BARLIANT officer of Iovance
the board of directors starting Ronald Barliant is of counsel Biotherapeutics, Inc. He
January 7, 2016. with the Chicago law firm brings over 30 years of
Goldberg Kohn, where he had professional finance and
Dr. Durrant’s expertise and been a principal in the accounting experience, of
business career has revolved Bankruptcy & Creditors’ Rights which 19 have been as a
around transformations, Group after joining in chief financial officer. He has
whether for brands, business September 2002. He has raised over $980 million in
units, or small companies. He represented debtors and equity and convertible
has particular therapeutic creditors in complex securities for six companies.
experience in infectious bankruptcy cases, and He has extensive deal
diseases, pediatrics and counseled major financial experience with over 65
oncology – coupled with institutions, business firms transactions with a
experience as a practicing and boards of directors in combined value of more
physician. connection with workouts. than $2 billion.

DR. TONY HO
Head of Research and JIM KASINGER
Development General Counsel and DR. LAWRENCE KLEIN
Secretary to the Board of Head of Business
Dr. Tony Ho is a highly Directors Development and Strategy
accomplished R&D leader with
experience across all phases of Jim Kasinger has nearly 20 Dr. Lawrence Klein combines
R&D, including: discovery, early years of experience advising significant experience in
and late-stage clinical and counseling private and biotech corporate strategy
development, and regulatory, public companies in the and business development
throughout his nearly 20 year biotechnology and technology with an advanced technical
career. sectors. background.
Richard Daniell
Executive Vice President,
European Commercial
Share on Facebook Share on
LinkedIn Share on Twitter

Richard Daniell

Mr. Daniell became Executive

Vice President, European
Commercial in November 2017.
 Paul R. Eisenberg
Senior Vice President, U.S.
Medical
Dr. Paul R. Eisenberg is
Senior Vice President, U.S.
Raymond Deshaies Medical. Before assuming
Senior Vice President, this role, Eisenberg was
Discovery Research Senior Vice President, Global
Raymond Deshaies, Ph.D., is Medical and Chief Medical
senior vice president, Officer, overseeing global
Discovery Research. medical and scientific affairs.
Judy Gawlik Brown Dr. Eisenberg joined Amgen
Senior Vice President, Global Prior to joining Amgen, in 2005 as Vice President of
Business Solutions and Finance Deshaies served as a professor Global Safety and was
Judy Gawlik Brown is senior at the California Institute of subsequently promoted to
vice president, Global Business Technology (Caltech) and an Senior Vice President of
Solutions and Finance, executive officer in Caltech’s Global Regulatory Affairs and
responsible for the Global Division of Biology and Safety. In 2014 assumed
Business Solutions, Global Biological Engineering. He was responsibility for Amgen’s
Internal Audit, Tax and Treasury also an investigator at the Global Medical Affairs
organizations and Full Potential Howard Hughes Medical organization and appointed
initiatives for Finance. Institute. Chief Medical Officer.
 JENNIFER LOCKRIDGE, PH.D.
Senior Vice President, DAVID MILLER, PH.D.
Program Development Senior Vice President,
Jennifer Lockridge, Ph.D., is VP Corporate Operations
of Program Development at David Miller, Ph.D., has
JACK GREEN Dicerna Pharmaceuticals and successfully combined
Chief Financial Officer has twenty years of leadership roles in both
Jack Green joined Dicerna as experience in the business and research
Chief Financial Officer in April development of capacities. He has been a
2016. Prior to Dicerna, he was oligonucleotide therapeutics. member of five early stage
Chief Financial Officer of Prior to joining Dicerna, Dr. biotech companies, each of
Verastem, Inc. (VSTM). Lockridge spent nine years which has successfully
Previously, Jack served for over consulting with multiple transitioned to a public
15 years as Chief Financial biotech and large company. Currently, he is
Officer of GTC Biotherapeutics, pharmaceutical companies to Senior Vice President,
Inc. (GTCB; formerly Genzyme provide direction and support Corporate Operations at
Transgenics Corporation), which for early development stage Dicerna Pharmaceuticals,
was spun out from Genzyme oligonucleotide programs as Cambridge, MA, where he
Corporation as a stand-alone well as pharmacology and has been the past eight
public company. pharmacokinetics expertise. years.

Denise Duca, Ed. M.

Andrew R. Blight, Ph.D. Executive Vice President, Andrew A. Hindman
Chief Scientific Officer Emeritus Human Resources Chief Business Officer
 ERIK PHELPS

GARY PALMER, MD Executive Vice President and

General Counsel
Chief Medical Officer NIKE BEAUBIER, MD
Erik Phelps serves as
Dr. Gary Palmer serves as Chief Director of Pathology and Executive Vice President and
Medical Officer at Tempus, Medical Lab Operations General Counsel at Tempus,
where he is responsible for where he is responsible for a
leading clinical activities for the Dr. Nike Beaubier serves as broad range of legal areas for
company and supporting Director of Pathology and the company, including
external collaborations and Medical Lab Operations at general corporate matters
strategic partnerships. Tempus. and strategy.

Susanne M. Gollin, Ph.D.,

FFACMG
Consultant, Clinical Cancer
Cytogenetics
Professor(Tenured) of
Human Genetics,
Daniel B. Bellissimo, Ph.D. Jie Hu, M.D., Ph.D Otolaryngology, and
Co-Director Clinical Genomics Associate Director of the Pathology
Laboratory Cytogenetics Laboratory University of Pittsburgh
Visiting Associate Professor of Associate Professor of Graduate School of Public
OB?GYN & Reproductive OB/GYN & Reproductive Health and School of
Sciences Sciences Medicine

gation of important DNA, RNA and Proteins. Research studies continue to demonstrate the clinically utility and actionability of multi-platfo
al organization dedicated to clinical laboratory science and its application to healthcare. Our leadership in education, advocacy and collabor

NIC JOHNSON LEONE DIETER NAVYATHA GAVVALA

TECHNICAL MANAGER HR / FINANCE MANAGER EMC TEST ENGINEER
 Dennis Bourgeault Robert Huizinga, Ph.D., R.N.,
Chief Financial Officer CNeph(C)
Executive Vice President,
Michael Martin Dennis Bourgeault Corporate Development
Chief Operating Officer Dennis has been the Chief
Financial Officer of the Robert Huizinga, Ph.D., R.N.,
Michael Martin Company since 1998 and is CNeph(C)
Michael is currently Chief responsible for the financial Rob has more than 25 years
Operating Officer of Aurinia and administrative operations of pharmaceutical
Pharmaceuticals Inc. of the Company development experience.

David Bick, MD
Founder | Chief Medical
Officer

Elizabeth Worthey, PhD David Bick has more than 20

Founder | Chief Product years of clinical experience as
Development Officer a board certified clinical
geneticist and experience
Dr. Worthey is a faculty translating molecular testing
investigator and the director of from the research laboratory
informatics at the Hudson to the clinical diagnostic
Alpha Institute for laboratory as a board certified
Biotechnology. clinical molecular geneticist.
 DANIEL HILL
STEPHEN MATHWIN COMPANY SECRETARY
NON-EXECUTIVE DIRECTOR CAROLINE POPPER Dan has worked as a
Stephen has more than 30 NON-EXECUTIVE DIRECTOR director, CFO or company
years’ experience as a legal Caroline Popper is a US-based secretary for a variety of
practitioner including being a pathologist and business companies in the
partner with the Adelaide law consultant, with more than 20 construction, technology and
firm, Kelly & Co from 1988 to years’ operational experience financial services sectors.
2001. In that time he headed in the international
the firm’s Employment, Indus... diagnostics. READ MOR

Jennifer L. Watkins, Ph.D.

Dr. Watkins joined BCR in
September 2012 as a Research
Associate.
Andreas Jeromin, Ph.D.
Chief Scientific Officer
Dr. Jeromin has successfully
developed clinical research
programs in translational
neurosciences in both academic
and industry for over 15 years.

David R. Demers, B.Sc.

Physics and Juris Doctor,
Tim W. H. Chan, B.Comm., CFA., Natalie E. Dakers, B.Sc. Chair of Crocus Advisors
Director President and CEO, Accel-Rx
Health Sciences Accelerator
Tim Chan Tim Chan began his David Demers is Chair of
investment career in 1985 after Crocus Advisors, a private
graduating from the University Natalie Dakers was appointed investment company focused
of British Columbia (UBC) with a Chair of the Augurex Board of on carbon reduction and
Bachelor of Commerce degree. Directors in March 2018. mitigation solutions
 DAVID HUNTSMAN MD,
FRCPC, FCCMG
SAMUEL APARICIO BM, BCH, CHIEF MEDICAL OFFICER
PHD, FRCPATH, FRSC Dr. Huntsman’s expertize is in
CHIEF SCIENTIFIC OFFICER the translation of genomics
Dr. Aparicio graduated in ALICJA PARKER MSC, MBA into assays leading into
medical and natural sciences CHIEF OPERATING OFFICER improved cancer control,
from Cambridge University (UK) Ms. Parker is a graduate of the which demands
and clinical medicine from University of Toronto where complementary expertize in
Oxford University (UK). He she earned her MSc degree in the development and
trained in internal medicine and the department of Molecular delivery of novel assays as
anatomic pathology. and Medical Genetics. well as discovery genomics.

Angela Carter
Angela Carter
Director, Customer and
Megan Eastwood, BSc(Hons) Business Development
Director of Operations Angela Carter has over 15
Megan Eastwood has over 20 years experience in in vitro
years of experience working in diagnostics primarily in the
a variety of manufacturing areas of new Product
environments in Research and Development, Clinical and
Development, Technical Technical Support and Sales
Transfer, Quality and Operations and Marketing.

LAWRENCE BLATT, PHD, MBA

Founder and Chairman of the
Board of Directors

Larry is a Founder and is SUMITA PENNATHUR, PHD

Chairman of the Board of Founder and Scientific
Directors of Alveo Technologies Advisory Board Member ISAAC BLECH, BA
as well as responsible for co- Vice Chairman of the Board
leading the Infectious Diseases Sumita is a Founder and of Directors
& Vaccines (IDV) Therapeutic member of the Scientific
Area at Janssen Research & Advisory Board of Alveo Isaac is the Vice Chairman of
Development Technologies. the Alveo Board of Directors.
Brandon Hants
Chief Financial Officer
Jessica McCarthy
Brandon has served as Chief Jeffrey Bishop, Ph.D. Vice President, Global
Financial Officer since 2018. Senior Vice President, Marketing &
Since joining Singulex in 2012 Diagnostics Operations Communications
as Director of Financial Planning
& Analysis, Brandon has Jeff Bishop joined Singulex in Jessica McCarthy joined
accepted roles of increasing 2013. Jeff has worked in the Singulex in 2016, responsible
responsibility including diagnostics industry for more for the company’s brand,
oversight of Medical Billing, IT, than 13 years at Biosite, worldwide product and
Supply Chain, Legal and Inverness Medical Innovations service launches and all
Facilities. and Alere. advertising and promotion.
oe Khoury, Ph.D., Director of James Bachand, Director of Michael Walsh, Director of
Cell and Molecular Biology Engineering Product Development
Prior to joining Exogenesis in Prior to joining Exogenesis in Prior to joining Exogenesis in
2009, Dr. Khoury held the 2010, Jim had more than 20 2009, Mike had 15 years of
position of Senior Scientist of years of extensive experience experience in managing the
Cell and Molecular Biology at in the design and manufacture development,
Histogenics Corp., where along of technically sophisticated manufacturing, global
with his position at Exogenesis capital equipment. He has deployment and support of
has gained over 6 years of held engineering leading edge high value
experience in the medical management positions with technology capital
device and tissue engineering PVD Products, Epion Corp. equipment production
fields and Multilevel Metals Inc. systems

George Anwar, PhD

Hany Nassef, PhD Sr. Hardware/Software Soenke Moeller, Ph.D
Vice President, Engineering Engineer Sr. Optofluidics Engineer
 Jennifer Doudna
Lucas Harrington Janice Chen Co-founder, Chair of
Co-founder, Chief Discovery Co-founder, Chief Research Scientific
Officer Officer Advisory Board

John Evans
Feng Zhang, Ph.D. Chief Executive Officer and Giuseppe Ciaramella, Ph.D.
Co-Founder and Board Member Board Member Chief Scientific Officer
Feng Zhang is a core institute John Evans joined Beam in Dr. Giuseppe Ciaramella is
member of the Broad Institute 2017 as CEO, bringing the Chief Scientific Officer of
of MIT and Harvard, an significant experience as a Beam Therapeutics. Dr.
investigator at the McGovern company builder, dealmaker, Ciaramella has more than 20
Institute for Brain Research at and drug developer in the years of drug discovery
MIT, and the James and Patricia biotechnology industry. Mr. experience at Moderna,
Poitras Professor in Evans is also a Venture Partner AstraZeneca, Boehringer
Neuroscience at MIT. with ARCH Venture Partners. Ingelheim, Pfizer and Merck.
Alexis Borisy
EXECUTIVE CHAIRMAN OF THE
BOARD ason Coloma, Ph.D. Christoph Lengauer, Ph.D.
CHIEF BUSINESS OFFICER PRESIDENT
Alexis is a successful
biotechnology entrepreneur Jason is an Entrepreneur-in- Christoph is a Venture
with more than 20 years of Residence at Third Rock Partner at Third Rock
experience building and Ventures where he focuses on Ventures, where he helps
operating innovative science- new company formation and discover, launch and build
based organizations. He has a business development across companies that boldly merge
passion for groundbreaking the portfolio. Jason’s role at science, strategy, business
science and utilizing functional Celsius is driving business and medicine. At Celsius, he
genomics to drive drug development, investor leads the company and
discovery. relations and value creation. mentors its members.

Bob Tepper, M.D. Cary Pfeffer, M.D.

Bob Tepper, M.D. Cary Pfeffer, M.D.
Interim Chief Science Officer Interim Chief Business Officer Leon Murphy, Ph.D.
Bob Tepper is a partner of Third Cary Pfeffer joined Third Rock Leon Murphy, Ph.D.
Rock Ventures, which he Ventures at its inception in Sr. Vice President of Biology
co‑founded in March 2007, and 2007 and has more than 20 Leon Murphy has broad
focuses on the formation, years of business expertise building and
development and scientific development and transaction leading teams that develop
strategy of Third Rock’s experience, along with a novel therapeutics for
portfolio companies, as well as broad array of biotech cancer, neurodegeneration
actively identifying and product development and metabolic and
evaluating new investments. experience. inflammatory disorders.
 Craig Muir brings decades of
experience in technology
development,
implementation and
application across the
Dale Porter, Ph.D. biopharma industry. A
Vice President, Biology partner and chief technology
Dale Porter joins Cedilla from officer at Third Rock
the Broad Institute of MIT and Neil Exter, MBA Ventures, Craig leads the
Harvard, where he directed the Interim Chief Business Officer identification and integration
William Sellers Lab, which Neil Exter brings more than of drug discovery and
focuses on cancer genomics two decades of experience in development technology
and novel therapeutic biotech business development platforms for portfolio
approaches. and strategy. companies.

Stephanie Fagan

David Davidson, M.D. Senior Vice President, Alison Finger

Corporate Communications
Chief Medical Officer Chief Commercial Officer
Stephanie Fagan joined us in
David Davidson, M.D., has December 2017 as our senior Alison Finger has served as
served as our chief medical vice president, corporate our chief commercial officer
officer since February 2012. communications. since February 2017.
 Annie Seibold Drapeau
Juan Andres Chief Human Resources
Chief Technical Operations and Marcello Damiani Officer
Quality Officer Chief Digital and Operational
Excellence Officer

Ms. Annie Seibold Drapeau

As Chief Technical Operations serves as Chief Human
and Quality Officer, Juan Andres As Chief Digital and Resources Officer at
is responsible for the supply of Operational Excellence Officer, Moderna, leading the
product required for Moderna’s Mr. Marcello Damiani brings a company’s talent and
preclinical and clinical wealth of experience from organizational strategy. Prior
development programs, as well both Tech companies and Life to joining Moderna, Ms.
as scaling the CMC (chemistry, Science companies and a true Drapeau served as an
manufacturing and controls) passion for making Digital a Operating Partner at Bain
processes across Moderna’s reality. He has 20 years Capital Private Equity, where
portfolio. Juan also will lead all experience working in the IT she partnered with
CMC late-stage development field, with the last 10 years companies across the private
and future commercialization being spent in leadership roles equity portfolio on a range of
activities. for multinational companies in talent and organizational
Europe and in the U.S. capability initiatives.

SAMUEL COLELLA
JEREL DAVIS, PHD Sam Colella is a Managing
Jerel-DavisJerel Davis is a Director who has been a
Managing Director based in venture capital investor since
Vancouver. Since joining Versant 1984. Recognized for his
in 2011, he has played a critical leadership in life science WILLIAM LINK, PHD
role in launching and investing investing, Sam co-founded Bill Link is a Managing
in a number of Versant’s Versant Ventures with six Director specializing in early-
portfolio companies including partners in 1999. Prior to stage investing in medical
Quanticel Pharmaceuticals, founding Versant, he launched devices at Versant. Prior to
Crispr Therapeutics, Blueline one of the first life science co-founding Versant
Bioscience, Northern Biologics venture groups as a General Ventures, Bill was a general
and several of the Inception Partner at Institutional partner at Brentwood
Sciences discovery start-ups. Venture Partners. Venture Capital.
 SAMUEL COLELLA
JEREL DAVIS, PHD Sam Colella is a Managing
Jerel-DavisJerel Davis is a Director who has been a
Managing Director based in venture capital investor since
Vancouver. Since joining Versant 1984. Recognized for his
in 2011, he has played a critical leadership in life science WILLIAM LINK, PHD
role in launching and investing investing, Sam co-founded Bill Link is a Managing
in a number of Versant’s Versant Ventures with six Director specializing in early-
portfolio companies including partners in 1999. Prior to stage investing in medical
Quanticel Pharmaceuticals, founding Versant, he launched devices at Versant. Prior to
Crispr Therapeutics, Blueline one of the first life science co-founding Versant
Bioscience, Northern Biologics venture groups as a General Ventures, Bill was a general
and several of the Inception Partner at Institutional partner at Brentwood
Sciences discovery start-ups. Venture Partners. Venture Capital.

SAMUEL COLELLA
JEREL DAVIS, PHD Sam Colella is a Managing
Jerel-DavisJerel Davis is a Director who has been a
Managing Director based in venture capital investor since
Vancouver. Since joining Versant 1984. Recognized for his
in 2011, he has played a critical leadership in life science WILLIAM LINK, PHD
role in launching and investing investing, Sam co-founded Bill Link is a Managing
in a number of Versant’s Versant Ventures with six Director specializing in early-
portfolio companies including partners in 1999. Prior to stage investing in medical
Quanticel Pharmaceuticals, founding Versant, he launched devices at Versant. Prior to
Crispr Therapeutics, Blueline one of the first life science co-founding Versant
Bioscience, Northern Biologics venture groups as a General Ventures, Bill was a general
and several of the Inception Partner at Institutional partner at Brentwood
Sciences discovery start-ups. Venture Partners. Venture Capital.
 SAMUEL COLELLA
JEREL DAVIS, PHD Sam Colella is a Managing
Jerel-DavisJerel Davis is a Director who has been a
Managing Director based in venture capital investor since
Vancouver. Since joining Versant 1984. Recognized for his
in 2011, he has played a critical leadership in life science WILLIAM LINK, PHD
role in launching and investing investing, Sam co-founded Bill Link is a Managing
in a number of Versant’s Versant Ventures with six Director specializing in early-
portfolio companies including partners in 1999. Prior to stage investing in medical
Quanticel Pharmaceuticals, founding Versant, he launched devices at Versant. Prior to
Crispr Therapeutics, Blueline one of the first life science co-founding Versant
Bioscience, Northern Biologics venture groups as a General Ventures, Bill was a general
and several of the Inception Partner at Institutional partner at Brentwood
Sciences discovery start-ups. Venture Partners. Venture Capital.

Orion Keifer, MD, PhD

Senior Director, Research

Orion Keifer is a neuroscientist

with neurosurgical training and
hands-on expertise in small and
large animal model
translational gene therapy
research.
Elior (Ori) Peles, PhD is a
Professor leading a Glial Biology
research group in the Carmine joined Pipeline
Department of Molecular Cell Therapeutics in October 2018
Biology at the Weizmann as President & CEO. His Brian was the former VP of
Institute of Science. He received previous role was President & Chemistry at Inception
his PhD in Biochemistry from CEO of Avelas Biosciences. Sciences - a Versant Ventures
the Weizmann Institute and Before that he served as discovery engine - where he
headed the Ligand-Receptor Senior Vice President, led all aspects of chemistry
group in SUGEN, a drug Business Development for COI and DMPK, including the
discovery company that Pharmaceuticals, where he acquisition of the Inception 5
pioneered protein kinases as helped co-found five new remyelination company by
therapeutic targets. biotech companies. Roche pharmaceuticals.

Chan Whiting
SENIOR VICE PRESIDENT,
RESEARCH AND
Alicia Levey DEVELOPMENT
CHIEF BUSINESS OFFICER
Chan C. Whiting, Ph.D. is the Jennifer McDevitt
Alicia Levey, PhD serves the role Senior Vice President of SENIOR VICE PRESIDENT,
of Chief Business Officer at Research and Development at CLINICAL SCIENCE AND
Tempest. Tempest CLINICAL OPERATIONS
 James Dermody, Ph.D.
Laboratory Director
Dr. James Dermody is the
Laboratory Director at Admera
Health. Dr. Dermody also Min Wei, Ph.D.
serves as the CLIA Lab Head of Clinical Services
Director at the Institute of Dr. Min Wei leads the Clinical
Genomic Medicine at Rutgers Services team at Admera
Medical School, the Specialty Health and serves as the
Allen Osofsky Lab Director at the New Jersey General Supervisor of
Corporate Controller Board of Medical Examiners, Admera’s CLIA-licensed,
Mr. Osofsky leads the Finance an Assistant Professor at the CAP-accredited molecular
Team at Admera Health. Prior University of Medicine and diagnostics laboratory.
to joining Admera Health. Mr. Dentistry of New Jersey, and a Previously, Dr. Wei led the
Osofsky gained over 20 years of member of the New Jersey Translational Genomics
experience in finance and Medical School Institutional Bioinformatics team at
accounting. Review Board. GENEWIZ, Inc.
 Aimee Hoyt Senior Vice
President & Chief People
Officer
Marc Stapley Executive Vice Aimee Hoyt is Senior Vice
President, Strategy & President and Chief People
Corporate Development Officer at Illumina, where
Marc Stapley joined Illumina she is responsible for all
in 2012 and holds the role of aspects of the company’s HR
Omead Ostadan Executive Vice Executive Vice President, strategies. Hoyt has a
President, Products & Strategy and Corporate successful track record for
Operations Development, responsible for leading workforce
Omead Ostadan is Executive corporate strategy, corporate transformation, driving
Vice President of Products and & business development and business growth and creating
Operations for Illumina. global infrastructure. high-impact teams.

Aimee Hoyt Senior Vice

President & Chief People
Officer
Marc Stapley Executive Vice Aimee Hoyt is Senior Vice
President, Strategy & President and Chief People
Corporate Development Officer at Illumina, where
Marc Stapley joined Illumina she is responsible for all
in 2012 and holds the role of aspects of the company’s HR
Omead Ostadan Executive Vice Executive Vice President, strategies. Hoyt has a
President, Products & Strategy and Corporate successful track record for
Operations Development, responsible for leading workforce
Omead Ostadan is Executive corporate strategy, corporate transformation, driving
Vice President of Products and & business development and business growth and creating
Operations for Illumina. global infrastructure. high-impact teams.
 Aimee Hoyt Senior Vice
President & Chief People
Officer
Marc Stapley Executive Vice Aimee Hoyt is Senior Vice
President, Strategy & President and Chief People
Corporate Development Officer at Illumina, where
Marc Stapley joined Illumina she is responsible for all
in 2012 and holds the role of aspects of the company’s HR
Omead Ostadan Executive Vice Executive Vice President, strategies. Hoyt has a
President, Products & Strategy and Corporate successful track record for
Operations Development, responsible for leading workforce
Omead Ostadan is Executive corporate strategy, corporate transformation, driving
Vice President of Products and & business development and business growth and creating
Operations for Illumina. global infrastructure. high-impact teams.

Chris Bowden, M.D.

Chief Medical Officer Steve Hoerter
Dr. Bowden joined Agios as Andrew Hirsch Chief Commercial Officer
chief medical officer in May Chief Financial Officer and Mr. Hoerter joined Agios as
2014. He has more than 18 Head of Corporate chief commercial officer in
years of experience in clinical Development February 2016 and has more
drug development, including Mr. Hirsch joined Agios as than 25 years of global
the approval of several cancer chief financial officer in pharmaceutical and
medicines. September 2016. biotechnology experience.

Jed Dean
VP of Operations and Aaron Kimball Tom Stephenson
Engineering Chief Technical Officer Chief Commercial Officer

At Zymergen, Jed is responsible At Zymergen, Aaron is At Zymergen, Tom oversees

for building and operating the responsible for building the all of our commercial
robotic workflows for genome data architecture to facilitate a interactions with clients,
engineering and high robotics-driven approach to including sales and business
throughput screening. genome engineering. development.
 Poonam Taneja, Ph.D.
VP/GM Asia Commercial
Operations & Global
Distribution
Martin Verhoef Poonam started in her
Susan Murphy Vice President of Strategy and current role in July 2010.
VP/GM, Global Marketing & New Product Generation From 2006 to 2010, Poonam
Western Markets Commercial Martin joined Molecular held the position of Director,
Operations Devices in August 2013. Over Global Distribution and was
As Vice President of Sales, the prior 10 years Martin held responsible for the
Western Markets, Susan is President and CEO positions in company’s business in India,
responsible for Molecular start-ups including Ciphergen South East Asia, Middle East,
Devices business in North BioSystems, PrimeraDx, Russia, Eastern Europe and
America, Europe and Brazil. MiraDx and Applied BioCode. Latin America.

Alka Chaubey, Ph.D., FACMG

Alice K. Tanner, Ph.D., M.S., Head of Cytogenomics and
CGC, FACMG Laboratory Director Christin D. Collins, Ph.D.,
Director, Laboratory Testing and Dr. Chaubey is an ABMGG- FACMG
Clinical Education board certified diplomate in Laboratory Director
Dr. Alice Tanner is a certified clinical cytogenetics/genomics Dr. Collins is an ABMGG-
clinical molecular geneticist and and clinical molecular board certified clinical
certified genetic counselor. genetics/genomics. molecular geneticist.
 Diana Chiu
Rick Burdsall Vice President, Agilent
Senior Vice President, Agilent Assistant General Counsel and
Global Infrastructure Services Assistant Secretary
Rick Burdsall Diana Chiu
Rick Burdsall is Senior Vice P. Diana Chiu is vice president,
President of Agilent's Global assistant general counsel and
Infrastructure Services assistant secretary of Agilent
organization. Technologies.

YVONNE GREENSTREET,
MBChB, MBA PUSHKAL GARG, MD
CHIEF OPERATING OFFICER CHIEF MEDICAL OFFICER LAURIE KEATING, JD
Dr. Yvonne Greenstreet Dr. Pushkal Garg joined SVP, GENERAL COUNSEL,
possesses 25 years of global Alnylam in 2014 with 15 years AND SECRETARY
experience in the of experience in clinical drug Laurie Bartlett Keating joined
pharmaceutical industry, where development. He oversees Alnylam in 2014 with more
she has been in senior roles in clinical research & operations, than 25 years of executive
research and development, biometrics & data experience at high
strategy, and portfolio management, and medical technology and
management. writing groups. biotechnology companies.
 Zhen Li, Ph.D.
Peter B. Leone, MBA Senior Vice President,
Vice President, Strategic Chemistry and Non-Clinical Ken Myszkowski, MBA, CPA
Business Initiatives Development Chief Financial Officer

DAN CHEVALLARD
Dan Chevallard
Dan Chevallard joined Regulus
in December 2012 as Vice
President, Accounting and
Financial Reporting, became CHRISTOPHER AKER, J.D.
our Vice President, Finance and Chris Aker
Accounting in May 2013 and Mr. Aker joined Regulus in
was appointed to the role of February 2011 and currently
Chief Financial Officer in May serves as Vice President, Legal
2017. Affairs.
JONATHAN ARNOLD ARIS GENNADIOS, PHD
PRESIDENT, ORAL DRUG PRESIDENT, SOFTGEL PAUL HEGWOOD, JR.
DELIVERY TECHNOLOGIES PRESIDENT, CLINICAL SUPPLY
Jonathan Arnold was named Aris Gennadios has served as SERVICES
President of our Oral Drug our President, Softgel Paul Hegwood, Jr. was
Delivery business in October Technologies since September named President, Clinical
2017. 2013 Supply Services in May 2018.

Dennis M. Mulroy | Chief James M. Rolke | Chief

Financial Officer Jennifer A. Carver, MBA | Scientific Officer
Mr. Mulroy has been the Chief Chief Operating Officer Mr. Rolke has been the Chief
Financial Officer of La Jolla Ms. Carver has over 20 years Scientifc Officer at La Jolla
since April 2015. Prior to joining of experience in the since January 2017. Prior to
La Jolla, Mr. Mulroy served as healthcare industry with that Mr. Rolke served as Vice
Chief Financial Officer of Taxus leadership experience in President of Research &
Cardium Pharmaceuticals pharmaceutical drug Development and Senior
Group Inc., a publicly traded development from early Director of Research &
biotechnology company, since development through Development at La Jolla
2005. commercialization. since January 2012.

Kimberly J. Manhard Robert E. Hoffman

Executive VP, Drug Paul Blake, FRCP Chief Financial Officer and
Development Chief Medical Officer Senior VP, Finance
Kimberly J. Manhard Robert E. Hoffman
Executive VP, Drug Paul Blake, FRCP Chief Financial Officer and
Development Chief Medical Officer Senior VP, Finance

Brian Fenton, M.S., MBA

Chief Business Officer
Brian Fenton joined the
Translate Bio team in 2015.
With more than 25 years of
Michael Heartlein, Ph.D. experience in the
Chief Scientific Officer John Schroer, CFA biotechnology industry and
Michael Heartlein joined Chief Financial Officer broad transaction
Translate Bio in 2016. He has John Schroer joined Translate experience in business
been in research and Bio in 2018 as chief financial development and alliance
development since 1989, when officer. With more than 25 management, Brian joined
he joined the founding team of years of healthcare Translate Bio from Shire
scientists at TKT (Shire acquired investment experience, John Pharmaceuticals, where he
TKT in 2005). Prior to his brings expertise in financial most recently served as head
current role, Mike was head of strategy and analysis, and of business development,
messenger RNA therapeutics at deep industry knowledge to neuroscience, supporting the
Shire. his role at Translate Bio. Commercial Business Unit.

Kim Seth
EVP, Head of Business & Michael Zinda
Corporate Development EVP, Head of R&D

Kim is Executive Vice President, Michael is the Executive Vice

Head of of Business & President, Head of Research
Corporate Development at and Development at Repare
Repare. Therapeutics.
 Todd Kinsella
Head of Biology
X
Todd Kinsella joined Vividion Jean Bemis
in 2017 as Vice President of Head of Alliance
Translational and Management
Larry Burgess Development Sciences. Todd X
Head of Chemistry supports all stages of Jean Bemis is Head of
X Vividion’s therapeutic pipeline Alliance Management at
Larry joined Vividion in from target identification, Vividion and has more than
September 2018 as Head of validation, drug discovery and 25 years of experience in
Chemistry, bringing extensive the translational biology drug development, from
scientific leadership and drug interface connecting pre- early discovery through IND
development experience to the clinical programs and acceptance and clinical study
company. development. initiation.

James E. Davis Catherine T. Doherty

Executive Vice President, Senior Vice President and
General Diagnostics Group Executive – Clinical
Franchise Solutions & Carrie Eglinton Manner
James E. Davis is Executive Vice Marketing Senior Vice President,
President, General Diagnostics, Advanced Diagnostics
for Quest Diagnostics. General Catherine T. Doherty is Senior
Diagnostics includes all of the Vice President, Group Carrie Eglinton Manner is
company’s routine testing, and Executive – Clinical Franchise Senior Vice President of
the commercial, marketing and Solutions & Marketing for Advanced Diagnostics for
clinical franchise organizations Quest Diagnostics. Quest Diagnostics
 Robert Discordia, Ph.D.
Vice President,
Pharmaceutical
Development &
Manufacturing
Barbara White, M.D. Robert Discordia, Ph.D.,
Chief Medical Officer joined Corbus as Vice
Barbara White, M.D., joined Sean Moran, CPA, MBA President, Pharmaceutical
Corbus as Chief Medical Officer Chief Financial Officer Development &
in June 2014. Dr. White's Sean Moran, CPA, joined Manufacturing in May 2018.
industry experience includes Corbus in January 2014. He Dr. Discordia brings to
Phase 1-4 clinical development has more than twenty years of Corbus more than 25 years
experience in inflammatory and senior financial experience of biopharmaceutical
autoimmune diseases, including with emerging biotechnology, industry experience in CMC
rheumatology, respiratory, and drug delivery and medical development and business
dermatology diseases. device companies operations.

Robert Sims, PhD

Brad Prosek Senior Vice President of
Senior Vice President, Research
Corporate Development Dr. Robert Sims,
Adrian Senderowicz, M.D. Brad Prosek, Constellation Constellation
Senior Vice President and Chief Pharmaceutical’s senior vice Pharmaceuticals’ senior vice
Medical Officer president, corporate president of research, joined
Serving as Constellation development, joined the the team in 2008 as a
Pharmaceuticals’ senior vice company in 2017 from All founding scientist. With
president and chief medical Terrain bioPartners LLC, where nearly 20 years of
officer, Dr. Adrian Senderowicz he advised and supported a experience in chromatin
is a board-certified medical global set of life sciences biology and transcription,
oncologist with more than two clients on transaction, Robert helped establish
decades of experience in the corporate and commercial Constellation’s integrated
life sciences. strategy as well as execution. epigenetics platform.
 Ben Munoz, M.Sc., Ph.D.
Chief Scientific Officer
Po-Shun Lee, M.D.
Executive Vice President, Chief Dr. Munoz is currently
Medical Officer serving as our Chief Scientific
Sheila Wilson, B.S.N., M.B.A. Officer since March 2017,
Senior Vice President, Clinical Dr. Lee has been serving as having served as our
Development Operations our Executive Vice President Executive Vice President,
since December 2015 and our Drug Discovery from
Ms. Wilson has been serving as Chief Medical Officer since September 2016 to March
our Senior Vice President, June 2015. 2017.

Timothy Myles, Ph.D., Director

of Protein Science

Dr. Myles is an experienced

protein biochemist with over 20
years experience in academia
and biotech/pharma. He
obtained his Ph.D in
Biochemistry and Biophysics
from the University of
Cambridge and has held
postdoctoral positions at
Novartis (FMI) and Stanford
University.
Raphael Levy, Ph.D.
Director, Antibody Engineering
Raphael Levy joined
LakePharma in March 2017, as
the new Director of Antibody
Engineering.
Peter Farrell, Chairman of the
Board Mr. Andrew Sassine, Director
Dr. Peter Farrell is the founder, of the Board
former long-term CEO and Andy Sassine serves on the
current Chairman of ResMed Board of Directors of Nasdaq
(NYSE:RMD). Farrell has been listed ICAD Inc. and Nasdaq
Chairman and a director of listed Gemphire Therapeutics,
ResMed since 1989, when the Inc.(GEMP). ICAD Inc. is a
company began as a leading provider of advanced Mr. James Barlow, Director of
management buyout of sleep image analysis, workflow the Board
technology from Baxter solutions and radiation James Barlow is a member of
Healthcare. Peter was therapy for early detection the Board of Directors of
previously Foundation Director and treatment of cancer. North American Health Care,
of the University of New South Gemphire Therapeutics, Inc. is Inc., a privately held
Wales (UNSW) Graduate School a clinical-stage company that provides
for Biomedical Engineering biopharmaceutical company contractual services to
(1978-89) while simultaneously focused on delivering and facilities specializing in post-
serving as Vice President of commercializing therapies for acute care, subacute care,
Research & Development for the treatment of short and long-term
Baxter Healthcare in Tokyo cardiovascular disease and rehabilitation, and skilled
(1984-89). Non-alcoholic steatohepatitis. nursing in the United States.

Cecilia Ganslandt John Lord

Dave Lowrance Head of Medical Affairs Head of CMC
CFO Dr. Cecilia Ganslandt (MD, Dr. Lord (PhD) serves as
David Lowrance has served as MSc Pharmaceutical Head of Pharmaceutical
Savara’s Chief Financial Officer Medicine) serves as Head of Development and is
since November 2016. From Medical Affairs and has more responsible for all CMC
September 2014 to... th... activities. He...
Mr Paul Foulger
Chief Financial Officer

Paul joined the Board in 2016.

Anne
Anne K. Vallerga, MA,PhD
-Director of Oncology Drug
r/amp Device Development
Extensive expertise in
physiology, tumor biology,
oncology, including
pharmaceutical chemistry
applications, drug, diagnostic
and device product
development.
 PAUL RUBIN, M.D.
EXECUTIVE VICE PRESIDENT
ADAM LEVY OF RESEARCH AND
CHIEF BUSINESS OFFICER DEVELOPMENT

Neal Sharpe, PhD, Vice

President, Translational
Sciences
Dr. Sharpe brings with him > 25- John van Duzer, PhD, VP CMC
years of experience in leading Dr. van Duzer is a senior
preclinical safety and drug pharmaceutical industry
discovery and development in executive with approx. 30-
pharmaceutical companies. years of experience in
Previously, Dr. Sharpe served as medicinal chemistry research,
Senior Director Preclinical chemical development
Safety and Operations at programs and GMP Neil Belloff, Executive Vice
Anavex Life Sciences (NASDAQ: manufacturing to support IND President, General Counsel
AVXL), a clinical stage filing and clinical trials. In and Corporate Secretary
biopharmaceutical company, addition, he is the inventor of Mr. Belloff joins Eloxx from
engages in the development of both Ricolinostat (ACY-1215) Celgene Corporation where
drug candidates for the and Citarinostat (ACY-241), he served as Senior
treatment of Alzheimer’s Selective HDAC 6 inhibitors, Corporate Counsel since
disease, other central nervous currently being developed for 2011. Mr. Belloff has more
system diseases, pain, and the treatment of Multiple than 30 years of legal and
various cancers Myeloma. business experience
 Benjamin M. Gaston, M.D.
Scientific Advisory Board
Member and Co-Founder
Edward G. Brooks, M.D.
Linda Heintz Dr. Gaston currently serves as Scientific Advisory Board
Controller Chief, Division of Pediatric Member
Pulmonary, Allergy and
Ms. Heintz currently manages Immunology and Professor of Dr. Brooks currently serves as
all financial and federal/state Pediatric Medicine at Case Professor of Pediatrics at the
compliance activities of the Western Reserve University University of Texas Health
Company. Soon upon joining School of Medicine in Science Center in San
the Company in 2005 Ms Cleveland, Ohio. Antonio, Texas.
 Benjamin Perrone, Ph.D.
Manager, Business
Development
Diane Joseph-McCarthy, Ph.D. ben.perrone(at)enbiotix-dot-
Vice President, Translational com
Science Benjamin Perrone has over
diane.j-m(at)enbiotix-dot-com effrey Radding, Ph.D. ten years of biomedical
Diane Joseph-McCarthy is Vice Vice President, Biology research, development, and
President of Translational jeff.radding(at)enbiotix-dot- translation experience.
Science at EnBiotix, with more com Before joining EnBiotix, he
than 17 years drug discovery Jeffrey Radding brings 24 worked as Senior Associate,
and leadership experience in years of drug discovery and New Ventures in the Boston
the pharmaceutical and biotechnology experience to University Office of
biotechnology sector. EnBiotix. Technology Development

Terry Kougoulos
Director of Pharmaceutical
Development
John C. Oakley Terry Kougoulos leads the
Chief Financial Officer pharmaceutical development
Mr. Oakley joined Cleaver- program for Vast
Brooks in 2013 as Chief Therapeutics. Dr. Kougoulos Kyle Kimble
Financial Officer. Throughout has 15 years experience in the Director of Intellectual
his career, Mr. Oakley has pharmaceutical industry Property
served in senior financial specializing in the Kyle W. Kimble, JD PhD, is an
positions for both publicly development of both small attorney focused on
traded and privately held molecules and pharmaceutical and
companies. macromolecules. intellectual property law.
 Carol Holland, PhD, MT
Thomas Monroe, PhD, Senior (ASCP), Laboratory Director, Lisa McDaniel, PhD, FACMG,
Laboratory Director Director of Quality Assurance Laboratory Director
 Chad Testa, Director of
Chemistry
Dr. Testa joins Curza after
12+ years at Echelon
Dustin Williams, PhD – Vice Biosciences where his
President of Microbiology & industrial career began.
Ryan E. Looper, PhD – Vice New Technologies Most recently, Dr. Testa
President of Discovery Dr. Williams is an Assistant served as Vice President of
Dr. Looper was born in Banbury, Professor in the Department Research & Development
England. After spending his of Orthopaedics at the after assuming positions of
formative years overseas, he University of Utah and Vice increasing responsibility
returned to the United States to President of Microbiology & from an initial role as
attend school. New Technologies at Curza. Research Scientist.

Vivi Jung, PharmD, RPh

Robert Desantis, PharmD, RPh PHARMACIST IN CHARGE AND Krupesh Patel, BS –
DIRECTOR OF OPERATIONS DIRECTOR OF MARKETING Pharmacology
Robert Desantis graduated with Vivi Jung graduated with DIRECTOR OF QUALITY
honors from the Philadelphia honors from the Philadelphia ASSURANCE
College of Pharmacy in 2014 College of Pharmacy in 2014 Krupesh Patel graduated
with a Bachelor of Science in with a Bachelor of Science in from the University of
Pharmaceutical and Healthcare Pharmaceutical and Sciences, Philadelphia with a
Studies and a Doctorate in Healthcare Studies and a Bachelor of Science in
Pharmacy. Doctorate in Pharmacy. Pharmacology in 2015.
 Danuta Radzioch, Ph.D. –
Patrick Colin, B.Pharm., Ph.D. - Chief Scientific Adviser
Chief Development Officer Danuta Radzioch, Ph.D, a
Patrick Colin, B.Pharm., Ph.D., is Fulbright Scholar, is a
a seasoned pharmaceutical Professor of Medicine and
industry executive who Human Genetics at McGill
managed drug development University and a researcher at
programs leading to 15 market the Research Institute of the
approvals in various therapeutic McGill University Health
areas. Centre since 1990.

Eric Yuen, MD
Chief Medical Officer

Kelly Copeland Rohit Mehta

Vice President – Commercial Head - Operations & Supply

Strategy Chain
Doug Gessl

Chief Financial Officer

Kelly Copeland has more than Rohit Mehta has nearly 25
18 years of experience years of broad and global
working in the healthcare experience in
Doug Gessl has more than 12 industry. She is a partner with biopharmaceutical supply
years of experience in biotech NeXeption and serves as the chain, operations, and
and nearly 20 years in the Vice President of Commercial business/corporate
financial services sector Strategy for Onspira. development.
Tom Zupancic, Ph.D.
Chief Scientific Officer Rich Brody, Ph.D., VP
Research and Development
Tom Zupancic, Ph.D. is a
molecular biologist with more Rich Brody is a biochemist
than 25 years of experience in with more than 30 years of
the design and execution of experience directing
applied biotechnology research laboratory programs in protein
projects. biochemistry.

Chairman

Chief Science Officer William “Bill” Ross began his

30-year career in healthcare
Alex Stenzler, (President, 12th technology as an executive
Man Technologies) was the Chief Regulatory Officer for SensorMedics Critical
former VP Advanced Care. Initially involved in the
Technologies for CareFusion Barry Sugarman is a Senior sales and marketing of their
Inc, (VIASYS, Cardinal Health). Pharmaceutical and Medical respiratory care product
Mr. Stenzler brings more than Device Executive with over 30 lines, he later drove major
30 years of clinical and years of public and private business development
commercial experience in company experience in all efforts and guided several
pulmonary medicine to his aspects of business including key acquisitions in the U.S.
position. domestic and Europe.

Sean M. Kaufman, MD – Robert F. Cardwell, BS – Chief

Medical Director Strategy Officer
 Christopher Ryan, Ph.D.
Kim Snyder, MBA Director of Manufacturing
Chief Financial Officer Gregory Fiore MD Dr. Christopher Ryan has
Ms. Kim Snyder has extensive Chief Medical Advisor extensive expertise in
experience in financial Dr. Gregory Fiore is the lead polysaccharide structural
reporting, budgeting and Medical Advisor of Synspira as analysis and interactions of
forecasting, mergers and well as the CEO of Sollis pathogens with human
acquisitions, and divestitures. Therapeutics. tissue.

Peter Crosby, Board of Directors ohn Foster, Board of Directors

Peter Crosby has been Chief John Foster has more than 30
Executive Officer or Chairman years of executive
of 7 medical device companies management experience and
in four countries. Peter is a proven expertise in
specialist at bringing new developing and bringing
medical devices to the global specialty pharmaceuticals and
market, from concept to drug-device combination
profitability. products to market.
 DAVID B. PEDEN, MD, MS
Professor of Pediatrics,
Medicine &
RIC BOUCHER, MD Microbiology/Immunology,
Kenan Professor of Medicine, UNC – Chapel Hill
UNC – Chapel Hill
Shaun D. McMeans
Senior Vice President of Sam M. Rua Jr.
Finance, Administration and Senior Vice President of
Chief Financial Officer Regulatory Affairs and Quality
Mr. McMeans has served as our Systems
Chief Financial Officer since Mr. Rua has served as our
February 2012, and as our Senior Vice President of
Senior Vice President of Regulatory Affairs and Quality
Finance & Administration since Systems since February 2018.
February 2018. He previously Previously he served as our
was our Vice President of Vice President of Regulatory
Finance & Administration from Affairs and Quality Systems
February 2012 until February from November 2011 until
2018 February 2018.
 MICHAEL GLEESON
Senior Vice President,
Corporate Accounts JAMES MCNALLY
Mr. Gleeson serves as Senior Senior Vice President, Sales BRIAN MITCHELL
Vice President, Corporate and Marketing Senior Vice President,
Accounts. He was previously Mr. McNally serves as the Operations
the Senior Vice President of Senior Vice President Sales Mr. Mitchell has served as
North American Commercial and Marketing, initially joining Senior Vice President,
Operations and has held various the Company in October 2016 Operations and has held
commercial sales roles within as the Senior Vice President, various roles with the
the company since joining in Marketing and Business company since joining in
November 2009 Development. November 2016

proprietary software technology based on magnetic resonance imaging data to risk-stratify multiple sclerosis patients. These tes
 René M. Lemieux, PhD, Head
of Chemistry and Drug
Design

René Lemieux is an
experienced and successful
drug hunter with nearly 20
years of experience in large
pharma and biotech bringing
first-in-class small molecule
ohn Trzupek, MBA, PhD, Chief drug candidates from
Financial Officer (interim) & discovery to clinical trials.
Head of Corporate Kimya Harris, PhD, Head of Prior to joining KSQ
Development Intellectual Property Therapeutics, René served as
Director of Medicinal
John Trzupek is an Kimya Harris is a skilled Chemistry at Agios
accomplished leader in the intellectual property Pharmaceuticals where he
biotech and pharmaceutical professional with significant was responsible for leading
industries with key oncology patent experience the discovery efforts for a
contributions spanning drug both within the number of programs in the
discovery, strategy, operations, biopharmaceutical industry area of cancer metabolism
and entrepreneurship. and in private practice. and rare genetic diseases.
RUSS B. ALTMAN, M.D., PH.D.
Presidents’ Advisory Group
Russ Biagio Altman is the JONATHAN WEISSMAN,
Kenneth Fong Professor of JENNIFER DOUDNA, PH.D. PH.D.
Bioengineering, Genetics, Presidents’ Advisory Group Presidents’ Advisory Group
Medicine, and Biomedical Data Jennifer Doudna, Ph.D. is a Jonathan Weissman received
Science (and of Computer professor of Molecular and his undergraduate physics
Science, by courtesy) at Cell Biology and Chemistry at degree from Harvard
Stanford University, and the University of California, College. After obtaining a
previously chaired its Berkeley, where she holds the Ph.D. in physics from the
Department of Bioengineering. Li Ka Shing Chancellor’s Chair Massachusetts Institute of
His primary research interest is in Biomedical and Health Technology, he was a
the application of computing Sciences, and is a Howard postdoctoral fellow at Yale
and informatics technologies to Hughes Medical Institute University School of
clinical medicine. investigator. Medicine.

Michael Cleary, MD, Co-founder

/ Associate Chair, Department
of Pathology, Stanford
University
Associate Chair for
Experimental Pathology,
Stanford University School of
Medicine and Director of
Pediatric Cancer Biology,
Stanford University School of
Medicine, Dr. Cleary received
his MD from the University of
Cincinnati Medicine (1981).
 Hitesh Thakrar Hitesh is a
Partner of Syncona
Edward Perello Investment Management Ltd. Darrin Disley, PhD
CBO and Founder Edward has He is an experienced investor Advisor Darrin is a scientist
expertise in genome editing, in the sector, having spent with a track record of
synthetic biology, product over 20 years investing in securing over $275 million
development and marketing. public global equities in the business financing as well as
He currently heads the life sciences, technology and closing over $450 million of
marketing team at Desktop the innovation sectors product, service, license and
Genetics. Chairman M&A deals.

Ellen Ridge Peter Nell, Ph.D.

Senior Vice President, Vice President, Strategy and Paul Schneider
Operations Business Development Vice President, Finance
 Louise Hall, PMP
Vice President, CMC and
Program Management
Louise Hall is Vice President
of CMC and Program
oseph Nixon, MBA Management for Locus
Vice President, Business Biosciences. Before joining
Development Locus in 2018, Louise led the
Paul Kim, PhD Joseph Nixon is Vice President Pharmaceutical
Chief Development Officer of Business Development for Development Services site
Dr. Paul Kim is the Chief Locus Biosciences. Before for Patheon Greenville North
Development Officer or Locus joining Locus in 2017, Joseph Carolina where she piloted
Biosciences. Paul is an led the investment team at creation of the steriles
experienced leader in the the North Carolina flagship development site
pharma/biotech industry Biotechnology Center where and oversaw activities
spending over 17 years in drug he directed investments in supporting a client
development and more than 60 early-stage life development portfolio of
commercialization. science companies. 150 projects.
Daniel Dornbusch, MBA Neal Kaplan, C.F.A.
Senior Vice President, Business Vice President, Operations
Development
Kenneth I. Kohn, Ph.D.
Neal Kaplan, CFA is the VP of Senior Director, Intellectual
Mr. Dornbusch has worked in Financial Operations for Property and Legal Affairs
the biotechnology industry for Excision BioTherapeutics Inc.
over 20 years for large In this capacity, Neal analyzes
pharmaceutical, small the financial statements and Ken Kohn currently serves
biotechnology, diagnostics and assesses the financial our management team as
specialty commercialization condition of the company. In Senior Director, Intellectual
companies in business addition to providing financial Property and Legal Affairs.
development, mergers and analysis and management, Dr. Kohn has over 30 years of
acquisitions, marketing, sales, Neal is also focused on experience in intellectual
commercial strategy, and bringing Excision property protection and
product development. Daniel BioTherapeutics to the litigation in the health
most recently served as attention of the investment sciences sector. In addition
founder and CEO of Acteris, community and helping to Excision, Dr. Kohn is
Inc., an immunoncology develop alliances with currently the Principal
company located in San business partners and Executive at Kohn and
Francisco. investors. Associates in Michigan.
KENNETH FAN, Chief Operating
Officer
Mr. Kenneth Fan brings to
eGenesis more than a decade
of entrepreneurial experience,
including operations, business
strategy, financial planning,
international partnerships and
team building. Prior to this role,
Mr. Fan was the co-founder and
chief operating officer of
Addgene, where he grew the
business to become the
worldwide leader for plasmids
and CRISPR technologies for
research. He began his career
as an investment banker for
Credit Suisse.
Mitch Abrahamsen, PhD
Executive Vice President, Chief
Commercial & Scientific Officer
Previously to joining
Recombinetics, Dr. Abrahamsen Dan Carlson, PhD
was the Senior Vice President Senior Vice President of
of Research and Development Research and Development
at Cobb-Vantress for Tyson Dr. Carlson is a “farm kid”
Foods, Vice President of from southwestern
Research at Hill’s Pet Nutrition Minnesota who took an
for Colgate-Palmolive, Vice interest in biotechnology
President of Research and when his family began
Development, Chief Scientific ohn Burtis, JD planting GM crops in the
Officer of Pyxis Genomics, Inc, Vice President of Legal 90’s. In pursuit of this
and a professor in the Burtis has more than 20 years interest, Dr. Carlson attended
Department of Veterinary of experience representing the University of Minnesota
Pathobiology and Director of clients in complex where he earned a PhD in
Graduate Studies, Molecular transactional, corporate, Animal Sciences with an
Veterinary Biosciences at litigation and intellectual emphasis in biotechnology
University of Minnesota. property legal matters. and molecular genetics.
 NATHAN JONES VP of Process LEONELA AMOASII, PHD
Development and Director, Gene Editing
Manufacturing Leonela Amoasii, PhD, has
Nathan Jones, PhD, joined worked in the laboratory of
JESPER GROMADA Chief Exonics Therapeutics as Vice Dr. Eric Olson at the
Scientific Officer President of Process University of Texas
Jesper Gromada joined Exonics Development and Southwestern Medical
Therapeutics as Chief Scientific Manufacturing in 2018. Prior Center in Dallas since 2012.
Officer in 2018. He brings to the to this role, Dr. Jones was Dr. Amoasii obtained her
company more than 20 years of head of the Gene Therapy Skill undergraduate degree in
experience working in various Center at Sanofi, where his Molecular Biology and
roles at Novo Nordisk, Eli Lilly, team developed Biochemistry and master
Novartis and most recently at manufacturing processes for degree in Molecular and
Regeneron Pharmaceuticals, early phase gene therapy Cellular Physiopathology at
where he served as Vice programs and was responsible the Louis Pasteur University
President. for platform innovation. in Strasbourg, France.

Bruce Conklin, M.D.

Deputy Director Jill Banfield, Ph.D.
Bruce Conklin is a Senior Scientific Director,
Mike Botchan, Ph.D. Investigator at the Gladstone Microbiology
Deputy Director Institute and a Professor of Jill Banfield is a Professor of
Mike Botchan is the Dean of Medicine, Ophthalmology and Earth and Planetary Science
Biological Sciences and a Pharmacology at the and Environmental Science,
Professor of Molecular and Cell University of California, San Policy, and Management at
Biology at the University of Francisco. The Conklin lab is the University of California,
California, Berkeley. The developing genome surgery Berkeley with an
Botchan lab studies the methods to treat severe appointment in Earth &
mechanisms and regulation of mono-allelic genetic diseases Environmental Sciences at
DNA replication and gene of the retina, motor neurons, Lawrence Berkeley National
expression in eukaryotes. and cardiomyocytes. Lab.
Dr. Gillian Hendy
Head of Business Development
Dr. Hendy leads the Avectas
business development team.
She has broad commercial
expertise including
management of sales,
marketing, commercialisation
and long-term strategic
planning for the Avectas
product line.
 ohannes Zuber, PhD, MD
× Dr. Zuber received an M.D. at
Lukas Dow, PhD Humboldt University of
Luke completed his Berlin. From 2005-2010, he
Yuting Yang, PhD undergraduate and graduate served as a postdoctoral and
Director of Embryology, work in Melbourne, Australia, clinical fellow at Cold Spring
Mirimus Inc focused on defining the role Harbor Laboratory where he
of core cell polarity regulators made major advances in
Research Assistant Professor, in controlling cell migration RNAi technology, including in
Cell Biology, SUNY Downstate and transformation in mouse vivo TetOn-RNAi and pooled
Medical Center and human epithelial cells. RNAi screening.

Steve Lo
George Church, Ph.D. Matthew Rabinowitz, Ph.D. Business development
Scientific advisory board Advisory board advisor
Professor, Harvard CEO, Natera, Inc. CCO, Puma Biotechnology
 RAMEECH MCCORMACK,
M.S.
JESSICA M. SIDO, PH.D. R&D Engineer
JAMES HEMPHILL, PH.D. Research Scientist Rameech McCormack, M.S.
Research Scientist Jessica M. Sido, Ph.D. master’s graduate from the
James Hemphill, Ph.D. is a graduated from the University Mechanical Engineering
genetic engineer focused on of South Carolina School of Department at MIT. He is
building new functionality into Medicine where she worked also a co-inventor of the high
human cells for therapeutic on T cell driven inflammatory throughput Flowfect™
application. responses. technology.
Curt Becker
Gerald Yakatan, Ph.D
As a founder of Applied
Biosystems Inc., Curt Becker Gerald J. Yakatan, Ph.D. is a
was in the forefront of NIcolas Dean,Ph.D serial entrepreneur who has
developing, commercializing been a founder of multiple
and supporting many of the companies in the
enabling technologies of the Dr. Nicolas M. Dean joined the pharmaceutical R&D arena
biotech industry including TriPhos Therapeutics Scientific and currently serves as
automated DNA synthesis, DNA Advisory Board in March of Chairman & CEO of IriSys,
sequencing and QPCR. 2013. Inc.
 on Davis
Vice President of Operations Christopher Cooney, PhD
Mr. Davis joined Akonni Director of Engineering
Darrell Chandler, PhD Biosystems April 2007 and As Director of Engineering at
Chief Science Officer currently manages all aspects Akonni Biosystems, Dr.
Dr. Chandler, a founding of Akonni’s day-to-day Cooney leads an innovative
scientist, joined Akonni operations, to include quality multi-disciplinary team of
Biosystems after 15 years of control, human resources, engineers and scientists in
service at Pacific Northwest and information technologies, the pursuit of affordable,
Argonne National Laboratories, IP/legal, facilities, highly-informative
where he led and managed procurement, security and diagnostics. Dr. Cooney
multidisciplinary teams of ES&H. Mr. Davis has over 20 draws upon more than 15
biologists, analytical chemists, years of general management years of multi-disciplinary
engineers, statisticians and experience with expertise in bioengineering experience
computer scientists in the design, construction, and from both academia and
development of integrated maintenance of research industry – four years in post-
nucleic acid-based biodetection laboratories to include BSL-2, graduate academia and
systems for environmental and chemical, optical and class more than ten years in
clinical applications. 10,000 clean room facilities. industry.

BOB SKURLA
As one of the company co-
founders, Bob Skurla has been
with BioServe from day one
back in 1989. Today, Bob
serves as the Director of RNA
MIKE SEDDON Services, as well as plays an
important role with special
Mike Seddon joined BioServe in and custom project requests
1992 and is responsible for our by our customers. Prior to
lab operations. In this capacity, joining BioServe, Bob worked
he oversees the for 7 years at the National
implementation of SOPs, Institutes of Health, both at
equipment maintenance, and the National Cancer Institute
scheduling of the projects. Mike and National Institute of
is also responsible for Allergy and Infectious
converting a large number of Diseases. He graduated from
BioServe’s extraction and East Carolina University in
genotyping processes to high 1982 with a B.S. in
throughput formats. biochemistry.
John Tabone, Ph.D.
Vice President, Chemistry
25+ years in a startup
environment developing
innovative technologies in the Melud Nabavi
areas of nucleoside chemistry, Vice President, Molecular
molecular diagnostics, genomic Engineering
measurement, and high 20+ years of experience in Danielle Jones
throughput automation of biotechnology developing CFO
oligonucleotide and gene innovative genomics 15+ years of experience in
synthesis. technologies. accounting and finance.
c.suite leaders and titles6 c.suite leaders and titles7 c.suite leaders and titles8

Scott Gradia, Ph.D.

Vice President of Platform
Research

Kyoko Kurosawa MT(ASCP)

Medical Laboratory Scientist

Mr. James Lewis SVP Dr. Abigail McElhinny SVP Mr. Antony Newton SVP

Ms. Crystal Park is deeply

committed to ensuring a
Mr. Richard Puritz is the Vice positive and successful
President of Business outcome for every client
Development ICMD supports

Trey Langley, PhD Humberto Huerta

Vice President of Product Eric Baker Senior Director Business
Development and Reporting Senior Director of Sales Developmen

Tamara Mihailovski, MSCLS

Gloria Coker, MD Ms. Mihailovski is the quality Connie Ng, CLS
Dr. Coker is the Medical manager and technical Connie Ng is a clinical
Director of Louisiana supervisor at Machaon laboratory scientist (CLS) at
Coagulation Diagnostics Machaon Diagnostics
 Richard Rew
Randall “Randy” Myers Senior Vice President, Eric S. Shapiro
Senior Vice President, Global General Counsel and Senior Vice President,
Manufacturing and Quality Corporate Secretary Global Marketing

Kara Cannon
Global Head of Sales and
Marketing
 Martin Krusin Dinesh Srinivasan
Mathieu Schué Vice President for Finance PhD, Vice President for
PhD, Head of Laboratory and Business Development Translational Research

George A. Mensah, M.D.,

FACC
Center for Translation
Lenora Johnson, DrPH, MPH James P. Kiley, Ph.D. Research and
Office of Science Policy, Division of Lung Diseases Implementation Science
Engagement, Education and (DLD) (CTRIS)
Communications (OSPEEC) Division Director, 1984 - Division Director, 2013 -
Director, 2013 - Present Present Present

CHIA-LING GAU, PH.D., BRIAN PAYNE

SHARON MEXAL, PH.D. DABMG Sr. Vice President,
VP, Clinical Operations VP, Executive Lab Director Information Technology

Vu L. Truong, Ph.D.
Founder, Chief Executive
Officer and Director
Mitchell H Rosner, Ph.D. Jeffrey J. Fessler, J.D.
Vice President of Quality Acting General Counsel
 Rod Rootsaert
Rod is an experienced legal
and corporate secretary with
over ten years’ experience in
providing corporate, legal
and administrative services to
start-up companies. He Jasmine Kway
David Vanston previously served as Jasmine has a proven track
David has 20 years of corporate secretary for record in achieving positive
financial management several junior mining business results by
experience. Prior to Volition companies in the United developing strategic
and Octo Telematics, David Kingdom. Rod received a business alliances,
held positions as Vice Bachelor of Laws degree identifying new markets,
President of Excorp Medical, from the University of and developing business
Inc. Western Australia. processes.

Cagatay M. Culcuoglu, MBA

Co-founder, Chief Operating
Officer & Chief Technology Joshua Hecht
Officer Chief Financial Officer

Yuman Fong, MD
Riccardo Lencioni, MD, PhD Memorial Sloan-Kettering
Pisa University Hospital Cancer Center

SHABNAM STANICKY Clinical JOHN ZUCARO Senior Vice BARBARA C. GALAINI

Operations Officer President, CMC Corporate Controller
 Aayush Beri
Software

Aayush is a computer
science student at Cornell
University, with interest in
machine learning, artificial
intelligence and software
engineering

John McHutchison, AO, MD Brett A. Pletcher

Chief Scientific Officer, Head Executive Vice President, Alessandro Riva, MD
of Research and General Counsel and Chief Executive Vice President,
Development Compliance Officer Oncology Therapeutics

EVP & CHIEF

COMMUNICATIONS
EVP & CHIEF HUMAN OFFICER
RESOURCES OFFICER Alex Kelly
Karen L. Ling, Esq. EVP & CHIEF R&D OFFICER Alex Kelly is the EVP,
Karen Ling is the Chief C. David Nicholson, PhD Corporate Affairs and Chief
Human Resources Officer, David Nicholson is the Chief Communications Officer,
and has served in this role R&D Officer, and has served and has served in this role
since July 2014. in this role since March 2015. since April 20, 2015.

er population of patients with respiratory and breathing conditions

Duncan Bathe Professor Asher Tal, MD

Vice President of Steve DiPalma, MBA Senior Vice President of
Engineering Chief Financial Officer Clinical Research
Henry O. Gosebruch Timothy J. Richmond Azita Saleki-Gerhardt, Ph.D.
Executive Vice President and Senior Vice President, Human Senior Vice President,
Chief Strategy Officer Resources Operations

Henry O. Gosebruch Timothy J. Richmond Azita Saleki-Gerhardt, Ph.D.

Executive Vice President and Senior Vice President, Human Senior Vice President,
Chief Strategy Officer Resources Operations

Henry O. Gosebruch Timothy J. Richmond Azita Saleki-Gerhardt, Ph.D.

Executive Vice President and Senior Vice President, Human Senior Vice President,
Chief Strategy Officer Resources Operations

Henry O. Gosebruch Timothy J. Richmond Azita Saleki-Gerhardt, Ph.D.

Executive Vice President and Senior Vice President, Human Senior Vice President,
Chief Strategy Officer Resources Operations

Henry O. Gosebruch Timothy J. Richmond Azita Saleki-Gerhardt, Ph.D.

Executive Vice President and Senior Vice President, Human Senior Vice President,
Chief Strategy Officer Resources Operations

Henry O. Gosebruch Timothy J. Richmond Azita Saleki-Gerhardt, Ph.D.

Executive Vice President and Senior Vice President, Human Senior Vice President,
Chief Strategy Officer Resources Operations

Henry O. Gosebruch Timothy J. Richmond Azita Saleki-Gerhardt, Ph.D.

Executive Vice President and Senior Vice President, Human Senior Vice President,
Chief Strategy Officer Resources Operations

Henry O. Gosebruch Timothy J. Richmond Azita Saleki-Gerhardt, Ph.D.

Executive Vice President and Senior Vice President, Human Senior Vice President,
Chief Strategy Officer Resources Operations
Henry O. Gosebruch Timothy J. Richmond Azita Saleki-Gerhardt, Ph.D.
Executive Vice President and Senior Vice President, Human Senior Vice President,
Chief Strategy Officer Resources Operations

Henry O. Gosebruch Timothy J. Richmond Azita Saleki-Gerhardt, Ph.D.

Executive Vice President and Senior Vice President, Human Senior Vice President,
Chief Strategy Officer Resources Operations

Nancy Vitale
Senior Vice President of
Human Resources,
Genentech and Regional
Human Resources Head,
North America

Nancy Vitale
Senior Vice President of
Human Resources,
Genentech and Regional
Human Resources Head,
North America

Nancy Vitale
Senior Vice President of
Human Resources,
Genentech and Regional
Human Resources Head,
North America

Nancy Vitale
Senior Vice President of
Human Resources,
Genentech and Regional
Human Resources Head,
North America
Ross Lobell
Vice President, Regulatory
Affairs
Ross Lobell joined Corbus as
Vice President, Regulatory
Affairs in April 2018.

Elmar Weber, Vice President Kyle Stretch, Vice President

Finance & Corporate North America
Services Kyle joined EXTEDO in 2012
Elmar Weber is Vice and brings over two decades
President of Finance & of experience include 10
Corporate Services of years in enterprise software
EXTEDO GmbH. for life science.

Robert Cornelisse is our

Chief People and
Organization. Robert joined
us in May 2014. Robert is an
experienced and driven
entrepreneur, a skilled
people manager and used to
develop and structure young
organizations.
 Dr. Daniel Muruve
Chief Science Officer and
Richard Rossman Conor Gunne Co-Founder
Director Director and Chairman of the Daniel Muruve is a Professor
Richard Rossman has a large Audit Committee in the Department of
private practice in the area Conor Gunne is a chartered Medicine at the University
of gastroenterology. accountant and lawyer of Calgary

Dr. Daniel Muruve

Chief Science Officer and
Richard Rossman Conor Gunne Co-Founder
Director Director and Chairman of the Daniel Muruve is a Professor
Richard Rossman has a large Audit Committee in the Department of
private practice in the area Conor Gunne is a chartered Medicine at the University
of gastroenterology. accountant and lawyer of Calgary
 Dr. Michelle Welborn
Haran Schlamm, MD Dr. Michelle Welborn, serves
Dr. Haran Schlamm, is a as a pharmaceutical
globally recognized consultant and provides
infectious disease-trained regulatory consulting to
physician. manage the project in FDA.

Geoffrey S. Gilmartin, M.D.,

M.M.Sc.
Chief Development Officer
Shao-Lee Lin, M.D., Ph.D.
Executive Vice President,
Head of Research and
Development and Chief Irina Konstantinovsky Michael DesJardin
Scientific Officer Executive Vice President, Executive Vice President,
Shao-Lee Lin, M.D., Ph.D., Chief Human Resources Technical Operations and
joined Horizon in January Officer Corporate Quality
2018 as executive vice Irina joined Horizon in 2017 Mike joined Horizon in
president, head of research as executive vice president, October 2016 as part of the
and development and chief chief human resources Raptor Pharmaceutical
scientific officer. officer. Corp. acquisition.

Shao-Lee Lin, M.D., Ph.D.

Executive Vice President,
Head of Research and
Development and Chief Irina Konstantinovsky Michael DesJardin
Scientific Officer Executive Vice President, Executive Vice President,
Shao-Lee Lin, M.D., Ph.D., Chief Human Resources Technical Operations and
joined Horizon in January Officer Corporate Quality
2018 as executive vice Irina joined Horizon in 2017 Mike joined Horizon in
president, head of research as executive vice president, October 2016 as part of the
and development and chief chief human resources Raptor Pharmaceutical
scientific officer. officer. Corp. acquisition.

Shao-Lee Lin, M.D., Ph.D.

Executive Vice President,
Head of Research and
Development and Chief Irina Konstantinovsky Michael DesJardin
Scientific Officer Executive Vice President, Executive Vice President,
Shao-Lee Lin, M.D., Ph.D., Chief Human Resources Technical Operations and
joined Horizon in January Officer Corporate Quality
2018 as executive vice Irina joined Horizon in 2017 Mike joined Horizon in
president, head of research as executive vice president, October 2016 as part of the
and development and chief chief human resources Raptor Pharmaceutical
scientific officer. officer. Corp. acquisition.

Barbara McCullough Vice

Mariam Koohdary Deputy President, North America Kathy Monday Regional Vice
General Counsel Compliance President, Supply, Americas
 Barbara McCullough Vice
Mariam Koohdary Deputy President, North America Kathy Monday Regional Vice
General Counsel Compliance President, Supply, Americas

Barbara McCullough Vice

Mariam Koohdary Deputy President, North America Kathy Monday Regional Vice
General Counsel Compliance President, Supply, Americas

Lori Henderson, J.D., General John Mendlein, Ph.D.,

Counsel and Corporate Lorence Kim, M.D., Chief President, Corporate and
Secretary Financial Officer Product Strategy

Lori Henderson, J.D., General John Mendlein, Ph.D.,

Counsel and Corporate Lorence Kim, M.D., Chief President, Corporate and
Secretary Financial Officer Product Strategy

Vic Myer, Ph.D.

Chief Technology Officer

Anita Woodring, Vice Nina Church, Executive

President of Clinical & Director of Clinical
Regulatory Operations Operations

Brent Furse • Director Phillip Sager, MD, FACC,

Mr. Furse has over 25 years FAHA, FHRS • Director
David E. Thompson • of healthcare commercial Dr. Sager is a Fellow of the
Director leadership experience with American College of
Mr. Thompson has served as extensive experience in the Cardiology, a Fellow of the
a member of our board of areas of sales and marketing, American Heart Association
directors since November commercial product launch and a Fellow of the Heart
2005. and partnerships. Rhythm Society.
 Marcio Souza | Chief
Megan Sniecinski | Senior Operating Officer
Vice President, Business Marcio Souza
Martin Rexroad | Senior Vice Operations and Program Marcio Souza joined PTC in
President, Human Resources Management July 2014 as Vice President
Martin Rexroad Megan Sniecinski of Global Marketing and
Martin Rexroad joined PTC in Megan Sniecinski serves as was subsequently Senior
September 2013 as Senior our Senior Vice President Vice President and Head of
Vice President of Human Business Operations and Global Product Strategy
Resources. Program Management. since June 2016

Naresh Mandava, MD Jeffrey Olson, MD

James Taylor Professor and Chair, Associate Professor,
Chief Executive Officer University of Colorado University of Colorado
 Andrew D. Schiermeier, Jennifer Mound Smoter
Ph.D. Senior Vice President,
Executive Vice President, External Affairs &
Corporate Strategy Communications

NATHALIE DUBOIS-
STRINGFELLOW, PH.D.
Vice President, Product
R. ANDREW RAMELMEIER, Development and
PH.D. Management
Chief Manufacturing & CLOSE
Quality Officer Nathalie Dubois-
CLOSE Stringfellow, Ph.D., has
R. Andrew “Andy” served as Vice President,
Ramelmeier, PhD, currently Product Development and
serves as Senior Vice HEATHER TURNER, J.D. Management since January
President and Chief Senior Vice President, 2015 and oversees the
Manufacturing & Quality General Counsel development and execution
Officer and is responsible for CLOSE of project team strategy for
Technical Operations at Heather Turner, JD, has Sangamo’s ZFP therapeutic
Sangamo, including served as Senior Vice programs in hemophilia,
manufacturing, quality President and General lysosomal storage disorders,
supply chain, and process Counsel since joining hemoglobinopathies, HIV
and analytical development. Sangamo in February 2018. and Huntington’s disease.

cal company spun out of Biogen’s hemophilia business, we bring a strong legacy of innovation, world-class science, and commitment to the
RAINER BOEHM, MD, MBA
Boehm brings more than
three decades of
biopharmaceutical
leadership experience to
Humanigen’s board. At
Novartis for 29 years, he
held roles of increasing
responsibility culminating
with his position as Chief
Commercial and Medical
Affairs Officer and as ad
interim CEO of Novartis’
pharmaceuticals division.

DR. JON TERRETT MICHAEL TOMSICEK

Head of Immuno-Oncology Chief Financial Officer
MEGAN WHERRY MENNER Research and Translation
Head of Human Resources Michael Tomsicek has
Dr. Jon Terrett has an significant experience in
Megan Wherry Menner has extensive track record for corporate finance,
extensive HR experience in discovering and progressing operations management
the pharmaceutical, biotech immuno-oncology drug systems, and corporate
and life sciences industries. candidates into the clinic. collaborations and licensing
 Murdo Gordon
Executive Vice President,
Global Commercial Sean E. Harper
Operations Executive Vice President
Steven K. Galson Murdo Gordon is executive Dr. Harper joined Amgen in
Senior Vice President, Global vice president, Global 2002 as vice president,
Regulatory Affairs and Safety Commercial Operations for Development, and has held
Dr. Steven K. Galson, senior Amgen. In this role, which he several leadership roles,
vice president, Global assumed in September 2018, including most recently as
Regulatory Affairs and Gordon is responsible for the executive vice president,
Safety, joined Amgen in 2010 ensuring Amgen’s innovative Research and Development,
as vice president, Global medicines reach patients from February 2012 through
Regulatory Affairs. around the world. July 2018.
RALF ROSSKAMP, M.D.
Chief Medical Officer JAMES B. WEISSMAN
Ralf Rosskamp, M.D., joined Chief Business Officer
Dicerna as chief medical James B. Weissman joined BART WISE, PH.D., J.D.
officer in June 2017. Dr. Dicerna as chief business Senior Vice President,
Rosskamp brings to Dicerna officer in January 2012. He Intellectual Property
more than 20 years of has more than 25 years’ Bart Wise joined Dicerna as
research and development experience in the life senior vice president,
(R&D) experience spanning sciences industry, with intellectual property in
the entire drug development extensive international October 2015. He has
cycle, from pre-clinical management experience in practiced for more than 15
through product biotech and pharmaceutical years in the life sciences
commercialization. He will general management, industry, with extensive
be responsible for leading product development, experience in intellectual
the Company’s clinical licensing, business property (IP) strategy and
development, medical affairs development, marketing and patent portfolio
and regulatory functions. M&A activities. management.

David Lawrence, M.B.A.

Chief, Business Operations Tierney Saccavino
and Principal Accounting Lauren Sabella Executive Vice President,
Officer Chief Commercial Officer Corporate Communications
 KIMBERLY YEATTS
SHANE COLLEY
RYAN FUKUSHIMA Senior Director of Clinical
Senior Vice President of Lab Operations
Chief Operating Officer Engineering
Kimberly Yeatts serves as
Ryan Fukushima serves as Shane Colley is the Senior the Senior Director of
Chief Operating Officer at Vice President of Engineering Clinical Lab Operations at
Tempus. at Tempus. Tempus.

Dr. Urvashi Surti, Ph.D.

Consultant, Clinical Maureen Sherer,
Cytogenetics Sally Kochmar, M.S.,CG(ASCP)CM
Professor Emeritus of M.S.,CG(ASCP)CM Supervisor, Oncology-
Pathology and OB/GYN & Laboratory Manager of the Section of the Cytogenetics
Reproductive Sciences Cytogenetics Laboratory Laboratory

inically utility and actionability of multi-platform profiling with Caris Molecular Intelligence. Enhance R&D innovation and maximize comme
adership in education, advocacy and collaboration helps lab professionals adapt to change and do what they do best: provide vital insight a

KARTHIK VEPURI DUSTIN HOFFMAN

EMC TEST ENGINEER EMC TEST ENGINEER
Erik Eglite, D.P.M., J.D.,
M.B.A.
Senior Vice President,
General Counsel & Chief
Corporate Compliance
Officer
Rashieda Gluck
Erik Eglite, D.P.M., J.D., Senior Vice President, Global
M.B.A. Clinical Operations Ron Demers
Prior to joining Aurinia, Erik Vice President,
was Vice President, Chief Rashieda Gluck Manufacturing and Supply
Compliance Officer and Rashieda has over 25 years of Chain
Corporate Counsel for pharmaceutical and biotech
Marathon Pharmaceuticals industry experience Ron oversees all
and Vice President, Chief specializing in strategic manufacturing
Compliance Officer and planning and delivery of requirements, drug supply
Corporate Counsel for global clinical development and manages the CMC team
Lundbeck Pharmaceuticals. programs at Aurinia.
MATTHEW MICHALEWICZ GLENN HAIFER
NON-EXECUTIVE DIRECTOR NON-EXECUTIVE DIRECTOR
Matthew Michalewicz has Glenn Haifer has over 30
more than 20 years’ years’ experience in the
experience in starting and healthcare sector. He has
running high-growth tech successfully established four
companies, particularly in different businesses
the areas of predictive operating in primary medical
analytics and optimisation services, histopathology and
software. cosmetic medical ...
 JOHNSON CHIANG, PHD
Chief Technical Officer

Previous to Alveo, Johnson BRENNA LORD

ROBIN STEELE, JD, LL M was the Head of Systems Director of Operations
Member of the Board of Integration & Molecular
Directors Biology at Foundation Brenna is the Operations
Medicine, Inc. and held Director at Alveo
Robin is a member of the senior management positions Technologies. She balances
Alveo Board of Directors and at Life Technologies and diverse responsibilities for
has practiced corporate and Thermo Fisher Scientific the company, including IP,
tax law for 30 years, where he led systems design, HR, Recruiting, Quality,
primarily in the integration, verification and Regulatory, Facilities, Event
biotechnology and validation for qPCR and Next- Coordination, Contracts,
pharmaceutical industries. Gen Sequencing platforms. and Communications
 Darin Leigh
Vice President, Global Sales
Patricia Ryan Byron Clendenen
Compliance Officer Vice President, Human Darin Leigh has joined
Resources Singulex in 2018. Darin has
Patricia Ryan joined Singulex worked in the life science
in 2014, bringing over 20 Byron Clendenen joined and IVD industries for over
years of experience focused Singulex in 2014 and 25 years, for Abbott,
on the internal control possesses 25 years of HR Luminex, Asuragen and
environment. leadership experience. Metabalon
Julie Yu
R&D Scientist
Pedro Galarza Andy Lane James Broughton
Research Technician CRISPR Scientist RNA Scientist

Francine Gregoire, Ph.D.

Vice President for Liver
Diseases Kristina Burow
Dr. Francine Gregoire is the Board Member
Vice President for Liver Kristina Burow is a
Diseases. Dr. Gregoire has Managing Director with
Courtney Wallace over 20 years of drug ARCH Venture Partners.
Vice President, Head of discovery experience,
Business Development and covering roles from the early Ms. Burow is focused on the
Strategy phases of drug discovery to creation and development
Courtney Wallace is Vice the identification of small of biotechnology,
President, Head of Business molecules, RNA therapeutics, pharmaceutical, and
Development and Strategy and gene editing clinical agbiotechnology
at Beam. candidates. companies.
Jeff Saunders, Ph.D.
Sr. Vice President of Drug
Discovery
Jeff Saunders brings over 25
years of drug discovery, Daniel Ory, M.D.
team building and Sr. Vice President of
leadership experience in Translational Medicine
start-up and early stage Dan Ory comes to Casma
discovery organizations. from Washington University
Over the last decade he has School of Medicine in St. Caren Block
been a pioneer and leader in Louis, where he served as the Vice President of People &
developing and evolving Alan A. and Edith L. Wolff Culture
outsourcing models for Professor of Cardiology and Caren Block serves as a
effective and highly was a tenured professor of strategic business partner,
productive drug design medicine, cell biology and coach, and mentor to the
teams. physiology. entire Casma organization.
 Iván Cornella-Taracido, Ph.D.
Vice President, Proteomics
and Chemical Biology
Iván Cornella-Taracido joins
Brian Jones, Ph.D. Cedilla from Merck Research Sarah Larson
Chief Scientific Officer Laboratories, where he was Interim Chief Human
Brian Jones has more than the director of chemical Resources Officer
25 years of drug discovery biology. Prior to Merck, Iván Sarah Larson comes to
experience and has led the held leadership positions at Cedilla with more than 20
molecular discovery behind AstraZenca, where he years of experience in
more than 20 INDs across established and managed the human resources and
several therapeutic areas. global chemical biology team leadership development.

Nick Leschly
Philip D. Gregory,
D. Phil. chief bluebird
Susanna High
Chief Scientific Officer Nick Leschly has served as
Chief Operating Officer our chief bluebird since
Philip D. Gregory, D. Phil., September 2010. Formerly,
has served as our chief Susanna High has served as Nick was a partner and
scientific officer since June chief operating officer since founding member of Third
2015. 2016. Rock Ventures in 2007.
Lori Henderson, J.D.
General Counsel and
Corporate Secretary Lorence Kim, M.D. John Mendlein, Ph.D.
Chief Financial Officer President, Corporate and
Product Strategy

As general counsel and

corporate secretary, Ms. Dr. Lorence Kim joined
Henderson leads Moderna’s Moderna from Goldman As President, Corporate and
legal, governance and Sachs where he was a Product Strategy, Dr.
corporate compliance managing director and co- Mendlein is responsible for
efforts. She comes to head of the U.S. corporate strategy, product
Moderna with nearly 30 biotechnology investment advancement and strategy,
years as a corporate attorney banking ef fort. He joined partnering and product
in both law firm and general Goldman Sachs in 1999 as a protection. He was
counsel roles guiding both summer associate and was previously a member of
global public and private named managing director in Moderna’s Board of
companies. 2008. Directors.

KIRK NIELSEN
Kirk Nielsen joined Versant ROBIN PRAEGER – CFO THOMAS WOIWODE, PHD
in 2006 from Medtronic, Robin Praeger is Versant’s Tom Woiwode is a
where he worked in sales & Chief Financial Officer and a Managing Director who has
marketing in the company’s Managing Director. Prior to been with Versant Ventures
Cardiac Rhythm joining Versant in 2000, Robin since 2002. Most recently,
Management division. was a tax partner with Arthur Tom served as the Chief
Previously, he spent time at Andersen where he Operating Officer of Okairos,
Fluidigm (a Versant portfolio developed extensive a biopharmaceutical
company) and he also experience in partnership tax company developing genetic
served as a consultant at planning and structuring. At vaccines for major infectious
Bain & Company, where he Anderson, his client base diseases. Tom led the
advised clients in healthcare, included large real estate process that culminated in
private equity, and other partnerships and the sale of Okairos to GSK
industries. corporations. for $325M
KIRK NIELSEN
Kirk Nielsen joined Versant OBIN PRAEGER – CFO THOMAS WOIWODE, PHD
in 2006 from Medtronic, Robin Praeger is Versant’s Tom Woiwode is a
where he worked in sales & Chief Financial Officer and a Managing Director who has
marketing in the company’s Managing Director. Prior to been with Versant Ventures
Cardiac Rhythm joining Versant in 2000, Robin since 2002. Most recently,
Management division. was a tax partner with Arthur Tom served as the Chief
Previously, he spent time at Andersen where he Operating Officer of Okairos,
Fluidigm (a Versant portfolio developed extensive a biopharmaceutical
company) and he also experience in partnership tax company developing genetic
served as a consultant at planning and structuring. At vaccines for major infectious
Bain & Company, where he Anderson, his client base diseases. Tom led the
advised clients in healthcare, included large real estate process that culminated in
private equity, and other partnerships and the sale of Okairos to GSK
industries. corporations. for $325M

KIRK NIELSEN
Kirk Nielsen joined Versant OBIN PRAEGER – CFO THOMAS WOIWODE, PHD
in 2006 from Medtronic, Robin Praeger is Versant’s Tom Woiwode is a
where he worked in sales & Chief Financial Officer and a Managing Director who has
marketing in the company’s Managing Director. Prior to been with Versant Ventures
Cardiac Rhythm joining Versant in 2000, Robin since 2002. Most recently,
Management division. was a tax partner with Arthur Tom served as the Chief
Previously, he spent time at Andersen where he Operating Officer of Okairos,
Fluidigm (a Versant portfolio developed extensive a biopharmaceutical
company) and he also experience in partnership tax company developing genetic
served as a consultant at planning and structuring. At vaccines for major infectious
Bain & Company, where he Anderson, his client base diseases. Tom led the
advised clients in healthcare, included large real estate process that culminated in
private equity, and other partnerships and the sale of Okairos to GSK
industries. corporations. for $325M
KIRK NIELSEN
Kirk Nielsen joined Versant OBIN PRAEGER – CFO THOMAS WOIWODE, PHD
in 2006 from Medtronic, Robin Praeger is Versant’s Tom Woiwode is a
where he worked in sales & Chief Financial Officer and a Managing Director who has
marketing in the company’s Managing Director. Prior to been with Versant Ventures
Cardiac Rhythm joining Versant in 2000, Robin since 2002. Most recently,
Management division. was a tax partner with Arthur Tom served as the Chief
Previously, he spent time at Andersen where he Operating Officer of Okairos,
Fluidigm (a Versant portfolio developed extensive a biopharmaceutical
company) and he also experience in partnership tax company developing genetic
served as a consultant at planning and structuring. At vaccines for major infectious
Bain & Company, where he Anderson, his client base diseases. Tom led the
advised clients in healthcare, included large real estate process that culminated in
private equity, and other partnerships and the sale of Okairos to GSK
industries. corporations. for $325M
Dan was the VP of Biology at
Inception Sciences - a
Versant Ventures discovery
engine - where he led all
aspects of biology and non-
clinical pharmacology,
including the acquisition of
the remyelination company
Inception 5 by Roche
pharmaceuticals. Prior to
joining Inception,

Amanda Enstrom Derek Metzger

Elia Borbas SENIOR DIRECTOR, SENIOR DIRECTOR,
VICE PRESIDENT, CLINICAL RESEARCH AND PROGRAM LEADERSHIP AND
OPERATIONS DEVELOPMENT PROGRAM MANAGEMENT
 Mostafa Ronaghi, PhD Senior
Vice President & Chief
Technology Officer
Mostafa Ronaghi, Ph.D.,
joined Illumina in August
2008. As Senior Vice
President and Chief Sam Samad Senior Vice
Charles Dadswell Senior Vice Technology Officer, he is President & Chief Financial
President & General Counsel responsible for leading Officer
Charles (Chuck) Dadswell is internal research and Sam Samad joined Illumina
Senior Vice President and technology development in 2017 and holds the role
General Counsel of Illumina, (RTD) and is co-founder of of Senior Vice President and
where he has worldwide Illumina Accelerator, the Chief Financial Officer with
responsibility for all legal world’s first business responsibility for the
and intellectual property accelerator focused solely on company’s finance,
matters and is also Illumina's creating an innovation accounting, investor
code of ethics compliance ecosystem for the genomics relations, internal audit, and
officer. industry. treasury functions.

Mostafa Ronaghi, PhD Senior

Vice President & Chief
Technology Officer
Mostafa Ronaghi, Ph.D.,
joined Illumina in August
2008. As Senior Vice
President and Chief Sam Samad Senior Vice
Charles Dadswell Senior Vice Technology Officer, he is President & Chief Financial
President & General Counsel responsible for leading Officer
Charles (Chuck) Dadswell is internal research and Sam Samad joined Illumina
Senior Vice President and technology development in 2017 and holds the role
General Counsel of Illumina, (RTD) and is co-founder of of Senior Vice President and
where he has worldwide Illumina Accelerator, the Chief Financial Officer with
responsibility for all legal world’s first business responsibility for the
and intellectual property accelerator focused solely on company’s finance,
matters and is also Illumina's creating an innovation accounting, investor
code of ethics compliance ecosystem for the genomics relations, internal audit, and
officer. industry. treasury functions.
 Mostafa Ronaghi, PhD Senior
Vice President & Chief
Technology Officer
Mostafa Ronaghi, Ph.D.,
joined Illumina in August
2008. As Senior Vice
President and Chief Sam Samad Senior Vice
Charles Dadswell Senior Vice Technology Officer, he is President & Chief Financial
President & General Counsel responsible for leading Officer
Charles (Chuck) Dadswell is internal research and Sam Samad joined Illumina
Senior Vice President and technology development in 2017 and holds the role
General Counsel of Illumina, (RTD) and is co-founder of of Senior Vice President and
where he has worldwide Illumina Accelerator, the Chief Financial Officer with
responsibility for all legal world’s first business responsibility for the
and intellectual property accelerator focused solely on company’s finance,
matters and is also Illumina's creating an innovation accounting, investor
code of ethics compliance ecosystem for the genomics relations, internal audit, and
officer. industry. treasury functions.

Melissa McLaughlin
Chief People Officer
Ms. McLaughlin joined Agios
in January 2015 as vice
president, human resources.
She brings more than 15 Min Wang, J.D., Ph.D.
years of human resources SVP General Counsel
experience, with a focus on Dr. Wang joined Agios in
leading business and HR February 2010 and has nearly Clive Patience, Ph.D.
transformations, building 15 years of intellectual SVP Technical Operations
organizational capabilities, property and transactional Dr. Patience joined Agios as
and shaping high legal experience in the SVP of technical operations
performance cultures. biopharmaceutical industry. in June 2017.

Judy Gilbert
Chief People Officer Enakshi Singh
VP of Finance
Judy leads our efforts to Richard Pieters
build a culture that supports President, Products Prior to joining Zymergen,
collaboration, learning, and Ena was focused on
innovation, allowing us to At Zymergen, Richard is semiconductor investments
attract, develop, and responsible for our overall at Mubadala, Abu Dhabi’s
challenge amazing people products business. sovereign wealth fund.
 Jennifer Marasco
Vice President, Human
Resources
Jennifer joined Molecular
Devices in March 2017.
Jennifer began her career
with Danaher at Beckman
Dominik Arnold Coulter Diagnostics in 2014 Dean Ding
VP/GM, Biologics Business as the Sr. Manager, Human Vice President, Global
Unit Resources and was promoted Operations
Dominik was appointed Vice to Director, Human Resources Dean joined Molecular
President and General in 2015, where she Devices in June 2010 and
Manager for the Biologics supported a number of was appointed Vice
Business Unit of Molecular global functional groups in President of Global
Devices in April 2018. her two roles Operations in Apr.2017.
JOHN MARAGANORE, PhD
CHIEF EXECUTIVE OFFICER
Since 2002, Dr. John
Maraganore has served as SARASWATHY V. NOCHUR, MANMEET S. SONI
the CEO and a Director of PhD CHIEF FINANCIAL OFFICER
Alnylam. SVP, CHIEF REGULATORY Manmeet Soni joined
OFFICER Alnylam in May 2017. He
Prior to Alnylam, Dr. Dr. Saraswathy (Sara) Nochur provides strategic leadership
Maraganore served as an joined Alnylam in 2006 as the over all financial
officer and a member of the Vice President of Regulatory management company-
management team for Affairs, and also held roles as wide, including the global
Millennium Pharmaceuticals, Program Leader for 2 late- finance, investor relations,
Inc. stage programs. and communications teams.
Patrick O’Brien, J.D., PharmD
General Counsel
 WILL DOWNIE
BARRY LITTLEJOHNS SENIOR VICE PRESIDENT, STEVEN FASMAN
PRESIDENT, BIOLOGICS & GLOBAL SALES AND SENIOR VICE PRESIDENT &
SPECIALTY DRUG DELIVERY MARKETING GENERAL COUNSEL
Barry Littlejohns was named Will Downie has served as Steven Fasman was named
President, Biologics & Senior Vice President, Global Senior Vice President and
Specialty Drug Delivery in Sales & Marketing since June General Counsel in October
October 2017. 2010. 2014.

David L. Szekeres Thomas B. Ottoboni, Ph.D.

Senior VP, General Counsel, Senior VP, Pharmaceutical Anita Gupta D.O., Pharm.D.
Business Development and and Preclinical Research and Senior VP, Medical Strategy
Corporate Secretary Development and Government Affairs
David L. Szekeres Thomas B. Ottoboni, Ph.D.
Senior VP, General Counsel, Senior VP, Pharmaceutical Anita Gupta D.O., Pharm.D.
Business Development and and Preclinical Research and Senior VP, Medical Strategy
Corporate Secretary Development and Government Affairs

Paula Cloghessy, SPHR,

SHRM-SCP
Chief Human Resources
Officer
Paula serves as Translate Frank DeRosa, Ph.D.
Bio’s Chief Human Resources Senior Vice President,
Officer and is responsible for Paul Burgess, J.D. Research and Process
leading human resources Chief Legal Officer Development
and organizational Paul is Translate Bio's Chief Frank joined the Translate
development. Legal Officer Bio team in 2016.
 Dean Stamos
Head of Chemistry
Innovation
X
Dr. Dean Stamos joined
Matt Patricelli Vividion Therapeutics in 2017
Head of Early Discovery as Vice President of
X Chemistry. In his current role,
Matt Patricelli joined Dean oversees the strategic
Vividion in 2016 as a growth and implementation
founding scientific member of Vividion’s cutting edge
of the company’s chemical proteomics
management team. In his platform to support all
current role, Matt supports aspects of the drug discovery
all early drug discovery process. Central towards this
efforts including target goal is the full utilization of
selection and validation, as modern synthetic
well as the continued methodologies coupled with
development and execution chemical biology insights to
of Vividion’s chemical deliver high-quality small
proteomics platform. molecule therapeutics.

Mark J. Guinan
Executive Vice President and
Chief Financial Officer
John B. Haydon
Mark J. Guinan is Executive Vice President, Global
Vice President and Chief Markets
Financial Officer for Quest
Diagnostics. John Haydon is Vice
Lidia Fonseca President, Global Markets
Senior Vice President and From 2010 until joining Quest for Quest Diagnostics.
Chief Information Officer Diagnostics in 2013 as Senior Previously, Mr. Haydon was
Vice President and Chief Vice President of Joint
Lidia Fonseca is Senior Vice Financial Officer, Mr. Guinan Venture Partnerships and
President and Chief served as Chief Financial previous to that, he was
Information Officer (CIO) for Officer for Hill-Rom Holdings Senior Vice President,
Quest Diagnostics. Inc. Operations.
Ross Lobell
Vice President, Regulatory
Affairs
Ross Lobell joined Corbus as
Vice President, Regulatory
Affairs in April 2018. Mr.
Lobell is an expert in
regulatory affairs with an
extensive biopharmaceutical
background in leading
preclinical, clinical and
nonclinical regulatory
strategies and operations to
support the drug
development process.

Brenda J. Sousa
Senior Vice President of
Human Resources and
Operations
Brenda Sousa is
Constellation
Pharmaceuticals’ senior vice
president of human Karen H. Valentine
resources and operations. Chief Legal Officer and
Prior to joining Constellation Patrick Trojer, PhD General Counsel
in 2010, Brenda was the vice Senior Vice President, EZH2 Karen H. Valentine joined
president of human Franchise and Head of Constellation
resources and operations at Translational Sciences Pharmaceuticals as chief
EPIX Pharmaceuticals, where Dr. Patrick Trojer joined legal officer and general
she served as a member of Constellation counsel in July 2018.
the global executive Pharmaceuticals as a Previously, she served as the
management team and founding scientist in 2008 chief legal officer and
focused on the development and currently serves as senior general counsel of Agenus
and implementation of vice president, EZH2 Inc., a publicly traded
business strategy, franchise and head of immuno-oncology company,
operations, and translational sciences. Patrick from September 2015 to
organizational development has held multiple positions of July 2018 and served as vice
for U.S. companies with increasing responsibility at president and general
international offices. Constellation. counsel of Agenus Inc.
Geoffrey S. Gilmartin, M.D.,
M.M.Sc.
Chief Development Officer

Dr. Geoffrey Gilmartin joins

Proteostasis Therapeutics
from AstraZeneca where he
served as Clinical Research
Physician for Global
Medicines Development
from January 2014 to August
2016.
r. Magda Marquet, Director
of the Board
Dr. Magda Marquet is the
co-founder and co-CEO of
Alma Life Sciences, an
investment and consulting
firm with a portfolio of over
twenty companies in the
areas of diagnostics, digital
health and pharmaceuticals,
Chairman and co-Founder of
Althea, an Ajinomoto
company, and Co-founder of
AltheaDx, a precision
medicine company.

Inge Tarnow John K. John

Head of Nonclinical Mette Vinge Vice President & Head of
Development Head of Regulatory Affairs Quality
Dr. Tarnow serves as Head of Ms. Vinge serves as Head of John K. John serves as Vice
Nonclinical Development Regulatory Affairs and is President & Head of Quality
and has more than 15 years responsible for all regulatory for Savara. He is responsible
of experience from biotec... activities. She has ... for global GxP qual...
 David P. Snow, Chief Business
Officer Andi Leubitz, Senior Director
Mr. Snow has over 25 years of Clinical Operations
Greg Williams, PhD, Chief of experience in the global Ms. Leubitz joined Eloxx in
Operating Officer pharmaceutical industry August 2016 and is currently
Dr. Williams has over 30 developing global brands, Senior Director of Clinical
years of Pharmaceutical and leading large commercial Operations and the Site
Biotechnology experience organizations across major Head for the Israel branch.
leading regulatory affairs, markets, driving She brings more than 18
compliance, quality, transformation and growth, years of clinical operations
manufacturing, commercial and delivering a successful experience in both the
and product development track record of business pharmaceutical and medical
programs. development. device industries.
Michael D. Davis, RRT, PhD.
Scientific Advisory Board
Member

Mr. Davis is an Assistant

Professor at the Division of
Pulmonary Medicine,
Children’s Hospital of
Richmond, Virginia
Commonwealth University
and a Registered Respiratory
Therapist.
 Rebecca Anthouard
McDonald
Senior Microbiologist
Rebecca A McDonald is the
Senior Microbiologist at Vast
Therapeutics. Her work
William Roberts includes aiding in the
Principal Scientist of development of therapies
Darlene Dendy Inhalation that are effective against
Director of Administration William Roberts is the antibiotic-resistant bacteria,
Darlene Dendy is the Principal Scientist of testing Vast Therapeutics’
Director of Administration at Inhalation at Vast lead compound against a
Vast Therapeutics. She Therapeutics. He leads the wide range of deadly
manages daily operations to development of inhalation pathogens, and performing
ensure the business runs formulations and has 31 Research and Development
smoothly and operates years of experience in the work to bring nitric oxide
efficiently. pharmaceutical industry. therapeutics to market
Priscilla Fernandes, PhD,
FACMG, Associate
Laboratory Director
 Ryan T. VanderLinden, Ph.D.,
Principal Scientist, Structural
Paul Sebahar, PhD – Director Biology
of Chemistry Dr. VanderLinden has been
Prior to joining Curza, Dr. successful in purifying and
Sebahar served as the determining the structure of
Director of Quality for multiple multi-protein
Medical Horizons, a leader in complexes:
contract manufacturing of UCH37/RPN13/Ub and
dietary supplements, where RPN13/RPN2/Ub complexes
he was responsible for the which are subcomplexes of
implementation of quality the 26S proteasome and
strategy and corporate UCH37/NFR?B of the INO80
compliance with cGMP’s and chromatin remodeling
federal regulations. complex

Mary Campbell, RN BSN

SENIOR NURSE
COORDINATOR
Mary is a Registered Nurse
with over 12 years of
experience in nursing
education, medical-surgical,
pediatrics, oncology and
women’s health.
Co-Founder and Board
Member

William Zimlich is the former Board Member

CEO of Activaero America,
Inc., a pulmonary drug Steven Han is Vice President
delivery technology of 12th Man Technologies –
company specializing in Steve brings more than 20
severe lung diseases that years of product
was acquired in 2014 by development in medical and
Vectura Group. consumer products.
 ERIC STIER
Senior Vice President,
General Counsel and JENNIFER WILLIAMS
Secretary Senior Vice President, Human
Mr. Stier serves as Senior Resources
Vice President, General Ms. Williams serves as Senior
Counsel and Secretary of the Vice President, Human
company and has held Resources and has held
various legal affairs roles various roles within the
with the company since company since joining in
joining in November 2012. November 2010.

atify multiple sclerosis patients. These tests provide objective measures for the first time enabling physicians to personalize and
Andrew Wylie, PhD, Head of
Discovery Biology

Andrew Wylie has over 16

years of oncology drug
discovery experience in both
small biotech and big
pharma environments. Prior
to joining KSQ Therapeutics,
Andrew served as a Director
in the Oncology group at the
Novartis Institutes for
BioMedical Research where
he was responsible for
leading drug discovery
teams from early conceptual
stages to the nomination of
clinical candidates.
PETER S. KIM, PH.D. LUBERT STRYER, M.D.
Lead Investigator, Infectious Senior Advisor
Disease Lubert Stryer is the Winzer
Peter Kim carried out his Professor of Cell Biology,
Ph.D. thesis research on Emeritus, at Stanford
protein folding in Robert University. His research over
Baldwin’s laboratory at more than four decades has
Stanford University and then been centered on the
became one of the early interplay of light and life. Dr.
Whitehead Fellows at MIT’s Stryer’s laboratory discovered
Whitehead Institute. the primary stage of
Subsequently he held amplification in vision and
appointments as Professor elucidated the G-protein
of Biology at MIT, Member cascade that generates a
of the Whitehead Institute neural signal in visual
and Investigator of HHMI. excitation.
Jonathan Milner, PhD
Jonathan, co-Founder and
currently Deputy Chairman
of Abcam plc, is an
experienced entrepreneur
and investor and is
passionate about supporting
UK life science and high-tech
start-ups.
Advisor

Robin A. Walker
Vice President, Head of Legal
 Nick Conley, PhD
Principal Scientist
eter Potgieter, MD, PhD Dr. Nick Conley is Principal
Vice President, Clinical Scientist for Locus Aeron Hammack, PhD
Development & Medical Biosciences. Before joining Principal Scientist
Affairs Locus in 2018, Nick was co- Dr. Aeron Tynes Hammack is
Peter Potgieter, PhD trained founder of EpiBiome, a South a Principal Scientist for
in anesthesiology, critical San Francisco-based Locus Biosciences. Before
care and pulmonary precision microbiome joining Locus in 2018, Aeron
medicine and has worked in engineering company that was co-founder of
academic positions including built the world’s first fully EpiBiome, a South San
being Head of Respiratory automated high-throughput Francisco-based precision
and Medical ICUs at the phage discovery, microbiome engineering
University of Cape Town and characterization, and company that built the
Groote Schuur Hospital, and genomics platform, where he world’s first fully automated
subsequently Chairman of served in various roles, high-throughput phage
Critical Care at the National including CEO and Chief discovery, characterization,
Guard Hospital in Riyadh. Science Officer. and genomics platform.
Patricia Williams, Ph.D.
Director of Regulatory and
Clinical Affairs
Patrick Rush, D.P.M.
Head of Project Management
Dr. Williams is a
pharmaceutical executive
with over 35 years of Dr. Rush joined Excision in
experience in drug discovery June 2018 as Head of Clinical
and development in the Operations. He is an
pharmaceutical, accomplished
biotechnology and contract pharmaceutical leader and
service industries. Dr. scientist with more than 20
Williams is currently the years of clinical research
President & CEO of IND experience in Phase I-IV
Directions, LLC, a drug clinical development. Dr.
development consulting and Rush has held positions of
service company located in increasing responsibilities
Northern Virginia. Dr. within Clinical Development,
Williams was the founder, Project Management and
co-owner and Chief Regional Monitoring. Over his
Operating Officer of Summit career he has worked at
Drug Development Services, GlaxoSmithKline, Bristol
LLC, a drug development Myers-Squibb, Idenix,
service company in Rockville, CanFite BioPharma and the
Maryland for five years University of Pennsylvania.
 Veterans Administration
David A. Largaespada, PhD Walter Low, PhD Medical Centers.
Chief Scientific Officer of Chief Scientific Officer of
Surrogen Regenevida
Dr. Largaespada is a leading Dr. Walter Low is a leader in Tad Sonstegard, PhD
authority on mouse neuroscientific research and Chief Scientific Officer of
genetics, gene modification, bioengineering. He’s a Acceligen
cancer genes and disease professor and Director of the Dr. Tad Sonstegard is an
models. His expertise guides Research Laboratories in the internationally recognized
the science behind Department of Neurosurgery leader in livestock genetics
Recombinetics’ biomedical at the University of with more than 20 years of
subsidiary, Surrogen. Minnesota. experience in the field.
 Brian Staskawicz, Ph.D.
Alex Marson, M.D., Ph.D. Scientific Director, Agriculture
Scientific Director, Brian Staskawicz is the
Biomedicine Maxine J. Elliot Professor of
Alex Marson is an Associate Plant and Microbial Biology
Professor in the Department at The University of usan Jenkins, Ph.D.
of Microbiology and California, Berkeley. The Managing Director
Immunology at the Staskawicz lab studies the Susan Jenkins leads
University of California, San molecular basis of plant- institute-wide
Francisco. The Marson lab pathogen interactions and administration and also
uses genome editing to applies their discoveries to manages education and
study how different DNA engineer resistance in crop outreach, communications,
sequences control human T species. READ MORE external collaborations, and
cell function intellectual property.
 Christof Fellman Ph.D. ×
Dr. Fellmann is a leader in the Stephen Elledge
development of RNA Dr. Elledge is the Gregor
interference as an Mendel Professor of
cott W. Lowe, PhD experimental tool for basic Genetics in the Department
Dr. Lowe is a member of the and biomedical research. He of Genetics at Harvard
Cancer Biology and Genetics pioneered the establishment Medical School and in the
Program and the Geoffrey of a functional “Sensor Division of Genetics at
Beene Chair in Cancer assay” that enables the Brigham Women’s Hospital
Biology at the Memorial biological identification of and is an investigator with
Sloan-Kettering Cancer effective shRNAs at large the Howard Hughes Medical
Center. scale. Institute.

Stephanie Marrus
Operation advisor
Director, Entrepreneurship
center at UCSF
Sandra Foster, PhD
Director of Quality Rebecca Holmberg, PhD,
Assurance PMP
Dr. Foster joined Akonni in Director of Application
September of 2015 as Development Michael Reinemann, MPH
Director of Quality Dr. Holmberg joined Akonni Director of Business
Assurance, and brings a Biosystems in 2008 and Development
unique blend of scientific currently leads the Mr. Reinemann has an
knowledge and Quality commercialization effort for exceptional track record of
experience. She began her Akonni’s sample preparation developing and
scientific career as a Medical product line including the implementing strategic,
Technologist (MT, ASCP) TruTip Automated data-driven marketing and
working in hospital Workstation, on track to be a sales initiatives for
laboratories. From the FDA Class I device, and diagnostic products,
clinical lab she transitioned Purification Kits covering a resulting in strong double-
to research before going to wide range of clinical digit growth and increased
graduate school. applications. market share.
c.suite leaders and titles9 c.suite leaders and titles10 c.suite leaders and titles11

Dr. Mary Padilla VP Dr. Mark Sausen VP Mr. William Stevens CFO

Kerry B. Gunning, PhD Margaret Teasdale, PhD

Director of Laboratory Nicholas Rouse Quality, Safety, and
Operations Director of Bioinformatics Compliance Manager

Bjorn Stromsness Timothy Shurtleff, MPA Jooeun Lim Choi, PhD

Bjorn Stromsness is the Timothy Shurtleff is Machaon Dr. Jooeun Lim Choi is Senior
Director of Client Services at Diagnostics’ Vice President of Clinical Research Scientist at
Machaon Diagnostics Laboratory Operations Machaon Diagnostics
Monica Gangal
Vice President for Clinical
Operations

Kate O'Sullivan, M.S., MBA

Laura K. Moen, Ph.D. Office of Amy Patterson, M.D.
Division of Extramural Management/Executive Office Office Of The Director
Research Activities (DERA) (OM/EO) Chief Science Advisor and
Division Director, 2017 - Director and Executive Officer, Director of Scientific Research
Present 2011 - Present Programs, 2015 - Present

JESSICA NOVAK MICHELLE STOVER SMITH

Vice President, People General Counsel

Eric J. Patzer, Ph.D. Isaac Blech Robert Ruffolo, Ph.D.

Chairman of the Board Vice Chairman Director
 Mark Eccleston
Scott Powell Dr Mark Eccleston is an
Scott has nearly 20 years of enthusiastic and passionate
experience in the U.S. biotechnology entrepreneur
capital markets and investor with over 20 years experience
relations. in the sector.

THOMAS COOK Vice

President of Public Relations
 Taiyin Yang, PhD
Robin L. Washington Katie L. Watson Executive Vice President,
Executive Vice President Executive Vice President, Pharmaceutical Development
and Chief Financial Officer Human Resources and Manufacturing

EVP, GLOBAL OPERATIONS

Wayne R. Swanton
Prior to his current
appointment, Mr. Swanton
served as Senior Vice
President, Global
Operations of Allergan.

Ali Ardakani
Senior VP Device & Business Wulff-Erik Von Borcke
Development President, Pharmacyclics
Karen Hale
Vice President, Chief Ethics Wulff-Erik Von Borcke
and Compliance Officer President, Pharmacyclics

Karen Hale
Vice President, Chief Ethics Wulff-Erik Von Borcke
and Compliance Officer President, Pharmacyclics

Karen Hale
Vice President, Chief Ethics Wulff-Erik Von Borcke
and Compliance Officer President, Pharmacyclics

Karen Hale
Vice President, Chief Ethics Wulff-Erik Von Borcke
and Compliance Officer President, Pharmacyclics

Karen Hale
Vice President, Chief Ethics Wulff-Erik Von Borcke
and Compliance Officer President, Pharmacyclics

Karen Hale
Vice President, Chief Ethics Wulff-Erik Von Borcke
and Compliance Officer President, Pharmacyclics

Karen Hale
Vice President, Chief Ethics Wulff-Erik Von Borcke
and Compliance Officer President, Pharmacyclics

Karen Hale
Vice President, Chief Ethics Wulff-Erik Von Borcke
and Compliance Officer President, Pharmacyclics
Karen Hale
Vice President, Chief Ethics Wulff-Erik Von Borcke
and Compliance Officer President, Pharmacyclics

Karen Hale
Vice President, Chief Ethics Wulff-Erik Von Borcke
and Compliance Officer President, Pharmacyclics
 David G. Kelly
Executive Vice President, Geoffrey M. Curtis
Vikram Karnani Company Secretary and Executive Vice President,
Executive Vice President, Managing Director, Ireland Corporate Affairs and Chief
Chief Commercial Officer David joined Horizon Pharma Communications Officer
Vikram joined Horizon in September 2014 as Geoff joined Horizon Pharma
Pharma in July 2014 and executive vice president, in 2015 and has more than
has been in his current managing director, Ireland two decades of global
position since February and was appointed company healthcare communications
2018. secretary in November 2014. experience.

David G. Kelly
Executive Vice President, Geoffrey M. Curtis
Vikram Karnani Company Secretary and Executive Vice President,
Executive Vice President, Managing Director, Ireland Corporate Affairs and Chief
Chief Commercial Officer David joined Horizon Pharma Communications Officer
Vikram joined Horizon in September 2014 as Geoff joined Horizon Pharma
Pharma in July 2014 and executive vice president, in 2015 and has more than
has been in his current managing director, Ireland two decades of global
position since February and was appointed company healthcare communications
2018. secretary in November 2014. experience.

David G. Kelly
Executive Vice President, Geoffrey M. Curtis
Vikram Karnani Company Secretary and Executive Vice President,
Executive Vice President, Managing Director, Ireland Corporate Affairs and Chief
Chief Commercial Officer David joined Horizon Pharma Communications Officer
Vikram joined Horizon in September 2014 as Geoff joined Horizon Pharma
Pharma in July 2014 and executive vice president, in 2015 and has more than
has been in his current managing director, Ireland two decades of global
position since February and was appointed company healthcare communications
2018. secretary in November 2014. experience.

William Mongan Vice

President, Business
Development, New Product Olivier Nataf Vice President, Tarek Rabah Vice President,
Planning and Mature Brands US Oncology Renal-Cardio
William Mongan Vice
President, Business
Development, New Product Olivier Nataf Vice President, Tarek Rabah Vice President,
Planning and Mature Brands US Oncology Renal-Cardio

William Mongan Vice

President, Business
Development, New Product Olivier Nataf Vice President, Tarek Rabah Vice President,
Planning and Mature Brands US Oncology Renal-Cardio

Megan Pace, Chief Tal Zaks, M.D., Ph.D., Chief

Corporate Affairs Officer Medical Officer

Megan Pace, Chief Tal Zaks, M.D., Ph.D., Chief

Corporate Affairs Officer Medical Officer
Christine Utter | Principal
Financial Officer and
Treasurer
Christine Utter
Ms. Utter joined PTC in
2010 as the Assistant
Controller and advanced
with increasing
responsibilities and
positions to her most recent
position as Senior Vice
President, Finance, in
January 201

Akiteru Furukawa Claude Benedict, MD, PhD

Hoya Corporation Hoya Corporation
 MCDAVID STILWELL
HEATHER ERICKSON Vice President, Corporate
Chief of Staff DUNCAN MCKAY Communications and Investor
CLOSE Vice President, General Relations
Heather Erickson has served Manager of Europe CLOSE
as Chief of Staff since July CLOSE McDavid Stilwell has served as
2016 and is responsible for Duncan McKay has served as Vice President, Corporate
the execution of Sangamo's Vice President and General Communications and Investor
daily operations and special Manager of Europe since Relations since November
projects. January 2018. 2016.

ation, world-class science, and commitment to the rare blood disorders community. We are united by a singular purpose: to create progres
 Raymond C. Jordan
Senior Vice President,
Corporate Affairs
Raymond C. Jordan joined
Amgen as senior vice
president, Corporate Affairs, in
Anthony C. Hooper Lori Johnston October 2012. In this role,
Executive Vice President Senior Vice President, Human Jordan is responsible for
Anthony C. Hooper joined Resources strategic communications
Amgen in October 2011 as Lori Johnston is senior vice across Amgen, including
executive vice president of president, Human Resources, internal and external
Global Commercial responsible for overseeing communications, issues
Operations, a role he held Amgen’s global Human management, and
until August 2018. Resources function. philanthropy.
Jane Wasman, J.D.
President, International &
General Counsel
 DAVID AGUS, MD ARUL CHINNAIYAN, MD, PHD
DR. ANDREA CALIFANO
Scientific Adviser Scientific Adviser
Scientific Adviser
Dr. David Agus is Chairman Dr. Arul M. Chinnaiyan serves
of the Scientific Advisory Dr. Andrea Califano, serves as as Scientific Adviser at
Board at Tempus. Scientific Adviser at Tempus. Tempus.

Susie Mann, M.S.,

CG(ASCP)CM
Supervisor, Non-Oncology
Section of the Cytogentics
Laboratory

e. Enhance R&D innovation and maximize commercial value with advanced and comprehensive molecular insights that can be customized
e and do what they do best: provide vital insight and guidance so patients get the care they need.
 Lawrence (Larry) D. Mandt
Celia Economides Vice President, Quality &
Vice President, Corporate & Regulatory Affairs
Public Affairs Bradley J. Dickerson
Lawrence (Larry) D. Mandt General Manager, Americas &
Celia Economides Larry has been with Aurinia Global Commercial Lead
Celia has over 15 years of since its inception in 2012 and
experience in the life brings 30+ years’ experience Bradley J. Dickerson
sciences and biotech in global regulatory affairs, in Brad has more than 15 years
industries, spanning large and small companies, of experience in the
communications, investor across a variety of therapeutic healthcare industry with a
relations, finance, patient areas. During his career, he focus on pharmaceutical
advocacy, marketing and has operated at the executive market access, distribution
clinical development. level for 10+ years. and patient services.
 SHAD PIERSON
Senior Hardware Engineer /
Technology Architect
RIXUN FANG, PH.D.
KYLE MONTGOMERY Shad is the Senior Hardware Director of Assay
Director of Engineering Engineer / Technology Development
Architect at Alveo
Kyle is the Engineering Technologies. Shad Rixun brings over 20 years of
Director at Alveo conceptualizes technical experience in IVD
Technologies, guiding solutions to bring visionary development to his role as
products from early stage ideas to the benchtop for Alveo's Director of Assay
R&D to manufacturing. testing Development
Mark Fishman, M.D. Robert Nelsen
Board Member Board Member
Mark C. Fishman, M.D., is Robert Nelsen is a co-founder
Professor in the Harvard and a Managing Director of
Department of Stem Cell Stephen Knight, M.D. ARCH Venture Partners.
and Regenerative Biology Board Member
and Chief of the Pathways Stephen Knight joined F-Prime He joined ARCH at its
Clinical Service service at Capital, where he serves as founding and played a
the MGH for patients with President and Managing significant role in the early
complex medical disorders. Partner, in 2003. He has sourcing, financing, and
His current research focus is worked in the pharmaceutical development of more than 30
on the genes that guide and biotechnology industries companies, including 19
social behavior, using for over 25 years and invests which have reached
genetics of the zebrafish. broadly across healthcare. valuations exceeding $1 billion
Colleen DeSimone
Interim Head of Finance
Colleen DeSimone is an
independent financial
consultant working with
Casma Therapeutics, Inc.
Most recently, she served as
VP of finance and controller
at Syros Pharmaceuticals.
 Alexandra Glucksmann, Ph.D.
President and Chief Executive
Officer
Colleen DeSimone Sandra Glucksmann is a
Interim Head of Finance veteran biopharma executive
Colleen DeSimone most and experienced scientist who
recently served as vice most recently served as
president of finance and founder and chief operating
controller at Syros officer of the gene editing
Pharmaceuticals. company Editas Medicine, Inc.

Andrew Obenshain

Head of Europe Joanne Smith-Farrell, Ph.D.

Andrew Obenshain has Senior Vice President, Jeffrey T. Walsh

served as head of Europe Corporate Development and
since 2016. He was most Strategy Chief Financial and Strategy
recently at Shire in Paris, Officer
France where he was the Joanne Smith-Farrell, Ph.D.,
general manager of France joined us in April 2017 as our Jeff Walsh has been with
and Benelux overseeing a senior vice president, bluebird since May 2011 and
portfolio including seven corporate development and currently serves as our chief
rare disease products. strategy. financial and strategy officer.
Megan Pace
Chief Corporate Affairs
Officer
Tal Zaks, M.D., Ph.D.
Chief Medical Officer

As chief corporate affairs

officer, Ms. Pace is
responsible for Moderna’s As Chief Medical Officer, Dr.
communications and public Tal Zaks oversees clinical
affairs activities, including development and regulatory
corporate and internal affairs across Moderna. Prior
communications, to joining Moderna, Dr. Zaks
government affairs, was senior vice president and
community relations and head of Global Oncology at
patient advocacy. She joins Sanofi, where he was
Moderna after nearly 20 responsible for all a spects of
years working with and for oncology drug discovery,
leading biotechnology and development and
pharmaceutical companies. commercialization.
Peppi Prasit
ACTING CHIEF SCIENTIFIC
OFFICER/DIRECTOR
Mark Van Oene Senior Vice
President & Chief
Commercial Officer
Mark Van Oene is Senior
Vice President and Chief
Commercial Officer for
Illumina, a position he has
held since 2017.

Mark Van Oene Senior Vice

President & Chief
Commercial Officer
Mark Van Oene is Senior
Vice President and Chief
Commercial Officer for
Illumina, a position he has
held since 2017.
Mark Van Oene Senior Vice
President & Chief
Commercial Officer
Mark Van Oene is Senior
Vice President and Chief
Commercial Officer for
Illumina, a position he has
held since 2017.

Duane Valz
VP & General Counsel

Duane has counseled a

wide variety of privately
held and public companies
on law, technology and
business matters.
 John Olson
Vice President and Global
Danaher Business Systems
Leader
Jim Reutlinger John started his current
Vice President, Global position in April 2013. From
Professional Services 2010 to 2013, he was Director Julia Daneman
Jim was appointed Vice of Manufacturing for the Lead Legal Counsel
President of Global company’s US and Europe Julia is serving as Lead Legal
Professional Services in plants. Prior to this, John held Counsel of Molecular Devices
January of 2018 and multiple positions in since November 2016 and has
previously served as the Operations, running all been with the company
Director of the Americas & aspects of both reagent and progressing through a series
Oceania Service and Service instrument operations in the of roles in the legal team since
Sales since January of 2015. US, China and Europe March 2012.
AKSHAY VAISHNAW, MD,
PhD
PRESIDENT, RESEARCH &
DEVELOPMENT
Dr. Akshay Vaishnaw joined
Alnylam in 2006, coming
from Biogen, Inc., where he
was most recently Senior
Director, Translational
Medicine.
SCOTT GUNTHER ALESSANDRO MASELLI
SENIOR VICE PRESIDENT OF SENIOR VICE PRESIDENT, LANCE MIYAMOTO
QUALITY & REGULATORY GLOBAL OPERATIONS SENIOR VICE PRESIDENT,
AFFAIRS Alessandro Maselli was HUMAN RESOURCES
Scott Gunther was named named Senior Vice President Lance Miyamoto was named
Senior Vice President of of Catalent’s Global Senior Vice President of
Quality & Regulatory Affairs Operations in September Human Resources of Catalent
in May 2017. 2016 in March 2011.

John C. Arthur, Ph.D. Sean T. Ristine

VP, Manufacturing & Supply VP, Human Resources
John C. Arthur, Ph.D. Sean T. Ristine
VP, Manufacturing & Supply VP, Human Resources
Cecilia McKenney
Senior Vice President, Chief
Human Resources Officer
Michael E. Prevoznik
Cecilia McKenney is Senior Senior Vice President and
Vice President, Chief Human General Counsel
Resources Officer for Quest
Diagnostics. She is Michael E. Prevoznik is Senior
responsible for all human Vice President, Legal and
resources activities across Compliance, and General
the company. Counsel for Quest Diagnostics.
Mike Ciesla Peter Ginsberg
VP Finance and Director of Vice President Business
SEC Reporting Development Kate McCabe
Mike Ciesla serves as Peter Ginsberg serves as Vice Vice President of Legal Affairs
Savara’s VP Finance and President of Business Kate McCabe serves as
Director of SEC Reporting. Development. An Savara’s VP of Legal Affairs.
Mr. Ciesla has over twenty accomplished orphan lung Prior to joining Savara, Ms.
years... disease busi... McCabe practiced corpora...
t time enabling physicians to personalize and monitor therapy. Over 400,000 US patients and 2,500,000 world-wide have MS. Am
Greg Hannon
Dr. Hannon is a professor
and Senior Group Leader at
the Cancer Research UK
Cambridge Institute at the
University of Cambridge.
c.suite leaders and titles12 c.suite leaders and titles13 c.suite leaders and titles14 c.suite lea c.suite lea

Mr. Doug Ward CEO

Ymkje Cuperus, MS
Senior Genetic Counselor

Sheila Flaherty, CLS Walter Jeske, PhD

Ms. Flaherty brings 38 years Dr. Jeske assists Machaon
of esoteric clinical coagulation Diagnostics with the planning
testing experience to and execution of clinical trials
Machaon Diagnostics and contract research studies
 Shawn
Lu, M.S.,
Craig Gibbs, Ph.D., M.B.A. Robert K. Coughlin John F. Hamilton, M.B.A. M.B.A
Director Director Director Director
 Tom Valerio Executive Rod Wooten Vice President,
Rick R. Suarez Vice President, Director, US Strategy and Cardiovascular and
Market Access Business Planning Metabolic Diseases
 Tom Valerio Executive Rod Wooten Vice President,
Rick R. Suarez Vice President, Director, US Strategy and Cardiovascular and
Market Access Business Planning Metabolic Diseases

Tom Valerio Executive Rod Wooten Vice President,

Rick R. Suarez Vice President, Director, US Strategy and Cardiovascular and
Market Access Business Planning Metabolic Diseases
united by a singular purpose: to create progress where patients need it most.
 FUNMI OLOPADE, MD ERIC TOPOL, MD

Scientific Adviser Scientific Adviser

Dr. Funmi Olopade serves as Dr. Topol serves as Scientific

Scientific Adviser at Tempus. Adviser at Tempus.

sive molecular insights that can be customized to your needs.

Sue Evans, MBA, RAC
Head, Regulatory Affairs Simrat Randhawa, M.D.,
M.B.A.
Sue has over 22 years of Head of Global Medical Affairs
experience in the
pharmaceutical and biotech Simrat Randhawa, M.D.,
industry, spanning multiple M.B.A.
roles; regulatory affairs, global Simrat brings over 20 years of
program management, experience to Aurinia across
business development, clinical practice, medical
process improvement, and affairs and business
analytical chemistry. development.
Kathy Wilkinson

Chief People Officer

Kathy Wilkinson joined us in

2012 as a senior director of
human resources, and since
joining us, she has overseen
our growth from 38
employees to over 300 while
building and fostering a
culture we love – passionate,
fun and relentlessly focused
on patients and our people.
ents and 2,500,000 world-wide have MS. Among the issues MS patients and their doctors wrestle with is deciding on the correc
c.suite lea c.suite leaders and titles18
deciding on the correct therapy, where drugs are expensive, often ineffective and the best have life-threatening side effects.
e-threatening side effects.